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Summary 
This thesis investigated access to medical care for tuberculosis (TB), with a focus on 
the economic component of access. TB is among the worst infectious diseases globally, 
causing about 2 million deaths per year. TB control will not be possible, if the most 
vulnerable and poorest sections of society do not have access to appropriate treatment. 
Studies for the present thesis were carried out in Tajikistan, one of the poorest countries 
of the world. The health system of Tajikistan is firmly rooted in its Soviet history with 
a dense network of facilities and allegiances to separate vertical programs for different 
tasks of the health system. Low expenditure for the health system and inefficiencies 
severely affect its performance. Several post-Soviet countries share at least some of the 
above characteristics and our studies may serve as a showcase for access to TB care in 
other countries of the former Soviet Union. 
The thesis used a previously described analytical framework for access to care in 
contexts of livelihood insecurity. Within this framework it focussed on access more 
than on livelihoods. For the categorisation of costs of illness, the thesis used a 
conceptual framework of the economic burden of illness for households. 
The seven studies in this thesis used qualitative and quantitative methods to investigate 
access to care and specific aspects of it. The first study took advantage of the 
explorative nature of focus group discussions to comprehensively investigate any 
factors that community members, TB patients and health care providers considered 
important for access to care. Factors that were reported to be important were discussed 
in depth. At the end of the discussion, the relative importance of the mentioned factors 
was rated. The results showed that community members associated cough with TB 
disease and that they were aware of facilities providing care for TB in their districts. 
The main finding of the study was that all respondent groups (community members, 
patients and providers) considered economic factors the most important barriers to 
medical care. 
A subsequent study investigated health care seeking and the relationship between 
organisational aspects of health care delivery and delay to TB treatment. Data for this 
study, two studies on illness-related costs and one study on food supplements were 
collected jointly, in a questionnaire survey among registered TB patients. Generally 
moderate delays (median 52 days) until start of TB treatment were found. However, 
Summary 
 x 
two subgroups of patients had high hazard ratios for long health system delays. These 
were the patients who first presented to peripheral primary care facilities and especially 
those who developed active disease while working in Russia and who presented to 
health care in Russia. The long delays of the former are related to the vertical structure 
of TB control inherited from Soviet times: primary care providers were reluctant to 
diagnose TB and chest radiography, which is not available at primary care facilities, 
was over-used for diagnosis. Diagnosis at the primary care level based on sputum 
smear microscopy should be promoted to shorten the delays of these patients. For 
labour migrants developing active TB in Russia, an international referral system is 
needed, including availability of treatment until sputum conversion for Tajik citizens in 
Russia. 
The third study investigated extent and timing of illness-related costs at the level of the 
patients’ households. It attempted to measure all material and monetary costs related to 
the TB disease, but not psychological pain or costs in terms of missed education. Mean 
self-reported total costs of an episode of TB were USD1’053, or c. USD4’900 
purchasing power parity. Of these costs, USD396 were incurred in the form of 
expenditure (direct costs) and USD657 in the form of lost income due to the inability to 
pursue usual income-generating activities. Almost three fourths of the total costs were 
incurred during anti-TB treatment, despite the availability of free TB drugs. The costs 
peaked before starting TB treatment and in the intensive phase of TB treatment. It was 
concluded that the costs of an episode of TB are catastrophic and that both strategies to 
reduce costs and strategies to help patients cope with costs are urgently needed. These 
strategies should be timed early in treatment in order to correspond with the highest 
cost peak. 
The fourth study identified factors associated with higher direct costs of TB, including 
factors relating to case management. It further investigated coping strategies that may 
lead to impoverishment: selling productive assets and borrowing money. The final 
mixed-effects regression model showed that receiving ‘additional medication’ was the 
most important predictor of higher direct costs. ‘Additional medication’ refers to drugs 
received in addition to the anti-TB therapy, mainly for symptomatic treatment and for 
iatrogenic problems. Further significant predictors were the delay until start of TB 
treatment and hospitalisation. TB patients raised on average USD182 through selling 
productive assets and through borrowing. Based on the results, it was suggested that 
Summary 
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changes in the management of TB, namely reducing additional treatment and 
hospitalisation, should be considered in order to avoid the high costs for patients. The 
rationality of both additional treatment and hospitalisation is questionable in many 
cases and there is room for improvement. The potentially detrimental coping strategies 
employed confirm the severe economic burden that TB patients carry. 
The fifth study used data from the TB registry to identify predictors of hospitalisation. 
It investigated eight independent variables as predictors of hospitalisation. Treatment 
result was studied as a secondary outcome, using the same eight variables plus 
hospitalisation as potential predictors. Sputum smear result was the most important 
predictor of hospitalisation, with age and sex being further significant factors. 
Treatment success was significantly lower for sputum-smear positive patients and there 
was a tendency for lower treatment success among hospitalised patients. The finding 
that sputum smear positive patients were much more likely to be hospitalised is 
consistent with national guidelines, but not necessarily with international 
recommendations that focus more on outpatient care. It is recommended that national 
guidelines be adapted to emphasise outpatient treatment. 
A survey among patients found that a considerable proportion of TB patients had 
already received the three food supplements that they are entitled to – before the end of 
the treatment. The number of food supplements received was significantly associated 
with the time elapsed since start of treatment and with residing in four out of the six 
districts with a food distribution program. Food supplements made a contribution of 
about USD225 to the household economy. 
Bayesian modelling of the sensitivity of routine sputum smear microscopy in peripheral 
laboratories in Tajikistan yielded an estimate of sensitivity of 53% for the examination 
of a single slide. The contribution of the third slide to total case finding through sputum 
microscopy was estimated at 13%. These results are important from a global and from 
a national perspective. On the global level they contribute to the surprisingly scarce 
evidence about the sensitivity of sputum microscopy in peripheral routine settings. This 
scarcity of evidence is probably linked to the difficulty of conducting the gold standard 
test, culture, in such settings. Our evidence suggests that the third serial sputum 
specimen could make a substantial contribution to case finding, if it were carried out 
with equal quality as previous examinations – a conclusion that is highly relevant to an 
ongoing policy discussion. From the national perspective, these findings highlight that 
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the sensitivity of routine sputum microscopy is reasonably good and that its use should 
be promoted. Concurrently, strengthening of the quality assurance should continue. 
The present thesis found that an analytical framework for access to care, developed in 
the context of a malaria control program, is useful also in the area of TB. Adaptations 
to make the analytical framework fit better to the context of access to TB care are 
suggested. The theoretical framework used for the classification of illness-related costs 
also proved useful. The studies conducted in the frame of this thesis identified 
economic factors as the main barriers to access medical care for TB. Several 
characteristics of health care delivery that are rooted in the Soviet health system 
contributed to the high costs faced by patients and to the long delays until treatment 
experienced by certain subgroups of patients. The importance of factors related to the 
Soviet history of health care suggests that many of our findings may also apply to other 
post-Soviet countries. 
In order to improve access to TB care and hence TB control in Tajikistan and possibly 
other countries of the former Soviet Union, the economic burden for the patients must 
be reduced as a matter of priority. Further, the long delays of certain subgroups of 
patients need to be shortened. The latter can be achieved more easily than the former, 
among others by improving referral systems, by further integrating TB services with 
general health care and by promoting the use of sputum smear microscopy. Reducing 
the economic burden for TB patients requires measures on both sides: reducing the 
costs faced by patients and increasing their ability to cope with these costs. 
Collaboration between the health system, implementing partners like non-governmental 
organisations and funding agencies as well as between different programs within the 
health system, like the TB control program and primary care, will be necessary. Several 
measures that can be implemented and that will contribute to the much-needed 
reduction of the economic burden have been identified in the studies conducted in the 
frame of the present thesis. 
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Zusammenfassung 
Diese Doktorarbeit untersuchte Zugang zu medizinischer Pflege für Tuberkulose (TB), 
mit einem Fokus auf den ökonomischen Komponenten dieses Zugangs. TB gehört zu 
den schlimmsten Infektionskrankheiten weltweit und verursacht etwa 2 Millionen 
Todesfälle pro Jahr. Die Kontrolle dieser Krankheit wird nicht möglich sein, wenn die 
Randgruppen der Gesellschaft und die Ärmsten keinen Zugang zu wirkungsvoller 
Behandlung haben. Die Studien für die vorliegende Dissertation wurden in Tadschi-
kistan ausgeführt, einem der ärmsten Länder der Welt. Das tadschikische Gesundheits-
wesen ist stark in seiner sowjetischen Geschichte verwurzelt, weist ein dichtes Netz-
werk von Gesundheitseinrichtungen wie Praxen und Kliniken auf und Loyalitäten zu 
jenem System, welches aus getrennten vertikalen Programmen für verschiedene 
Aufgaben des Gesundheitswesens bestand. Tiefe Staatsausgaben für das Gesundheits-
wesen und Ineffizienzen haben einen starken negativen Einfluss auf das seine Leistung. 
Mehrere post-sowjetische Länder teilen wenigstens einen Teil der obgenannten Eigen-
schaften und unsere Studien könnten Zugang zu Pflege exemplarisch auch für andere 
Länder der ehemaligen Sowjetunion abbilden. 
Diese Dissertation verwendete einen analytischen Rahmen für ”Zugang zu Pflege im 
Kontext unsicherer Lebensgrundlagen”, der bereits beschrieben war. Innerhalb dieses 
analytischen Rahmens konzentrierte sie sich mehr auf den “Zugang” als auf die 
Lebensgrundlagen der Menschen. Für die Einteilung von Krankheitskosten verwendete 
die vorliegende Doktorarbeit ein Rahmenkonzept für die “ökonomische Last von 
Krankheiten für Haushalte”. 
Die sieben Studien in dieser Dissertation verwendeten sowohl qualitative als auch 
quantitative Methoden um Zugang zu Pflege und spezifische Aspekte hiervon zu 
untersuchen. Die erste Studie nutzte den Vorteil der explorativen Eigenschaften von 
Fokusgruppendiskussionen um umfassend jegliche Faktoren zu untersuchen, welche 
von Vertretern der Allgemeinbevölkerung, von TB-Patienten und von Pflegepersonal 
als ausschlaggebend erachtet wurden für den Zugang zu Pflege. Faktoren, welche als 
wichtig erachtet wurden, wurden eingehend diskutiert. Am Ende der Diskussion wurde 
die relative Stärke des Einflusses diskutierter Faktoren bewertet. Die Studienergebnisse 
zeigen, dass Vertreter der Bevölkerung Husten mit TB assozierten und über Gesund-
heitseinrichtungen in ihren Distrikten, welche TB behandeln, Bescheid wussten. Das 
Hauptergebnis der Studie war, dass alle Gruppen von Informanten (Vertreter der 
Zusammenfassung 
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Allgemeinbevölkerung, Patienten und Pflegepersonal) die ökonomischen Komponen-
ten des Zugangs zu medizinischer Pflege als die einflussreichsten erachteten. 
Eine nachfolgende Studie untersuchte das Verhalten von betroffenen Personen im Falle 
von Krankheit und den Zusammenhang zwischen organisatorischen Eigenschaften der 
Gesundheitsdienste und dem Ausmass von verspätetem Behandlungsbeginn. Die Daten 
für diese Studien, zwei Studien über Krankheitskosten und eine Studie über Nahruns-
mittel-Ergänzungsleistungen wurden gemeinsam gesammelt, in einer Umfrage unter 
registrierten TB-Patienten. Über Alles gesehen wurden moderate Verspätungen bis 
Behandlungsbeginn gefunden (Median von 52 Tagen). Allerdings gab es zwei Gruppen 
von Patienten, die eine hohe statistische “Hazard Ratio” für lange Verspätungen auf-
wiesen. Dies waren Patienten, die sich zuerst an einen Grundversorger in peripheren 
Gebieten wandten, und insbesondere diejenigen Patienten, die eine aktive TB 
entwickelten, während sie in Russland am Arbeiten waren und dort einen Gesundheits-
versorger aufsuchten. Die langen Verspätungen der ersteren hängen mit der von 
Sowjetzeiten geerbten vertikalen Struktur der TB-Kontrolle zusammen: es widerstrebt 
den Grundversorgern, eine TB-Diagnose zu erstellen, und Röntgenbilder, welche bei 
Grundversorgen nicht vorhanden sind, wurden für die Diagnose von TB übermässig 
verwendet. Die Diagnose bei den Grundversorgern und abgestützt auf mikroskopische 
Untersuchung eines Ausstrichs von Auswurf sollte gefördert werden um die Verspä-
tungen dieser Patienten zu verkürzen. Für die Migranten, die in Russland eine aktive 
TB entwickeln, wird ein internationales Überweisungssystem benötigt, inklusive der 
Verfügbarkeit der Behandlung für tadschikische Bürger in Russland bis zur 
sogenannten Konversion des Auswurfs. 
Die dritte Studie untersuchte das Ausmass und das zeitliche Auftreten von 
Krankheitskosten für den Patienten und seinen Haushalt. Sie zielte darauf ab, alle 
materiellen und finanziellen Kosten in Zusammenhang mit einer TB-Erkrankung zu 
messen, aber nicht den psychischen Schmerz oder Kosten wie verpasste Ausbildungs-
möglichkeiten. Durchschnittliche Gesamtkosten einer TB-Erkrankung waren 1’053.- $ 
oder etwa 4’900.- $ gemessen in Kaufkraftparität. Von diesen Kosten wurden 396.- $ 
als Ausgaben getätigt und 657.- $ waren Einkommensverluste, die durch die krank-
heitsbedingte Arbeitsunfähigkeit zustande kamen. Beinahe drei Viertel der 
Gesamtkosten traten während der TB-Behandlung auf, obwohl die TB-Medikamente 
gratis verfügbar waren. Die höchsten Kosten traten vor dem Beginn der TB-
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Behandlung und während der sogenannten Intensiven Phase der Behandlung auf. Es 
wurde geschlussfolgert, dass die Krankheitskosten von TB katastrophal sind und dass 
Massnahmen sowohl zur Reduktion der entstehenden Kosten als auch zur Befähigung 
der Patienten, entstandene Kosten zu bewältigen, notwendig sind. Diese Strategien 
müssten frühzeitig während der Behandlung greifen, um mit den höchsten Kosten über-
ein zu stimmen. 
Die vierte Studie identifizierte Faktoren, welche mit höheren Ausgaben für TB 
zusammen hängen, einschliesslich Faktoren, die den Behandlungsmethoden zugehören. 
Weiter untersuchte sie Bewältigungsstrategien der Patienten, die zu weiterer Verar-
mung führen können: das Verkaufen von Produktionsgütern und das Borgen von Geld. 
Das resultierende statistische Model (“mixed-effects”) zeigte, dass “zusätzliche Medi-
kamente” der wichtigste Prediktor höherer Ausgaben war. “Zusätzliche Medikamente” 
bezieht sich auf Medikamente, die zusätzlich zur TB-Chemotherapie genommen 
werden, mehrheitlich für die Behandlung von Symptomen und von Nebenwirkungen. 
Weitere signifikante Prediktoren waren die Verspätung bis Behandlungsbeginn und 
Hospitalisierung. TB-Patienten trieben durchschnittlich 182.- $ durch den Verkauf von 
Produktionsgütern und durch Borgen auf. Aufgrund dieser Ergebnisse sollten Verände-
rungen der Behandlungsmethoden für TB in Betracht gezogen werden, nämlich den 
verminderten Gebraucht von zusätzlicher Medikation und von Hospitalisierung. Die 
medizinische Notwendigkeit dieser beiden Methoden ist in vielen Fällen fragwürdig 
und Verbesserungen sind möglich. Die verwendeten potenziell schädlichen Bewälti-
gungsstrategien bestätigen die schwere ökonomische Last, welche TB-Patienten tragen. 
Die fünfte Studie verwendete Daten aus dem TB-Verzeichnis um Prediktoren der Hos-
pitalisierung zu untersuchen. Acht unabhängige Variablen wurden als Prediktoren der 
Hospitalisierung untersucht. Als sekundäres Studienergebnis wurde das Behandlungs-
ergebnis untersucht, wobei die gleichen acht unabhängigen Variablen und zusätzlich 
Hospitalisierung als potenzielle Prediktoren in Betracht gezogen wurden. Das Resultat 
der Auswurfuntersuchung war der wichtigste Prediktor der Hospitalisierung, während 
Alter und Geschlecht ebenfalls signifikant waren. Der Behandlungserfolg war signifi-
kant tiefer für Patienten mit positivem Auswurf und eine statistische Tendenz für tiefe-
ren Erfolg bei hospitalisierten Patienten wurde gefunden. Das Ergebnis, dass Patienten 
mit positivem Auswurf eher hospitalisiert wurden, stimmt mit den nationalen Richtli-
nien überein, aber nicht unbedingt mit internationalen Empfehlungen, die mehr auf 
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ambulatorische Behandlung abzielen. Es ist empfehlenswert, die nationalen Richtlinien 
anzupassen und stärker auf ambulatorische Behandlung auszurichten. 
Eine Umfrage unter Patienten ergab, dass ein beachtlicher Anteil der TB-Patienten die 
drei Nahrungsmittel-Ergänzungsleistungen, auf welche sie Anspruch hatten, bereits vor 
dem Ende der Behandlung erhalten hatten. Die Anzahl der erhaltenen Ergänzungsleis-
tungen war signifikant mit der Zeit korreliert, die seit Behandlungsbeginn verstrichen 
war, sowie damit in vier der sechs Distrikte mit Nahrungsmittelergänzungen zu leben. 
Die Ergänzungsleistungen trugen etwa 225.- $ zum Haushaltsbudget bei. 
Bayes’sche Modellierung der Sensitivität der routinemässigen mikroskopischen 
Auswurfuntersuchung in peripheren Laboratorien Tadschikistans ergab eine Schätzung 
von 53% für die Sensitivität der Untersuchung eines einzigen Auswurfes. Der Beitrag 
der dritten von drei aufeinanderfolgenden Auswurfuntersuchungen zur Gesamtzahl der 
identifizierten Fälle wurde auf 13% geschätzt. Diese Ergebnisse sind sowohl aus 
globaler als auch aus nationaler Perspektive wichtig. Global tragen sie zur erstaunlich 
mageren wissenschaftlichen Faktenlage über die Sensitivität der Auswurfuntersuchung 
unter Routinebedingungen bei. Die knappe Faktenlage hängt wahrscheinlich zusammen 
mit der Schwierigkeit, den Goldstandardtest, Kultur, unter solchen Bedingungen 
durchzuführen. Unsere Fakten suggerieren, dass die dritte Folgeuntersuchung von 
Auswurf einen substanziellen Beitrag zur Gesamtzahl der gefundenen Fälle beitragen 
könnte, wenn sie mit der gleichen Qualität ausgeführt würde wie vorhergehende 
Untersuchungen – eine Schlussfolgerung, die für eine laufende Debatte sehr relevant 
ist. Vom nationalen Blickwinkel zeigen diese Ergebnisse, dass die 
Routineuntersuchung von Auswurf gut funktioniert und gefördert werden sollte. 
Gleichzeitig müssen die Anstrengungen zur Qualitätssicherung weitergehen. 
Die vorliegende Doktorarbeit zeigte, dass ein analytischer Rahmen für ”Zugang zu 
Pflege”, der innerhalb eines Programmes zur Malariakontrolle entwickelt worden war, 
auch im Bereich der TB-Kontrolle nützlich ist. Es werden Änderungen vorgeschlagen, 
um den analytischen Rahmen besser an den Kontext von Zugang zu Pflege für TB 
anzupassen. Das Rahmenkonzept für die Einteilung von Krankheitskosten erwies sich 
ebenfalls als nützlich. Die Untersuchungen, die im Rahme dieser Dissertation 
durchgeführt wurden, identifizierten wirtschaftliche Faktoren als die Haupthindernisse 
zum Zugang zu medizinischer Pflege für TB. Mehrere Eigenschaften der 
Gesundheitsdienste, die ihren Ursprung im sowjetischen Gesundheitswesen haben, 
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trugen zu den hohen Kosten für Patienten und zu den langen Verspätungen bis 
Behandlungsbeginn für gewisse Gruppen von Patienten bei. Die Bedeutung der 
Faktoren, die mit der sowjetischen Geschichte des Gesundheitswesens zusammen-
hängen, weisen darauf hin, dass unsere Ergebnisse auch in anderen post-sowjetischen 
Ländern Gültigkeit haben könnten. 
Um den Zugang zu TB-Pflege und dadurch TB-Kontrolle in Tadschikistan und 
möglicherweise anderen Ländern der ehemaligen Sowjetunion zu verbessern, muss 
prioritär die wirtschaftliche Last für die Patienten vermindert werden. Weiter müssen 
die langen Verzögerungen bis Behandlungsbeginn für gewisse Patientengruppen 
verkürzt werden. Letzteres ist einfacher zu erreichen als Ersteres, unter Anderem durch 
eine Verbesserung der Überweisungsmechanismen, durch eine weitergeführte Integra-
tion der TB-Pflege mit allgemeiner Gesundheitspflege und durch eine geförderte Ver-
wendung der Auswurfuntersuchung. Um die wirtschaftliche Last für TB-Patienten zu 
vermindern, sind Massnahmen beiden Seiten notwendig: Verminderung der auftreten-
den Kosten, und Befähigung der Patienten, die auftretenden Kosten besser zu 
bewältigen. Dies wird Zusammenarbeit zwischen dem Gesundheitswesen, Partnern wie 
Nichtre-gierungsorganisationen und Entwicklungsorganisationen erfordern. Mehrere 
Massnahmen, die eingeleitet werden können und zur dringend benötigten 
Verminderung der ökonomischen Last beitragen werden, sind in den Untersuchungen 
im Rahmen dieser Doktorarbeit bestimmt worden. 
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1. Introduction 
1.1. Overview 
The main subject of this thesis – as the title suggests – is the ability of affected people 
to make use of medical care for tuberculosis (TB), summarised under the term ‘access 
to care’. Particular attention is given to illness-related costs at the level of patients’ 
households, i.e. the economic aspects of access to care. The introduction will first give 
a general overview of etiology, epidemiology and clinical features of TB, then 
introduce the concept of access to care and subsequently present some of the 
difficulties patients face in relation to TB and TB treatment. 
1.2. Etiology and basic epidemiologic features 
TB is caused by the gram-positive bacterium Mycobacterium tuberculosis (MTB). 
About one third of the world population, i.e. about 2 billion people, are infected with 
MTB (Dye et al 1999). However, only about 10% of people infected with MTB will 
develop the disease during their whole lifetime, 90% of infections will remain latent or 
be cleared (Hopewell & Jasmer 2005). Latency can last for years or even decades. The 
exact site and physiologic state of MTB during latency are debated, but clearly protect 
it from the fast effect of drugs that are rapidly bactericidal in vitro (Gomez & 
McKinney 2004). The risk of active disease is higher among HIV-positive people, 
where annual rates of progression from latent infection to disease of 2%-8% have been 
reported. A variety of organs can be affected, but most commonly the lungs are and 
then the disease is referred to as pulmonary TB (PTB). In the absence of HIV around 
85% of reported TB cases are PTB (Hopewell & Jasmer 2005). In areas with high rates 
of HIV, the proportion of extra-pulmonary TB (EPTB) is much higher. 
1.3. Burden of Disease 
The high and rising numbers of TB incidence from the mid 1980ies onwards prompted 
the World Health Organisation to declare TB a global public health emergency in 1993 
(World Health Organisation 1994). In the year 2007, an estimated 9.3 million people 
worldwide newly fell ill with TB and about 1.8 million people died from it (World 
Health Organisation 2009). An overwhelming proportion of the burden of disease is 
experienced by low- and middle-income countries (Figure 1.1). The highest incidence 
rates occur in Africa and Asia (Corbett 2003, World Health Organisation 2009). In the 
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former Soviet countries of Central Asia, TB burden was relatively low in 1990 at an 
incidence of about 66 cases per 100 000 of population per year (own calculations from 
data in World Health Organisation 2005). After the breakdown of the Soviet Union, 
there was a severe rise in TB incidence in the five post-Soviet countries of Central 
Asia. By the year 2003, the incidence rate had almost doubled to about 126 and 
approximately remained constant with 127 in 2005 (data source: World Health 
Organisation 2005, 2009). Within former Soviet Central Asia, Tajikistan has been and 
still is the country with the highest burden of disease. Moreover, Tajikistan was the 
only Central Asian country, for which the estimate of incidence increased substantially 
over the last years – reaching a new peak at 231 cases per 100 000 population in the 
year 2007 (World Health Organisation 2009). For another Central Asian country, 
Afghanistan, the World Health Organisation (2006) estimated an incidence rate of 333 
as well in 1990 as in 2004. This is one of the highest rates outside Africa and migration 
between Afghanistan and Tajikistan might affect the incidence rates in the two 
countries. 
Globally 1.74 times as many men are notified with TB than women (World Health 
Organisation 2004). The sex bias is in the opposite direction for the age group of 0 to 
14 years and less-than-average for the age groups of 15 to 24 and 25 to 34. In the older 
age groups, the rate is even more strongly male-biased. Borgdorff et al (2000) reviewed 
prevalence survey and notification data from 14 countries and concluded, that the 
higher number of men notified with TB “may be largely due to epidemiological 
differences and not to differential access to health care”. In a study in Vietnam, 1.5% of 
women and 1.3% of men reported symptoms consistent with TB (Thorson 2000). 
Among these, 14% of women and 36% of men indicated having given a sputum sample 
– a finding which suggests women have more difficulties accessing health care. 
Balasubramanian et al (2004) screened a study community in southern India by CXR 
and confirmed cases by sputum smear microscopy. They compared prevalence of 
symptoms and sputum-positivity in the community with notification rates, and 
concluded, that in their study site men had significantly less access to TB diagnosis and 
treatment than women. In a study in the Philippines, Tupasi et al (2000) found that 21% 
of men and 15% of women had symptoms consistent with TB. Unfortunately, the 
results of diagnosis by means of CXR and sputum microscopy are not given for the 
sexes separately. These results show that there is major variation among different 
settings in regard to gender disparities. 
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TB strains that are resistant at least against isoniazid and rifampicin are referred to as 
multi-drug resistant TB (MDR-TB). Their treatment is more complex and much more 
expensive than that of drug-susceptible TB. The post-Soviet countries of Eastern 
Europe and Central Asia are among the countries with the highest proportions of MDR-
TB cases (World Health Organisation 2003a). Specifically, Kazakhstan and the 
Qaraqalpoqston region of Uzbekistan are two of the settings with the highest rates of 
MDR-TB with estimates of 56% and 40%, respectively, among re-treatment cases. The 
corresponding rates for new cases are 14.2% and 13.2%. For Tajikistan an MDR-TB 
rate of 8.6% among new cases was estimated by means of a mathematical model, 
suggesting that there is also a large problem of MDR-TB (Zignol et al 2006). 
As mentioned above, HIV dramatically increases the risk of developing active TB 
(Hopewell & Jasmer 2005). It is therefore noteworthy, that the prevalence of HIV in 
Tajikistan is low, estimated at 0.3% among adults in the year 2008 (UNAIDS 2008). 
Mainly injecting drug users are known to be affected in Tajikistan. 
 
Figure 1.1. Estimated incidence rates of tuberculosis globally – in 2007. 
Reproduced with the kind permission of the World Health Organisation, Geneva, 
Switzerland. 
1.4. The DOTS strategy 
Adherence to the long-lasting traditional TB treatments – often associated with 
extended hospital stays – was low and the burden of TB increasing in the 1990ies. As a 
response, the World Health Organisation developed a new TB control strategy: the 
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Directly Observed Treatment, Short Course (DOTS) strategy, made available to 
national health authorities in 1993 (World Health Organisation 1993). The DOTS 
strategy is based on five components: i) political commitment, ii) access to quality-
assured sputum microscopy, iii) standardized short-course chemotherapy for all cases 
of TB under proper case management conditions (including direct observation of 
treatment), iv) uninterrupted supply of quality-assured drugs, and v) a recording and 
reporting system enabling outcome assessment of all patients and assessment of overall 
program performance (World Health Organisation 2003b). Based on the DOTS 
guidelines, each country defines its national guidelines for the treatment of TB. 
Implementing these guidelines should allow reaching the official DOTS objectives of 
detecting 70% of estimated PTB+ cases and of successfully treating 85% of them. 
DOTS relies on passive case finding, which means that screening of the population is 
not foreseen – not by sputum microscopy and even less by means of CXR (World 
Health Organisation 2003b). Rather, patients presenting to a health care facility with 
symptoms consistent with TB (especially cough lasting more than two or three weeks) 
should be referred to and actively motivated for sputum smear testing. This requires 
that patients actually do access the health care system if they have these symptoms, and 
that the health care system delivers diagnostic services according to guidelines for all 
patients. After diagnosis, patients are put on treatment according to three treatment 
categories. Treatment consists of two parts, the intensive and continuation phases (IP 
and CP). The exact duration of these two phases depends on the drug regimens used 
and on the patient’s history of previous TB treatment. In the IP, which lasts at least two 
months, treatment should take place daily or thrice weekly and invariably under direct 
observation (DOT). In the CP, which lasts four to six months, exemptions from DOT 
are more widely accepted. While DOT gave the DOTS strategy its name, the 
importance of direct observation has been questioned and is intensively debated 
(Volmink & Garner 2007, Frieden & Sbarbaro 2007, Maher et al 2007). There is a 
consensus, however, that assuring treatment adherence requires strong leadership and a 
multi-faceted and locally adapted approach that takes the patients’ needs into account. 
The regimens recommended by the World Health Organisation consist of a 
combination of four to five anti-tuberculous agents during the IP and of two to three 
during the CP. All standard regimens include isoniazid and rifampicin. Recommended 
regimens for cases with drug-resistant strains are more complicated. Guidelines for the 
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treatment of MDR-TB have been issued under the name of DOTS-plus (World Health 
Organisation 2000). 
The DOTS strategy was found to have improved access to diagnosis and treatment of 
TB for example in India (Khatri & Frieden 2002). However, a more general evaluation 
of the progress of DOTS showed, that global case detection had remained relatively 
constant from 1996 till 2003 at around 56%, i.e. substantially below the target of 70%, 
which DOTS designers hoped to reach by 2005 (World Health Organisation 2005). 
Dye et al (2002) made similar findings reviewing the numbers of detected cases in 
DOTS programs and summarised their findings as “low access to a highly effective 
therapy”. 
1.5. Health care delivery and DOTS in Tajikistan 
Tajikistan is a relatively small, very mountainous and land-locked country situated in 
Central Asia (Figure 1.2). It borders China to the east, Afghanistan to the south, 
Uzbekistan to the west and Kyrghyzstan to the north. After independence, Tajikistan 
fell into civil war and experienced a dramatic drop in economic output (Central 
Intelligence Agency 2009). Its gross domestic product per capita is estimated at USD 
2’100 purchasing power parity for the year 2008. 
 
Figure 1.2. Map of Asia showing Tajikistan (in black). Available from 
http://commons.wikimedia.org. 
 
At independence, Tajikistan inherited the Soviet health care system based on the 
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Semashko model, comprising a dense network of facilities (compare also table 5.1) and 
high in-patient capacity (Atun & Coker 2008, Falkingham 2004). Health care focussed 
on curative and specialist services, was universally available and free of charge at the 
point of delivery. Control of epidemic diseases and hygiene were the responsibility of 
the Sanitary-Epidemiological Services, a separate vertical system. Currently, health 
sector reform is ongoing in Tajikistan (Tediosi et al 2008). One of the main objectives 
of health sector reform is the strengthening of primary care, whereby primary care also 
takes over preventive and public health services that were organised vertically before. 
In the Semashko model, TB control was usually organised in four vertical structures: 
screening of the population by means of fluorography, the penitentiary TB program, 
hospital-based TB services, and primary care-based TB services (Atun & Coker 2008). 
In 2002 a DOTS program was started in Tajikistan – in Dushanbe and Rudaki districts, 
covering 13% of the country’s population. By the end of 2005 the program expanded to 
24 districts covering 44% of the population and by the end of 2007 it reached 100% 
(World Health Organisation 2006, World Health Organisation 2009). The program is 
steered by the National TB Program (NTP) (National Coordination Committee on 
malaria prophylactic and control in Republic of Tajikistan 2003). Generally there is one 
laboratory performing sputum smear microscopy per rayon (district), in the district 
centre. At the same site, the TB laboratory and treatment registries are kept. Primary 
care services refer TB suspects to the TB laboratory for diagnosis and provide 
treatment supervision. Case detection in the Tajik DOTS program has so far remained 
below international targets – at 39% in 2007 instead of 70%. Official data suggest that 
the rate of treatment success is close to international targets at 84% for the 2006 cohort 
(World Health Organisation 2009). 
1.6. Clinical manifestation and diagnosis 
1.6.1. Clinical diagnosis 
Clinical symptoms of TB are unspecific. They include night sweats, general weakness, 
lack of appetite, and weight loss. The most important symptom of PTB is prolonged 
cough; typically accompanied by expectoration after the initial period. Most TB control 
programs consider any patient with cough for at least two weeks (in some programs at 
least three weeks) to be a TB suspect and require that she or he be evaluated for TB 
diagnosis. Diagnostic tests include direct microscopy of sputum, fluorescence 
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microscopy, culture (including assessment with or without microscopy), a variety of 
rapid diagnostic tests, methods based on nucleic acid amplification, chest radiography 
and computed as well as positron emission tomography. However, in most parts of the 
world, only direct sputum microscopy is available – maybe complemented by a chest x-
ray (CXR) if the patient can afford to pay for such (Davies & Pai 2008). Some of the 
advantages and disadvantages of the most important diagnostic tests for TB are 
presented in table 1.1. 
1.6.2. Direct sputum microscopy 
For direct microscopy, sputa are collected from the patient, prepared as a smear, stained 
using the Ziehl-Neelsen technique and then analysed under the microscope. Ziehl-
Neelsen microscopy is an inexpensive and relatively quick test identifying acid-fast 
bacilli (AFB), which include MTB. AFB are visible in red against a background of 
light blue (Figure 1.3). With the Ziehl-Neelsen sputum smear examination, patients 
excreting a significant number of bacilli can be identified. These patients are obviously 
the most infectious ones and are called sputum smear positive PTB (PTB+) cases. 
Hence, the priority for the control of the TB epidemic is to detect and successfully treat 
PTB+ cases (World Health Organisation 2003b). However, the sensitivity of sputum 
smear microscopy is rather low. In part to compensate for low sensitivity, current 
diagnostic guidelines specify that three sputum samples should be obtained from each 
patient, usually an on-the-spot sample when the patient presents at the health facility, 
an early morning sample that the patient collects at home, and a second on-the-spot 
sample when the early morning sample is brought to the health facility. As a 
consequence of this schedule, the diagnosis of TB by means of sputum smear 
microscopy requires at least two days. 
1.6.3. Sensitivity of sputum smear microscopy 
Estimates of the sensitivity of sputum smear microscopy against the gold standard of 
culture vary enormously, from 8.8% to 94% (Aber et al 1980, World Health 
Organisation 1998, Steingart et al 2006). Part of this variation may be accounted for by 
the quality achieved by a particular laboratory. Another important factor is the bacillary 
load – the sensitivity of sputum smear microscopy in detecting the most infectious 
cases in the community has been postulated to be as high as 90% (World Health 
Organisation 1998, Grzybowski et al 1975). Chan et al (1971) have performed both, 
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microscopic (fluorescence microscope) and culture examination, on two sputum 
samples from each patient in their study population in Singapore. The numbers 
presented in their paper suggest, that microscopic examination of a single sputum 
sample on average could identify 58% to 65% of all cases that would be positive on 
repeated culture examination (own analysis of data in Chan et al 1971). Heifets & 
Desmond (2004) postulate that 60-70% of all culture-positive cases could be identified 
by high-quality direct microscopy. 
 
Figure 1.3. Mycobacterium tuberculosis. Ziehl-Neelsen stain. 
Image released into the public domain by CDC, Atlanta. 
It has repeatedly been found that the third diagnostic and the second follow-up sputum 
smear examinations contribute few cases and detect few failures of conversion  (Ipuge 
et al 1996, Harries et al 2000, Rieder et al 2005, Mabaera et al 2006). The third sputum 
contributed only a very small proportion of total cases detected in a four-country-study 
(Rieder et al 2005). The authors conclude that: “under prevailing settings in some of 
these countries, it makes little sense to require a third serial diagnostic smear [...]”. 
However, before implementing such a fundamental change in different countries across 
the world, it would be favourable to have more and independent estimates of the 
fraction of cases that would be missed if only two serial sputum smears were required. 
If the sensitivity of examining a single sputum smear were known, this could provide 
an independent estimate of cases missed by dropping the requirement for a third serial 
sputum. 
DANTB (2002) in a study in Orissa, India, report cultural factors inhibiting women to 
cough and to produce sputum. Many women reported feeling embarrassed when 
producing sputum. Unfortunately, these findings are not quantified. Good quality 
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sputum is essential for diagnosis, because saliva and nasopharyngeal discharge do not 
contain suitable numbers of bacilli (American Thoracic Society 2000). Whether sputum 
smear microscopy does diagnose one sex preferentially is unknown. Rieder et al (1997) 
analysed the number of slides from suspects that had to be analysed to find one case in 
four different countries. In all four countries, they found that a higher proportion of 
male than female suspects were diagnosed as cases, which they interpreted as true 
difference in prevalence among suspects. 
Table 1.1. Comparison of the most important diagnostic tests for tuberculosis† 
Test Advantages Disadvantages 
Conventional sputum 
smear microscopy 
Cheap, basic equipment, 
simple to learn, relatively 
quick, high specificity. 
Low sensitivity, considerable 
workload. 
Fluorescence 
microscopy 
Relatively cheap, quick, 
high throughput, better 
sensitivity than 
conventional microscopy, 
high specificity. 
Uninterrupted supply of 
electricity needed, training and 
maintenance more demanding 
than conventional microscopy, 
acceptability to laboratory staff 
is an issue. 
Culture Gold standard, sensitive 
and very specific, basis for 
species identification (to 
exclude other acid-fast 
bacilli). 
Obtaining results often takes 4 
weeks or more in low-resource 
settings, proficiency needed to 
avoid contamination and to 
assure quality. 
Chest x-ray Quick. Intra- and inter-rater variability 
high, sensitivity and specificity 
depend on rater, but neither is 
very good. 
Fluorography Quick. Similar to chest x-ray, but even 
less accurate. 
Rapid diagnostic tests Quick, no equipment 
needed, very simple to 
administer. 
Diagnose infection including 
latent infection, consequently 
limited utility in high-incidence 
settings. Sensitivity and 
specificity may be issues. 
Tests based on 
nucleic acid 
amplification 
Species identification is 
possible (to exclude other 
acid-fast bacilli), highly 
specific and fairly 
sensitive. 
Advanced equipment and 
expertise needed. 
† References: Davies & Pai (2008), Koppaka & Bock (2004), Steingart et al (2006), 
Steingart et al (2007), Van Deun (2008), World Health Organisation (1998). 
 
In several TB programs in Central Asia, including the Tajik NTP, unusually high rates 
of PTB- cases are noted (World Health Organisation 2009). Neher (2005) wrote about 
the high rate of PTB- cases in Tajikistan: “it has to be assumed that a high percentage 
Chapter 1 – Introduction 
 10 
of sputum smear negative and extra-pulmonary TB-cases are inactive cases and 
therefore over-treated”. So far there have been no studies investigating the sensitivity 
of sputum smear microscopy and its potential link to the high proportion of sputum 
smear negative cases in Central Asia. Understanding the possible role of the quality of 
microscopy examination in the high proportion of PTB- cases would be crucial. A 
study on the diagnostic accuracy of sputum smear examination in the routine program 
setting of Tajikistan is presented in chapter 10 of the present thesis. The quality of 
microscopy examination will also influence the choice of diagnostic test, which may 
determine access to diagnostic services. The result of microscopy examination may 
play a role in the decision about in- or outpatient treatment, which may strongly 
influence access to medical care, mainly but not exclusively through affordability of 
services. Chapters 5 and 7 elaborate on the links between accurate sputum smear 
examination and access to care for TB. 
1.6.4. Fluorescence microscopy 
The preparation of slides for fluorescence microscopy is generally similar to the 
procedure for sputum smear microscopy according to Ziehl-Neelsen. However, 
different dyes are used and consequently the requirements differ in some details. The 
slides are viewed in a darkroom under a fluorescence microscope and AFB appear as 
bright green rods against a dark, partly red background. Fluorescence microscopy is 
conducted at a magnification that is ten times lower than the magnification in 
conventional microscopy, but the bright green AFB are still well visible. Due to the 
lower magnification a larger area of the slide can be viewed and consequently the 
sensitivity of fluorescence microscopy is higher – especially in the case of scanty-
positive cases (Steingart et al 2006). However, fluorescence microscopy requires higher 
initial investment, the ability to assure maintenance of the more sophisticated 
microscopes, uninterrupted supply of electricity and that darkrooms be acceptable to 
the laboratory staff (Van Deun et al 2008). So far, no laboratory in Tajikistan is 
equipped for fluorescence microscopy. 
1.6.5. Culture of Mycobacterium tuberculosis 
Culture of MTB is conducted on egg-based or agar media and is considered the gold 
standard of TB diagnosis. Due to the slow doubling time (15-20 hours) of MTB 
compared to other bacteria, culture of MTB is time-consuming and results are not 
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available before two weeks even in the most advanced laboratories and may take up to 
eight weeks (Heifets & Desmond 2004). Consequently, culture plays only a limited role 
in the diagnosis of tuberculosis in high-incidence settings. However, culture capacity 
has been built up in recent years in the order to improve the possibilities of diagnosis of 
MDR-TB. 
1.6.6. Chest radiography for diagnosis of tuberculosis 
Chest radiography, or chest x-ray (CXR), is another very widely used means for the 
diagnosis of tuberculosis. At the initial site of infection in the lungs, the so-called Ghon 
complex will usually form, consisting of a calcified focus of infection and associated 
lymphatic lesions. The Ghon complex is usually visible on a quality CXR, even in 
people who do not develop active disease. During active disease, the lesions are more 
extended. However, the lesions caused by TB can take almost any form on CXR and 
diseases other than TB can cause patterns that have often been thought typical of TB 
(American Thoracic Society 2000, Koppaka & Bock 2004). Similarly, a recent study in 
Russia found considerable inter-observer variation in the interpretation of CXR in a 
sample consisting of tuberculosis specialists, radiologists and respiratory specialists 
(Balabanova et al 2005). CXR should not be confounded with fluorography, which has 
been used extensively and sometimes is still used for TB diagnosis. The World Health 
Organisation (2003b) explicitly discourages the use of fluorography in the diagnostic 
procedure for tuberculosis. 
While CXR is not required for the diagnosis of a PTB+ case, the diagnosis of sputum 
smear negative cases (PTB-) relies heavily on CXR in low-resource settings. The 
guidelines for national TB control programs recommend that PTB- be diagnosed only 
in patients of whom at least three negative sputum smears have been obtained, whose 
CXR shows abnormalities consistent with active TB, whose disease did not improve 
upon a full course of broad-spectrum non-TB antibiotics and who will be put on a full 
treatment course of anti-TB chemotherapy by a clinician (World Health Organisation 
2003b). 
1.6.7. Rapid diagnostic tests 
A large number of rapid diagnostic tests have been developed and are commercially 
available. All of these diagnose infection of TB – including latent infection – rather 
than exclusively active disease (World Health Organisation 2008, Davies & Pai 2008). 
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Advantages of rapid tests include the simplicity of their handling, which is expected to 
lead to more consistent results, as well as the availability of the result at the point-of-
care and within minutes. In comparison, obtaining a final result by means of sputum 
smear microscopy requires at least two days. Further, rapid tests could reduce problems 
of work overload in many TB laboratories in high-incidence countries. 
Several studies have investigated the accuracy of rapid diagnostic tests for the 
diagnosis of active TB disease and found that none of the currently available tests has 
the potential to play an important role in the diagnosis of either pulmonary or extra-
pulmonary TB (Steingart et al 2007a, Steingart et al 2007b, World Health Organisation 
2008). 
1.6.8. Other diagnostic tools 
Other diagnostic tools including nucleic acid amplification and tomography require 
advanced equipment and are currently hardly available in low-resource settings. Due to 
the very limited role that these techniques currently play in countries with medium to 
high incidence, they are not further explored here. 
1.7. Health care seeking 
Options for health seeking include self-treatment, informal providers (traditional 
healers), private doctors, and public medical facilities of any kind (Auer et al 2000, 
Hoa et al 2003, Storla et al 2008). The question of adequacy of choice of care for a 
particular health condition arises. Inadequate choice of the care provider may cause a 
health condition to progress or to spread to other people. Given that TB control relies 
mostly on passive case finding, i.e. on TB patients presenting to health services, 
adequate health care seeking of TB patients is important not only for the individual 
patient, but also from a societal perspective. Perception of causes and remedies for TB 
varies in different contexts and may differ from biomedical concepts to a varying 
degree. The patient’s perception of the causes and remedies for TB will shape the 
health care seeking behaviour and misperceptions of TB may lead to patients not 
accessing medical care. Even when patients access medical care, the choice of the 
provider can still strongly influence the time required to obtain a correct diagnosis and 
whether patients receive appropriate treatment. Moreover, the patient’s choice is 
influenced and often limited by the access to a particular kind of care. 
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1.8. Access to care 
1.8.1. Global perspective and theory of access 
The Universal Declaration of Human Rights (United Nations General Assembly 1948) 
is unequivocal: “Everybody has the right to [...] medical care [...]”. Contrary to this 
normative statement, many health systems do not provide health services in a way that 
all people can exert their right to medical care: access to medical care is not a matter of 
course, rather it is a key goal that health system are striving to achieve (Murray & 
Evans 2003). On a global scale, Victora et al (2003) have found that for a multitude of 
reasons, poor people lack access to medical care even though they are exposed to 
disease more often than wealthier people and consequently are more in need of medical 
care. Children in low-income countries face a risk of dying before their fifth birthday 
that is about 20 times higher than that of children in high-income countries. Gross 
inequalities are also found within many countries between the poorest and the 
wealthiest parts of societies. In addition to income, many other reasons – often 
correlated with poverty – can contribute to the lack of access to health care. These 
include among others education, cultural factors, or the location of health care facilities 
and are further discussed below. While poverty is not the only reason for lack of access 
to medical care and good health, it has a tremendous effect. Ill-health affects people’s 
ability to sustain their livelihoods and often forces them to make out-of-pocket 
expenditures for health care – two factors that often lead to further impoverishment and 
make affected households more susceptible to future disease. This vicious circle is 
known as the ‘medical poverty trap’ (Whitehead et al 2002). 
Access entails several components, namely availability, accessibility, affordability, 
adequacy and acceptability (Aday & Andersen 1974, Obrist et al 2007). These are 
sometimes referred to as ‘the five A’s’. No precise and universally accepted definitions 
of the five A’s exist, but a few of the main components will be presented in the 
following. Availability depends on the existence of diagnostic services, drugs, 
vaccines, trained health providers, and health care infrastructure in the wider area or the 
country of question. Accessibility depends on factors like geographical distance to the 
care provider, available infrastructure (roads, transport, etc.), and the patient’s ability to 
use the latter and to move. Affordability depends on direct and indirect costs as well as 
on the patient’s ability to pay. Adequacy describes the match between patients’ needs 
and expectations on the one side and the organisational characteristics of health 
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services on the other, including opening hours. Acceptability of health care services 
includes socio-cultural concepts of a disease, questions around confidentiality, as well 
as the perception of staff friendliness. Some authors have used utilisation as a measure 
of access to care (see also Obrist et al 2007, Andersen 1995), but here, utilisation is 
seen as the product of need and access. 
1.8.2. Access to tuberculosis services 
For various reasons access to care is of particular importance in the field of TB control. 
Maher & Nunn (1998) identified access as “the most important determinant of the 
outcome of treatment of TB”. All the components of access to care described above 
may affect access to TB treatment. One of the reasons exacerbating the issue of access 
in the area of TB treatment is that DOT requires daily or thrice weekly meetings with 
the DOT provider. Consequently any barriers to access have to be overcome on a daily 
or at least regular basis. So far, the analytical framework presented in the previous 
section has never been used to analyse access to care for tuberculosis – nor have any 
other comparably comprehensive theories of access to care. 
Some studies on adherence have examined several of the factors that are important 
barriers to access. Given that adherence is influenced by a multitude of factors, it is 
often easier to document, that a particular factor has some influence on adherence, than 
to assess the relative importance of different factors. Greene (2004) formulated this in a 
very eloquent way: “just because a culture-specific barrier [is present and therefore] 
might affect adherence to tuberculosis therapy does not mean it is the determining 
factor behind nonadherence” [emphasis by Greene]. From his studies in urban Bolivia, 
he concluded that structural barriers to TB care were much more important than 
patient-side factors. However, there is no consensus on the factors that are included on 
the demand- or patient-side. Contrary to Greene (2004), Ensor & Cooper (2004) 
included financial costs incurred outside the health facility (including among others 
transport costs) among demand-side factors. 
Despite the global burden of TB and the pivotal role that access to TB services plays in 
the fight against TB, surprisingly few studies exist on access to TB treatment – and 
even fewer from post-Soviet countries. No systematic study about access to care for TB 
in a former Soviet country is found in the scientific literature. A relatively recent article 
by Keshavjee & Becerra (2000) describes anecdotal evidence from Tajikistan of 
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serious problems of availability of TB services, which is one component of access to 
care. Patients were unable to access TB care due to drug shortages in the hospital of a 
regional capital. However, this relates to the pre-DOTS era and it is likely that the 
situation has considerably improved since. The distance between the patient and the 
health worker providing DOT was a serious obstacle to TB control based on the field 
experience of a program implemented in Uzbekistan (Shafer et al 2001). Understanding 
the determinants of access to TB treatment would be crucial to better tailor TB 
programs to the needs of patients. 
1.8.3. Delay 
Access is often not a binary trait that can either be present or absent. Rather patients 
can reach health care services and obtain treatment more or less readily, depending on 
how difficult access is for them and on the severity of their condition. The period from 
onset of symptoms to first consultation at a health care facility is referred to as patient 
delay. The period from first consultation to diagnosis is referred to as health system (or 
provider) delay. It may be followed by a treatment delay designing the time span from 
diagnosis up to onset of treatment. Seen from this point of view, patients who never 
reach the health care facility have an infinite patient delay. Many studies have shown, 
that people sick with TB may delay obtaining health care for long periods of time, 
which constitutes a serious problem for the control of the epidemic. Several studies 
tried to quantify the influence of delay on the TB epidemic. Asch et al (1998) found 
that during a mean delay of 74 days, TB patients in Los Angeles county infected an 
average of eight contacts. A commonly cited estimate is that an untreated case of TB 
will infect over 20 contacts during the natural history of the disease until death (Styblo 
1991, Grzybowski et al 1975, Lawn et al 1998). 
In a study in Brazil, the median delay found was three months and about 60% of 
patients had a delay longer than two months (dos Santos et al 2005). In Ghana, a 
median delay of four months was reported by patients (Lawn et al 1998). It can be 
assumed that there is a lot of overlap between factors hampering access to health care 
and factors leading to longer delay. Commonly, urban residence was associated with 
shorter delays than rural residence, which might reflect the better accessibility of health 
care in these areas (Lawn et al 1998; Lienhardt et al 2001). In general, however, health 
system delay tends to be longer than reported patient delay. A review identified several 
characteristics of health systems and their interaction with the patient as risk factors for 
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delay, including the type of the facility where the first contact with the patient took 
place (Storla et al 2008). Making the first contact at a low-level government health 
facility or with a private provider was often associated with longer delays. These 
findings show that there are links between the organisation of health care delivery, 
health care seeking and delay, which again is linked to the control of TB. How long 
patient and health system delays are and which patients experience the longest delays in 
Tajikistan or other former Soviet republics is all but unknown. Especially in view of 
the low estimated case detection rate in Tajikistan, a better understanding of factors 
influencing delay and access to care is urgently required. It will help policy makers and 
program managers to better tailor TB services to the needs of patients and thus to 
improve TB control. 
1.8.4. Affordability of tuberculosis services 
Studies comparing the health system costs of the DOTS strategy to more traditional 
ways of organising TB services, have shown that the relatively shorter duration of 
chemotherapy and the predominantly ambulatory provision of treatment foreseen by 
the DOTS strategy allows health systems to deliver TB services at lower costs (Jacobs 
et al 2002, MacIntyre et al 2001, World Health Organisation 2003b, Wurtz & White 
1999). Several studies tried to quantify the household costs of TB in different settings 
(Croft & Croft 1998, Kamolratanakul et al 1999, Needham et al 1998, Rajeswari et al 
1999, Wyss et al 2001). Russell (2004), in a review of household costs of different 
diseases, found that TB often has catastrophic effects on household economy and 
linked this to the long duration of the disease. Costs of disease are usually classified 
into direct and indirect costs (Russell 2004, Wyss et al 2001), where the former are all 
expenses incurred and the latter comprise missed income and intangible costs. Direct 
costs are further divided into medical (for consultation, diagnostic tests, medication, 
etc.) and nonmedical costs (for transport, special food items, etc.). Nonmedical and 
indirect costs often make up significant shares of the total cost of illness. Total costs of 
a TB episode may be as high as nine tenths of annual household income (Wyss et al 
2001). However, the total costs as well as the contribution of different kinds of costs 
are not fully understood. Availability of free medical services, need for transport, and 
need (perceived or actual) for special diets are just a few of the factors that may 
influence household costs and their breakdown (Russell 2004). As seen above, 
ambulatory as compared to inpatient treatment may lead to substantial savings for the 
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provider side. For the patient side, the picture is more complicated. Russell (2004) 
noted that hospitalisation for different diseases caused very high costs in some 
countries, where fees were charged, in contrast to other countries providing inpatient 
health care for free. Benefits of hospitalisation in Russia, for example, are not restricted 
to free care, but include a kind of substitute for social services (Atun et al 2005a, Floyd 
et al 2006). Very little is known about factors that potentially determine the illness-
related costs faced by TB patients. Male sex, longer delay until start of treatment and 
most importantly clinic-based DOT (versus self-administered treatment) were the 
determinants of higher costs in an urban setting in Zambia (Aspler et al 2008). The 
determinants of costs in settings where self-administered treatment is not foreseen by 
the program are unknown. 
1.8.5. Affordability of care in Tajikistan 
As seen above, affordability is one of the components of access to care. Falkingham 
(2004) investigated the influence of out-of-pocket payments on access to medical care 
in Tajikistan based on the data of the Tajik Livings Standard Survey. Almost half of the 
respondents who had consulted a doctor in the last two weeks preceding the interview 
indicated they had paid for the consultation. Among those who felt they had needed 
medical care, a significant proportion did not obtain it. Exact figures for the total 
population are not given, but for women of age 65 or above, almost two thirds who felt 
they needed care did not seek such. Of those who did not seek care, about one third 
indicated they couldn’t afford to do so. Among the wealthiest quintile, this proportion 
was at about 24%, while it was around 42% among the poorest quintile. Falkingham 
(2003) studied changes in the access to maternal health care services. She found a 
significant decline in the utilisation of these services since independence of Tajikistan 
from the Soviet Union. Whether the decrease in utilisation of non-sex-specific health 
services has decreased similarly remained unstudied. It is conceivable that women 
suffered particularly from deteriorating access to health care. Studies on sex-differences 
in access to TB care in Central Asia are so far missing. The decade-long Soviet area, 
when gender equity was relatively high on the political agenda, has been followed by a 
period of nation-building and cultural return to more conservative values. To what 
extent access to medical care for women was affected, is poorly known. 
The distinction between formal and informal payments is not clear to many patients 
(Falkingham 2004). Moreover, there is a tradition in Central Asia and the Caucasus to 
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thank caregivers with gifts that may be in-kind or cash. More detailed investigations are 
needed to document the purpose of payments and gifts as well as the degree to which 
these are made voluntarily. The case of TB is special in terms of informal payments 
because the health system and the patients receive considerable external support 
targeted specifically to TB control. This includes free TB-drugs provided to the health 
system and food supplies for patients’ families. Information on household costs of a TB 
episode is lacking, and it is unclear, how these relate to the support patients receive and 
to funds available at the household level. Evidence on household costs is needed to 
better understand the financial barriers to access to health care. 
1.8.6. Acceptability of tuberculosis services 
Acceptability of services comprises several domains, including perceived competency 
of providers, aspects of interpersonal communication, and confidentiality of services 
(Obrist et al 2007, Aday & Andersen 1974). In different contexts, TB was linked to a 
strong stigma. Stigma often translates into the patients’ unwillingness to disclose their 
disease to others. In a study in Pakistan, Khan et al (2000) found that patients were very 
unwilling to disclose their TB to anyone outside the immediate family. The reasons 
given were fear from seclusion and social boycott. Especially young women were 
afraid they would face difficulties marrying or would be sent away by their husbands. 
The researchers hypothesised that the observed stigma is closely linked with the 
community’s belief that TB is incurable and go on saying: “which in the current 
circumstances of Pakistan is probably a reasonable perception.” The problem that a 
stigma poses for the success of detection and cure of TB cases is accentuated in 
Pakistan by a lack of patient confidentiality. In Orissa, India, 2% of all TB patients 
expressed anxiety of social isolation (DANTB 2002). Only 2% of men and 9% of 
women expressed concerns about disclosing their disease to their families and to other 
people in the village. This is low in relation to a high proportion of more than 60% of 
patients who were sceptical about the curability of TB. In a study in southern India, at 
least three quarters of people in the study community stated that TB patients would 
hide their disease (Atre et al 2004). Almost 50% of respondents in this study thought 
that heredity played a role in TB. Such misperceptions of the causes of TB may mean, 
that patients do not perceive a need for conventional medical care. Furthermore the 
perceived necessity to hide the disease may hamper the acceptability of medical 
facilities, subject to the confidentiality of services. 
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Even if not connected to a stigma, knowledge about TB may influence the decision to 
seek care and the choice of services. Studies in Peru and Brazil have found that 
typically patients consulted TB diagnostic facilities if they noticed weight loss, rather 
than chronic cough (Baldwin et al 2004, dos Santos et al 2005). Another symptom 
found to prompt earlier care seeking was haemoptysis (Lienhardt et al 2001), whereas 
similar studies did not find a link between level of education or literacy status and the 
delay in treatment (Lienhardt et al 2001, Dhingra 2002). 
1.8.7. Adherence to TB treatment 
Greene (2004) identified five general approaches to non-adherence in the literature. 
Greene summarises them with the terms (i) “decontextualised blaming of the patient”, 
(ii) discussion of “the intrapersonal psychologic structures” in certain types of patients, 
(iii) prediction of non-adherence based on demographic factors, (iv) “targeting cultural 
difference as the chief determinant of non-adherence”, and (v) “structural violence”. 
His own study from Bolivia shows that structural constraints do play a determining role 
in non-adherence. In the literature blaming the patient or discussing intrapersonal 
psychological structures of the patient, her or his ability to rationally assess and 
prioritise need for medical care relative to other perceived needs, took a prominent 
position (Greene 2004, Sumartojo 1993). Demographic variables of course are not 
proximate causes of adherence or access. The cultural identity of the patient again may 
influence the acceptability of medical services but cultural identity may also be an 
ultimate factor and correlate with socio-economic characteristics of the patient, which 
then determine another component of access to care, e.g. affordability of services. 
‘Structural violence’ comprises many aspects of the health system. These may include 
components of access to medical care like availability, accessibility, affordability, 
adequacy and acceptability. 
Khan et al (2000) also investigated determinants of treatment adherence. They 
concluded that their results showed no clear pattern to allow distinguishing between 
patients who completed or defaulted treatment. However, they also observed that 
patients often stopped working after TB had been diagnosed, and the data they present 
indicate that this was more common in non-adherers than in adherers. Stopping to work 
comprises high indirect costs and it can therefore be hypothesised, that patients who 
have to stop working because of direct consequences of the disease and factors 
associated to treatment delivery, have a higher probability of defaulting. 
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1.9. Hospitalisation for tuberculosis treatment 
The strong variation in hospitalisation rates for TB and in reasons for hospitalisation 
are probably linked to the lack of detailed recommendations on hospitalisation in the 
guidelines for NTPs (World Health Organisation 2003b), which leaves room for 
national programs to handle hospitalisation according to the national context. Perelman 
(2000) emphasised the tradition of hospitalising TB patients in Russia. He linked the 
need for hospitalisation to overcrowding at the patient’s home and to patient-side 
problems like alcoholism and antisocial behaviour (cf. section adherence). Much of this 
tradition of hospitalisation and its reasons supposedly apply also for other parts of the 
former Soviet Union, because these shared the same health system over decades and 
have inherited its structure at independence. However, there have been no systematic 
studies of the reasons for hospitalisation in other parts of the Soviet Union. 
A study in the Samara region of the Russian Federation found that the system of 
service remuneration gives perverse incentives to the providers (Atun et al 2005b). 
There was no performance-related element. Providers benefited from maximising the 
time patients were under supervision, from repeatedly admitting the same patients to 
hospital, and from increasing the number of investigations or surgical activities 
performed. Such inefficient use of resources can negatively affect access to care. On 
the other hand, hospitalisation of TB patients in Russia also fulfilled the role of social 
services (Atun et al 2005a). In Tajikistan, the lack of resources likely means that the 
health system cannot fulfil the same role of social services for TB patients as in Russia. 
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2. Objectives 
The overall goal of this thesis was to make a scientific contribution to the 
understanding of access to medical care for TB in Tajikistan. This was not seen in 
isolation but as a showcase for other medical services in Tajikistan and for TB services 
in other countries. A comprehensive set of factors was considered as potential 
determinants of access to medical care, including availability, accessibility, 
affordability, adequacy and acceptability of care. Based on the results of the first study, 
special attention was given to household costs of TB and their determinants and timing. 
The general and specific objectives of the individual studies presented in chapters 4 to 
10 were: 
1. To identify key factors for access to care for TB. 
1.1. To identify factors impeding or contributing to access to medical care for TB 
as perceived by community members, TB patients and health care providers. 
1.2. To determine the relative importance of factors pertinent to availability, 
accessibility, affordability, adequacy and acceptability for access to TB care. 
1.3. To assess the general population’s knowledge and awareness of TB and its 
symptoms. 
2. To investigate delay to TB treatment. 
2.1. To estimate the patient and health system delays experienced by patients in the 
TB program of Tajikistan. 
2.2. To describe typical health care seeking patterns including the quantification of 
the use of different diagnostic tests. 
2.3. To analyse statistical relationships between the extent of delay and different 
predictors related to the patient and to the organisation of health care delivery. 
3. To quantify the cost burden faced by TB patients. 
3.1. To quantify all direct and indirect material costs incurred by TB patients and 
their households in relation to TB disease. 
3.2. To compare the total costs of a TB episode with measures of income in 
Tajikistan. 
3.3. To identify the time periods when patients face peaks of high costs. 
3.4. To quantify the contribution of different line items to total direct costs. 
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4. To identify quantitative determinants of affordability of TB care. 
4.1. To identify patient and system factors associated with higher direct costs. 
4.2. To quantify the use of selected economic coping strategies. 
4.3. To identify patient and system factors associated with coping strategies that 
can potentially lead to impoverishment. 
5. To analyse factors associated with hospitalisation of TB patients. 
5.1. To identify factors associated with hospitalisation. 
5.2. To assess predictors of treatment success. 
6. To assess the performance and potential impact of a food distribution program 
for TB patients. 
6.1. To assess whether patients are aware of their entitlement to food supplements 
and receive them. 
6.2. To quantify the local market value of food supplements and any costs 
associated with them. 
7. To model the sensitivity of routine sputum smear microscopy. 
7.1. To model the sensitivity and specificity of sputum smear microscopy as carried 
out in peripheral laboratories under routine program conditions. 
7.2. To inform the policy discussion on reducing the requirement for TB diagnosis 
from three to two serial sputum smears. 
7.3. To provide evidence to program managers and providers about the 
performance of sputum smear examination in Tajikistan. 
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3. Study framework and overview 
3.1. Theoretical framework of access to care 
The present thesis investigated access to medical care on the example of tuberculosis in 
Tajikistan. This chapter presents the theoretical framework that guided our studies 
conceptually. The ethos behind our framework is the conviction that people who need 
medical care should be able to use it, i.e. should have access to care. We define access 
to care as the ability of people with an objectivistic need for medical care to utilise 
such. We make use of a conceptual framework of access that was developed in the 
frame of a program for malaria control, but with the goal of providing a theory of 
access to care more generally (Obrist et al 2007). This framework emphasises the link 
between access and livelihood insecurity and relates these to the wider context of health 
systems and the vulnerability context (Figure 3.1). According to this concept, access 
consists of five components: availability, accessibility, affordability, adequacy and 
acceptability, called the five A’s. The key factors comprised in each of the five A’s are 
summarised in table 3.1. While the concept includes the wider context of livelihoods, 
our analyses were concentrated around the access itself. 
 
Figure 3.1. Framework of access. Figure from Obrist et al 
(2007), adapted. 
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3.2. Concepts and types of illness-related costs 
We used a framework for the analysis of the economic costs of illness at the level of 
the household that was given by Russell (2004, Figure 3.2). Studies of costs of illness 
at the level of the patients’ households differ in terms of the types of costs they 
included (Russell 2004, McIntyre et al 2006). In our studies we have been guided by 
the rationale that all material and financial costs that are incurred due to the disease 
should be included. In other words, a causal relationship between disease and the 
incurred costs was the criterion to include a specific cost. This causal relationship could 
be indirect or only perceived. An example for a perceived causality could be special 
disease-related diets (termed ‘special foods’ by some authors, Attanayake et al 2000, 
Needham et al 2004), which are not necessarily evidence-based but for which patients 
spend money. Costs related to co-morbidities (e.g. medication for diabetes) were not 
included. 
 
Table 3.1. Theoretical framework for access to care: its five components and some 
of the factors entailed§ 
Component Factors* (and examples) 
Availability Presence of health care facilities in near or not-too-far region 
Presence of health care staff (doctors, specialists, nurses, etc) 
Presence of consumables in facility/pharmacy (drugs, vaccines, test 
kits, etc) 
Accessibility Geographical distance to facility 
Available transport infrastructure (road, means of transport) 
Affordability Patient’s ability to pay 
Medical direct costs (consultation fee, drug costs, cost of surgery, 
informal payments, etc) 
Non-medical direct costs (cost of transport, special diets, etc) 
Missed opportunities (lost income due to inability to work) 
Adequacy Convenient opening hours 
Appropriateness of organisation of health services 
Physical state and cleanliness of infrastructure 
Acceptability Match between local health beliefs and health services 
Match between socio-cultural values and health services 
Expected quality of care (perceived competency, friendliness of staff) 
Confidentiality of services 
Side-effects of treatment 
§ Following Obrist et al (2007), adapted. 
* Access to care is a very comprehensive concept and the factors listed here are not 
meant to be exhaustive. 
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Illness-related costs are classified into direct and indirect costs (Wyss et al 2001, 
Russell 2004, McIntyre et al 2006). Direct costs denote expenditure, also called out-of-
pocket payments, and indirect costs denote opportunity costs, like income that was 
foregone due to the patient’s inability to work (Table 3.2). Other household members 
may also forego income because they accompany the patient to the facility or spend 
time on patient care at home (Russell 2004, Wyss et al 2001); their lost income was 
also included. Where income was in-kind, like often in subsistence agriculture, we 
estimated its monetary value based on the local market value reported by the patient. 
However, immaterial indirect costs like the psychological distress or foregone 
education opportunities when children were unable to attend school were not included. 
 
Figure 3.2. Analytical framework for economic costs of illness. Boxes with grey 
background designate the areas covered in chapters 5 to 7 of this thesis. 
Direct costs are further broken down into medical and non-medical direct costs (Russell 
2004, McIntyre et al 2006). For the line items included in medical and non-medical 
costs, we generally followed Russell (2004). We completed single line items found in 
other studies (e.g. Wyss et al 2004) and adapted the apportioning of certain items. 
Medical costs included costs of diagnostic tests, consultation fees, drug costs, cost of 
surgery, hospitalisation fees and other services delivered by the formal health system 
(Table 3.2). Some studies included costs for traditional healers in medical costs. We 
adapted this approach in order to increase the focus of medical costs on allopathic 
medicine. Consequently, we included costs of traditional healers in non-medical costs. 
Non-medical costs also include ‘additional food costs’, which is sometimes termed 
‘special foods’ and comprises the costs for special food items that contribute to cure 
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according to local health beliefs (Russell 2004). These are food items that are not 
usually part of people’s diets during times of good health (or only in smaller amounts) 
and that may be expensive. In Tajikistan, these may be expected to correspond to 
concepts of ‘warm’ and ‘cold’ foods also found in South Asia (Khan et al 2000, 
Attanayake et al 2000, Pool 1987). The distinction between special foods and 
traditional home-remedies may sometimes be gradual only. The last item among non-
medical costs that requires explanation is ‘changes in housing’. This term summarises 
expenditures for furniture or amendments in the housing that are made to better 
accommodate the patient. 
Table 3.2. Classification of illness-related costs at the household level 
Type of cost Examples 
1. Direct costs  
1.1 Medical costs  
Diagnostic examination Radiography, blood count, sputum smear examination, any 
laboratory test 
Consultation fees Medical doctor fee, prescription fee 
Drugs Anti-TB drugs, vitamins, medication for cough 
Hospitalisation Admission fees, cleaning of ward, washing sheets 
Surgery Consumables and fees for surgical procedures 
Other medical services Any medical service or good that has to be paid for 
1.2 Non-medical costs  
Transport costs Transport to pharmacy, to traditional healer, to family 
doctor, etc. 
Additional food costs Illness-related diets 
Home-remedies Herbs or special kinds of meat (marmot, dog, etc) 
Traditional healer fees Monetary or in-kind fees paid to a traditional healer (tabib) 
Modifications to housing Changes aimed at better accommodating the patient 
  
2. Indirect costs  
Patient loss of income Cash or in-kind income foregone due to the inability to 
continue usual income-generating activities 
Caregiver loss of income Income foregone while taking care of patient or 
substituting his labour 
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3.3. Overview over studies conducted for the present thesis 
In the following, an overview of the studies conducted in the framework of this thesis is 
given. We present brief information on the main subject, the methodology and the 
study area. The studies are presented in the same sequence in more detail in the 
chapters 4 to 10. The format of these chapters varies to a certain extent because most of 
these chapters are manuscripts that have been submitted or already published and the 
manuscripts are presented in the format of the respective scientific journal. 
We had a close collaboration with Project Sino for this thesis and many of our results 
have also been summarised in project reports in order to provide an evidence-base for 
certain aspects of project implementation. Project Sino has been supporting the 
Ministry of Health of the Republic of Tajikistan since 2003 in the implementation of 
health sector reform strengthening primary care. Among many other activities, the 
project was providing support to introduce DOTS in its pilot districts by 2005 and to 
integrate DOTS services with primary care services. 
The first study conducted for this thesis used focus group discussions to explore access 
to medical care for TB. A comprehensive range of factors were considered and two 
methods were used to determine their relative importance as determinants of access to 
care. The study was conducted in the four pilot district of Project Sino (Figure 3.3). The 
results of this qualitative study guided the focus of subsequent studies. 
The second study was a questionnaire survey among registered TB patients 
concentrating on health care seeking and delay to start of anti-TB chemotherapy. It was 
conducted in twelve study districts purposefully chosen among districts with an 
established DOTS program to represent the typical range of conditions found in 
Tajikistan. A map showing these twelve districts can be found in the corresponding 
chapter (Figure 5.1) and is not duplicated here. Data collection for this study was 
conducted together with the data collection for the two studies on illness-related costs 
at the level of the patients’ households and for the study on food supplements. 
Consequently, the study area and the study sample of those studies were the same. The 
study on health care seeking and delay investigated common referral patterns and the 
use of diagnostic tests in order to identify aspects of the organisation of health services 
that influence access to care and consequently delay until the start of TB treatment. 
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Figure 3.3. Map of Tajikistan showing the four districts, where Project Sino is 
supporting health sector reform to strengthen primary care (black). 
The qualitative study had found that affordability was the most important component of 
access to TB services and guided the focus of the third and the fourth study. They 
quantified illness-related costs at the level of patients’ households (‘household costs’), 
their repartition over different time periods of TB treatment, and statistical predictors of 
higher household costs. The fourth study additionally looked into a selection of coping 
strategies that are most likely to incorporate risks for impoverishment. 
The fifth study looked at hospitalisation as a management measure for pulmonary TB. 
It used registry data from ten TB centres to analyse predictors of hospitalisation out of 
a set of eight independent variables. As a secondary outcome, treatment success was 
analysed using the same independent variables and additionally the binary factor 
hospitalisation. 
The sixth study assessed the performance and potential impact of a food distribution 
program for TB patients. Data collection for this study was conducted alongside the 
studies on delay and household costs. Only six of the twelve study districts of these 
studies had a food distribution program and hence this study encompassed six study 
districts. We looked at the patients’ awareness early in treatment about their eligibility 
for food supplements, at the number of food supplements patients had received towards 
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the end of treatment, at the monetary costs involved in receiving and picking up food 
supplements and at their local market value and thus contribution to the household 
economy. 
The seventh and last study of this thesis mathematically modelled the sensitivity and 
specificity of sputum smear examination based on registry data. Only limited data is 
available about the accuracy of this test under routine conditions – even though it is the 
most widely used diagnostic test for TB, one of the most devastating diseases in the 
world. This study was important not only in terms of a global perspective and the 
information on the internationally recommended first test for TB, but also from a local 
perspective: the previous studies had shown a link between under-use of sputum smear 
microscopy and access to care. 
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Abstract 
Background: Tuberculosis control is based on early detection and complete treatment 
of infectious cases. Consequently, it is important that tuberculosis suspects and patients 
can readily access medical care. The present study investigated determinants of access 
to DOTS services as identified by patients, health providers and community members 
in four districts in Tajikistan. 
Methods: Thirteen focus group discussions involving a total of 97 informants were 
conducted. Content analysis of discussions and a rating to quantify the relative 
importance of discussed factors were carried out. A conceptual framework for access to 
care guided the analysis. 
Results: Financial factors were considered the most important determinants of access 
to diagnosis and treatment of tuberculosis. Expenditure for drugs and consultations, for 
transport, and for special foods as well as lost income were identified as major barriers 
to treatment. Notably, out-of-pocket expenditures were emphasized more than lost 
income. Stigma, doubts about curability and low perceived quality of care were not 
seen to be significant determinants of access to care for tuberculosis. Community 
members were well aware of symptoms of tuberculosis and of medical services. 
Conclusions: Illness costs to households formed the main barrier to tuberculosis 
diagnosis and treatment. Medication and the provision of food to hospitalised patients 
are thought to cause high costs. Patients and community members attributed less 
importance to lost income than found in other studies. To improve access and 
ultimately adherence to tuberculosis treatment, effective mitigation strategies, e.g. food 
contributions or financial stimuli, need to be explored and implemented. 
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Background 
The difficulty in controlling the global tuberculosis (TB) epidemic has been attributed 
to “low access to a highly effective therapy”[1]. The factors determining access of TB 
cases to treatment remain poorly understood. This qualitative study was conducted to 
identify factors influencing access to diagnosis and treatment of TB in Tajikistan and to 
investigate their relative importance. Thereby it used a framework of ‘access to care’ 
developed in a malaria control program[2]. 
Even when TB control programmes offer chemotherapy free of charge, suspected cases 
often considerably delay seeking care[3] and defaulting from treatment is frequent. 
Irregular drug intake and default can lead to relapse which causes further transmission 
of TB and increases the risk of drug-resistance[4]. Some of the countries with the 
highest rates of drug-resistant TB are in Central Asia, making treatment adherence even 
more important in this region[5]. Jones et al[6] identified a list of requirements for 
treatment adherence, including that patients understand the implications of their illness, 
regard their health to be a high priority issue, can afford and access treatment and be 
able to tolerate the inconvenience of clinic visits, medication regimens, and possible 
side effects of drugs. These requirements show wide overlap with affordability, 
accessibility, acceptability and adequacy of services, which are core components of 
access to care[2]. The fifth component of access is availability. 
In many contexts, TB is linked to stigma[7-10]. Many communities perceive TB to be 
incurable[9-11]. For those patients believing their illness be the result of supernatural 
causes, common sense dictates that they would not utilise biomedical health care. 
However, in rural Haiti, providing home visits, incentive payments and food 
complements in addition to free treatment had a strong positive influence on adherence, 
whereas no influence of sorcery beliefs was found[12]. In urban Bolivia, Greene found 
that structural barriers including costs of treatment such as transport and radiography 
were more important determinants of adherence than socio-cultural factors[13]. 
Saunderson[14] was among the first to emphasize the literature’s neglect of costs to 
patients' households. At large, there are many factors that potentially influence access 
to care for TB – which ones are the actual determinants is debated. 
Tajikistan has seen the breakdown of the previously comprehensive health system. 
Health care workers are badly paid and poorly motivated. Often patients have to pay for 
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health services that are stipulated to be free of charge. Since independence from the 
former Soviet Union in 1991, utilisation rates of services have decreased and incidence 
of TB has increased by about 80%[15]. A recent study in Tajikistan suggested costs of 
care to influence access to medical care[16]. Among people who reported not seeking 
care for their health problem, one third – 24% among the wealthiest quintile and 42% 
among the poorest – stated that lack of money was the reason for not doing so. 
The National TB Programme of Tajikistan adopted the DOTS strategy in 2002 assisted 
by several international NGOs, including Project Sino funded by the Swiss Agency for 
Development and Cooperation, which supports the ongoing integration of TB services 
into primary care in the study districts. Hospitalisation rates are typically above 50%. 
Official data for 2006 indicated 79% DOTS coverage, 33% case detection and 84% 
treatment success in Tajikistan[15,17]. In most areas, DOTS was introduced during 
2005 and 2006. 
Methods 
Setting and study population 
The present study received ethical approval from the Ministry of Health of Tajikistan. 
It was conducted in the four pilot districts of Project Sino, which include two of the 
districts of Tajikistan where DOTS was introduced earliest. The four districts lie within 
two hours road travel from the capital Dushanbe in the west of this extremely poor 
country that has a per capita gross domestic product of $1’300 purchasing power 
parity[18]. Varzob district lies immediately north of the capital in the rocky Hissor 
mountains. Most people in Varzob district rely on livestock farming, others work in 
different sectors in the nearby capital. Danghara, Shahrinaw and Tursunzoda are partly 
mountainous, mostly rural districts with semi-urban centres. In the lowlands there is 
extensive cotton farming. DOTS implementation in these districts started in 2004 
(Danghara and Varzob) and October 2005 (Shahrinaw and Tursunzoda). TB laboratory 
services and treatment are available at DOTS facility in each district centre. Primary 
care facilities collect sputa or refer patients for diagnosis and provide treatment 
supervision. 
Thirteen focus group discussions (FGDs) were conducted in early 2006 to investigate a 
comprehensive range of factors influencing access to care for tuberculosis. Five FGDs 
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were conducted with community members, four with TB patients and four with health 
services providers to cover opinions and experiences of stakeholders involved in TB 
treatment. Respondents with different backgrounds were selected and stratification 
along different criteria were used in order to obtain more valid results (Table 4.1). 
Patients were identified through the TB patient registry. Information on treatment 
adherence was incomplete. At the time of invitation, patients were asked whether they 
had been forced to interrupt treatment at any time. Patients reporting irregular treatment 
intake were included in the same FGD as defaulters. The language of the FGDs was 
Tajik. Participants who preferred to speak in Uzbek or Russian were free to do so. The 
research team consisted of a moderator, a transcriber and two observers. FGDs with 
patients took place in the offices of Project Sino in Dushanbe in order to assure the 
confidentiality of their health status within their communities and to provide patients 
with an additional sense of independence and thus improve the veracity of their 
responses. 
Table 4.1. Eligibility criteria for the 13 focus group discussions, by respondent 
category 
Community members Patients Providers 
1) Women from small rural 
town 
2) Men from remote rural 
village 
3) Women from rural village 
4) Men from rural village 
5) Women from semi-urban 
centre 
1) Women in treatment 
2) Men in treatment  
3) Women and men after 
treatment success 
4) Defaulters and patients 
indicating irregular 
drug intake 
1) Family doctors from 
Danghara 
2) Nurses from Varzob  
3) Family doctors from 
Shahrinaw and 
Tursunzoda 
4) TB specialists from 
all four districts 
 
Focus Group Discussions 
The FGDs covered the following topics: (i) symptoms and causes of TB, (ii) perceived 
appropriateness of treatment, and (iii) factors determining the communities’ ability to 
receive diagnosis and (iv) to complete treatment for TB. At the beginning of the FGDs 
with community members, participants were asked about diseases causing cough, 
without hint to TB. Then subsequently participants were asked about symptoms like 
sputum production, slight fever, fatigue, weight loss, night sweats and chills. After the 
discussion on diseases causing cough and the other named symptoms, the focus on TB 
was disclosed to the participants. In FGDs with patients and providers, the focus on TB 
was known from the beginning. 
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After the discussion, participants of community and patient FGDs were asked to rank 
the factors preventing "people from receiving full medical treatment" by importance in 
a participatory approach (‘rating’), using chickpeas to rank the perceived importance of 
different factors. No rating was conducted among providers, because it was felt to 
interfere with local concepts of professionalism. For the rating, all factors named 
during the discussion on access to care were listed. The following factors were 
suggested as potential relevant factors by the research team in case they were not 
spontaneously mentioned: attitude of providers, insufficient confidentiality of medical 
services, stigma of TB, attitude of other community members towards TB patients and 
lost income. Each participant was asked to allocate six, three and one chickpea to the 
three most important factors. This was done one by one without other participants 
being present during the ballot. 
Table 4.2. Analytical framework used in this study for factors influencing access 
to care† 
Main 
categories 
Affordability Acceptability Accessibility* Adequacy* 
Sub-
categories 
(and 
examples) 
 Missed opportu-
nities (lost 
income due to 
inability to work) 
 Medical costs 
(costs for diag-
nostic tests, 
drugs, etc.) 
 Non-medical 
costs (transporta-
tion costs, 
expenditure for 
disease-related 
diets, etc.) 
 Side effects of 
treatment 
 Perceived quality of 
care (technical 
specialisation of 
providers) 
 Attitude of provid-
ers (friendliness of 
doctors) 
 Lack of confiden-
tiality (other 
community 
members find out 
about TB patient) 
 Health beliefs (lack 
of belief in curabil-
ity) 
 Distance to 
facility (effort to 
cover distance, 
time needed) 
 Organisa-
tional 
appropriate-
ness of 
services 
 Physical 
state and 
cleanliness 
of facilities 
 Convenient 
opening 
hours 
†Adapted from reference 2. 
*In the participatory approach, factors relating to accessibility and adequacy were not 
regarded as important (no chickpeas allocated) and the results are presented without 
these factors. 
All FGDs were recorded on audio tape and transcribed to English. The principal 
researcher listened to the whole recording double-checking the transcription. Then 
transcriptions were read repeatedly and codes added in TAMS Analyzer (version 
3.31b2pt, Matthew Weinstein, 2005). 
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Analytical framework 
We used a previously described analytical framework of access to care in contexts of 
livelihood insecurity[2]. Our analysis focussed on access and did no go into details of 
livelihoods. Further, availability was not covered specifically, as TB services were 
known to be available (see above). The resulting adapted analytical framework is 
presented in table 4.2. Statements were grouped into three categories: factors relating to 
accessibility, affordability, acceptability (including stigma, perceived appropriateness 
of care, perceived quality of care) and adequacy. The number of statements for the four 
categories were summed up and expressed as a percentage along the three respondent 
groups. There were hardly any statements relating to adequacy and therefore only the 
other three categories are presented in the results. 
Results of the rating were analysed by calculating the proportion of chickpeas allocated 
to each factor, whereby each FGD was equally weighted, independent of the number of 
participants. The four categories from the content analysis were further divided into 
twelve sub-categories (Table 4.2). ‘Poor living conditions’ and ‘late presentation to the 
doctor’, each mentioned in one FGD, were excluded from the analysis as no 
meaningful relation to the topic of investigation could be established for the first and as 
the second is rather a consequence of barriers to access than a barrier by itself. 
Results 
FGDs consisted of five to 12 participants. 43 community members participated in the 
community FGDs, 21 women and 22 men with a mean age of 42 years. Among 
providers, 15 doctors, nine nurses and seven TB specialists participated. Their mean 
age was 45 years. Of 23 patients, eight were women and 15 were men. Participants 
were mainly from rural areas with about one fourth coming from semi-urban areas. 
First the results from the discussion on basic characteristics of TB and on barriers to 
treatment are presented, second the relative importance of identified factors from the 
rating and third the composition of illness costs to households from the rating. The 
topics that came up in the discussion on access to diagnosis and on access to treatment 
were very much the same. Participants also explicitly stated that the same factors were 
important at both times. Consequently the results are presented jointly. Further, the 
composition of illness costs was discussed and these results are presented at the end. 
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Upon presentation of symptoms of TB, community members mentioned a number of 
respiratory diseases, most prominently asthma, influenza and bronchitis. Community 
members also mentioned TB soon in all FGDs. Overall, knowledge of symptoms was 
accurate. Community members were able to identify medical facilities providing TB 
treatment in their surroundings. 
Knowledge about causes of TB was limited. In particular the belief that TB was 
inherited and normally incurable was found commonly among community members 
and also expressed by one patient and one provider. These beliefs were closely linked 
to the stigmatisation of the illness. The stigma was magnified by the fact that TB 
services are offered in separate facilities. Despite the misunderstandings on causes of 
TB and prospects of care, all respondent groups deemed medical treatment necessary 
and community members stated that they would seek medical care in case of illness. 
Community members showed themselves well aware of the availability of TB services 
at the DOTS centres. Overall it was revealed that due to the difficulties associated with 
accessing medical care, patients tended to delay presenting until their health status had 
become severe – despite community members being aware of better prospects of cure 
at earlier presentation to care. 
Respondents in all FGDs agreed that financial factors were the strongest determinants 
of access to care and the patient’s ability to take the full treatment, i.e. adherence. On 
the question, why people with TB do not get treatment, a woman (teacher, 47 years old) 
from Varzob town said: "No money, no treatment – money plays a great role." A 
general practitioner (40 years) from Danghara answered: "First, because of the financial 
situation, because of the funds." Other possible reasons were not perceived to be 
equally important. Although stigma of TB was acknowledged, most participants 
emphasized it would not prevent patients visiting medical facilities. Side-effects of 
treatment were experienced by some participating patients, but were not mentioned 
very often and were considered important by a small minority only. 
The perceived higher importance of economic factors relative to acceptability and 
accessibility of services was reflected in the number of statements among all 
respondent groups (Figure 4.1). Factors relating to adequacy of services were 
mentioned even less often and are not presented here. Notably, factors relating to 
acceptability of services were mentioned least often among patients. Financial factors 
included all direct costs and lost income. Geographical factors included the effort for 
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the patient to travel and time spent travelling. It did not include transport costs and 
statements linking travel time to money. 
Community members allocated 12%, 62% and 20% of chickpeas to the categories 
‘missed opportunities’, ‘medical expenditure’ and ‘non-medical expenditure’ 
respectively (Figure 4.2). Patients allocated 21%, 21% and 37% of chickpeas to the 
same factors. Thus a total of 94% and 78% of chickpeas respectively were allocated to 
financial factors. Factors related to acceptability unified only 11% and 6% of chickpeas 
in patient and community FGDs respectively, despite the moderator carefully probing 
for and explaining rational ways of action of these factors. 
 
Figure 4.1. Frequency of statements referring to three components of access to 
care. 
 
Figure 4.2. Relative importance of different barriers to tuberculosis treatment, 
measured by the proportion of chickpeas allocated by participants of FGDs. 
Costs mentioned in the FGDs can be grouped into six categories: diagnosis, drugs and 
consultation, hospitalisation, transport, increased expenditure for food and lost income. 
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Diagnostic expenditure was seen by patients as well as community members to be less 
important with the exception of radiography, which was considered expensive by 
patients and community members. Cost of drugs and consultation were identified as 
important barriers by patients and especially by community members (Figure 4.3). 
Three patients reported they were asked to pay for the TB drugs. For the majority of 
patients, ‘cost of drugs’ stands for symptomatic treatment, like vitamin injections or 
intravenous rehydration. Admission to hospital has received little attention, probably 
because there is no admission fee. Admission is however linked to a range of services 
that have to be paid for, including cleaning and disinfection with UV light. Expenditure 
for transport and increased expenditure for food were also closely associated with 
hospitalisation. Food for hospitalised patients has to be provided by caregivers such as 
family members leading to higher food-related expenditure during hospitalisation. 
Participants of the FGDs did not always conceptually separate the costs of travel for 
food provision from the cost of the food itself. Patients and community members 
mentioned increased expenditure for food mainly in connection with hospitalisation. 
 
Figure 4.3. Relative importance of financial factors regarding access to 
TB services, measured by the proportion of chickpeas allocated by 
participants of FGDs. 
Participants regarded time constraints and missed opportunities as less important than 
direct costs: "It's not about time, but she needs to spend money. She cannot find enough 
funds to buy drugs", a rural woman (farmer, 47 years) stated. Missed opportunities, 
although defined broadly (including ‘household expenditure’, a factor expressing 
difficulties to cover the usual expenditures of the household and the concurrent illness-
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related costs), received only 18% of chickpeas on average (Figure 4.4). The higher 
importance attributed to lost income by patients relative to community members was 
explained with the long duration of TB treatment, of which community members were 
only partially aware. 
 
Figure 4.4. Relative importance 
of direct versus indirect costs, 
measured by the proportion of 
chickpeas allocated by 
participants of FGDs. 
 
Discussion 
While several studies showed that patients face costs even where TB drugs are 
stipulated to be free of charge[19-21], few previous studies have investigated the 
relative importance of financial versus other barriers to TB care. We investigated the 
influence of various health system and household-related factors on access to care for 
TB in Tajikistan. Community members, patients and providers agreed that illness costs 
to households determine access to diagnosis and treatment to a large extent and deemed 
quality of care, stigma and other factors less important. 
The importance of financial factors is amplified for community members by their lack 
of awareness about anti-mycobacterial therapy being offered free of charge. This is 
likely to influence their health care seeking. The predominance of financial factors 
corresponds well to the results of the small number of previous studies investigating the 
importance of financial and a wide range of other factors[12-13]. To our knowledge, 
this is the first study to demonstrate that illness-related costs are experienced by a broad 
range of stakeholders including health care providers as the major determinant of 
access to TB treatment. 
Limitations of this study include the small sample size, possible reporting bias and the 
lack of quantification of illness-related costs. Reporting bias, however, should be 
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reduced in the confidential participatory approach. The high consistency between the 
open discussion and the participatory approach lead us to believe that reporting bias 
was limited. At the time of study implementation, DOTS was still new to two of the 
study districts. Further improvements may have happened since then. For the analysis 
of the participatory approach, the factors ‘poor living conditions’ and ‘late presentation 
to a doctor’ were excluded. Retaining these factors would not have changed the results 
and conclusions. ‘Poor living conditions’ relates to economic difficulties and would 
have reinforced the result that affordability is the key aspect of access to TB treatment 
– if anything. It should be kept in mind, that components of access to care are 
interrelated. For example, improvements in the quality and reliability of food provided 
at the hospital would reduce the need for patients’ relatives to travel on a daily basis to 
bring meals to hospitalised patients. 
Among different cost items, expenditure for drugs and consultation was deemed most 
important, especially by community members. The high importance of expenditure for 
drugs and consultation corresponds well with a study from Thailand, which also found 
that drugs caused the highest expenditures during TB treatment[21]. The lower 
importance attributed to cost of drugs by patients relative to community members may 
indicate that most patients received treatment for free – contrary to the experience of 
community members with other treatments. However, almost all patients receive and 
pay for additional, symptomatic medication (like vitamin injections, intravenous 
rehydration). Missed opportunities including lost income were perceived as important 
but far less important than suggested in the literature, where estimates reach from 69% 
to 95% of total costs[14,22-24]. This result may be linked to the qualitative method 
insofar as health care users see very directly when they spend money, but less directly 
that they forego income. The dominance of direct costs was more striking in FGDs 
amongst community members than amongst patients. Many patients are hospitalised 
for a long time and providers often advise them to abandon their current job. 
Nonetheless, patients perceived direct costs (the sum of expenditures) to be a more 
important barrier to TB treatment than lost income. 
Conclusions 
For TB control to be successful and Millenium Development Goals to be reached in 
Tajikistan and many other countries, financial barriers to TB treatment have to be 
considered by TB control programs. As long as people’s immediate concerns are not 
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addressed it is difficult to increase case detection, adherence and treatment success 
rates. Possible ways to ease the financial hardship of TB to affected households include 
refunding travel costs, financial stimuli and – as is already being done in Tajikistan – 
food complements[5,12,25-27]. 
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Abstract 
Background: Tajikistan has the highest incidence rate of tuberculosis (TB) in Central 
Asia. Its health system still bears many features from Soviet times and is under-funded. 
Affordability is a major barrier to health care. Little is known about health care seeking 
of TB patients in post-Soviet countries and their delay until the start of TB therapy. The 
low estimated case detection rate in Tajikistan suggests major problems with access to 
care and consequently long delays are likely. 
Methods: The study investigated extent and determinants of patient and health system 
delays for TB. A questionnaire was administered to a cohort of TB patients in twelve 
study districts representing a wide range of conditions found in Tajikistan. Common 
patterns of health care seeking were analysed. Cox proportional hazards models using 
eight predictor variables, including characteristics of health services delivery, were 
built to identify determinants of patient and health system delays. 
Results: Two-hundred-and-four TB patients were interviewed. A common pattern in 
treatment-seeking was visiting a specialised TB facility at some stage. Typical delays 
until start of TB therapy were moderate and did not confirm the expectation of long 
delays. Median patient, health system and total delays to TB treatment were 21.5, 16 
and 52 days, respectively. None of the investigated predictors was significantly 
associated with patient delay. The type of facility, where patients made their first 
contact with the health system, was the main determinant of health system delay 
(p<0.00005). We show for the first time that patients who had fallen ill and first 
presented to health care in Russia had the longest delays. Those who first presented to 
peripheral primary care facilities also had relatively long delays. 
Conclusions: While overall delays were moderate, further improvement is needed for 
different subgroups. An international referral system between Russia and Tajikistan to 
reduce delays of Tajik migrants who develop active TB in Russia is urgently needed 
and would benefit both countries. Within Tajikistan, diagnostic pathways for patients in 
the periphery should be shortened. To achieve this, strengthening of sputum smear 
examination possibly including collection of sputa at peripheral primary care facilities 
may be needed.  
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Background 
The tuberculosis (TB) incidence rate in Tajikistan is estimated at 231 cases per 100’000 
population in 2007[1]. The case detection rate ranges from 32% for sputum smear 
positive cases to 39% for all cases. While the incidence estimate from the national TB 
control program is slightly lower (160 – 180 cases per 100’000), it is clear that the TB 
epidemic is ravaging. Integration of the vertical TB program rooted in the Soviet 
tradition with primary care is not yet complete. Historically, TB diagnosis and 
treatment was the exclusive task of specialised TB facilities and providers. The DOTS 
strategy was introduced in two pilot districts in 2002 and by the end of 2007 has 
reached 100% coverage of Tajikistan. Under DOTS, primary care providers also have 
the task of diagnosing and treating TB. Despite insufficient funding, the health system 
has been latching onto a dense network of facilities with different levels of 
specialisation inherited from Soviet times (Table 5.1). Real government expenditure for 
health was less than US$2 per capita in Tajikistan in 2003[2]. Health care workers are 
poorly paid and informal payments are common[2-3]. Out-of-pocket payments are an 
important barrier to access health care services[4]. The policy in Tajikistan is to 
provide anti-TB chemotherapy free of charge. Currently, health reform is ongoing in 
order to strengthen primary care under the name of Family Medicine[3]. 
It is estimated that up to a fifth of the population of Tajikistan is working abroad, 
mainly in Russia, where Tajik migrant workers are very vulnerable[5]. Albeit labour 
migration has recently decreased due to the current economic crisis and the loss of job 
opportunities in Russia, remittances from labour migration are likely to remain an 
important component of the Tajik economy. 
TB control in low-income countries relies primarily on treatment of active cases. A 
dose-response relationship has been found between the delay to TB treatment and the 
transmission to household members[6]. Consequently, prompt start of treatment is of 
utmost importance. Passive case finding requires that patients present to a health care 
facility and that health providers take appropriate measures. Repeated referrals that do 
not result in a diagnosis and effective treatment can frustrate patients, leading to 
delayed or missed diagnoses. Storla et al[7] reviewed studies on delay to tuberculosis 
treatment–defined as the period from onset of symptoms until the start of treatment. 
They found that many factors can influence delay and that the same factor could lead to 
shorter or longer delays in different settings. The type of the first health care provider 
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chosen often influenced delay with findings relatively consistent among studies: 
patients who first visited a traditional healer, private provider, or a low-level 
government health facility had longer delays[8-16]. Poverty and rural residence were 
almost invariably associated with longer delays[7]. Factors that often led to longer but 
sometimes also to shorter delays were female sex and old age[7]. Despite the specific 
traditions of TB control in the former Soviet Union (FSU), no studies on the 
relationship between health services delivery and delay in a post-Soviet country were 
found in the scientific literature. The only study on delay from the FSU concentrated on 
stigma and patient delay in Russia[17]. Investigating delay to TB treatment in the FSU 
may contribute to the understanding of the devastating TB epidemic in this region. 
Table 5.1. Characteristics of facilities in the Tajik health system§ 
Facility type Specialisation 
of health 
worker† 
Hospital 
beds 
Description 
Medical House Nurse No Facility serving villages without a Rural 
Health Centre. Together with the latter 
forms the peripheral primary care. Basic 
services from a nurse or a trained health 
worker. 
Rural Health 
Centre 
Generalist/ 
family doctor 
No* Facility serving mid-sized and larger 
villages. Stands at the centre of Family 
Medicine and thus primary care. One or 
more family doctors and a number of 
nurses. 
Polyclinic Specialist 
doctor 
No Facility found in district centres and 
larger towns. Specialist doctors provide 
ambulatory services. 
Central District 
Hospital 
Specialist 
doctor 
Yes Found in district centres. Specialist 
doctors provide in- and out-patient 
services. Usually contains an 
ambulatory functioning like a Rural 
Health Centre. 
District TB 
facility (includ-
ing TB 
hospitals) 
TB specialist Partially Usually in the district centre. Often 
more than one in large districts. Part of 
the historical vertical structure providing 
care for TB exclusively. 
Republican 
Hospital 
Specialist 
doctor 
Yes Tertiary referral centres providing the 
most specialised services available. 
Private clinic Varying Varying Exist only in large towns, mainly in the 
capital. 
§This list is by no means complete, but contains the facilities of relevance to this study. 
†This column shows the highest professional specialisation that is usually found at 
facilities of the respective type. 
*Some Rural Health Centres are historically derived from rural hospitals with beds and 
in a transitional period may have hospital beds. 
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The objective of the present study was to describe common health care seeking 
behaviours of new pulmonary TB patients in Tajikistan and to identify determinants of 
delay based on the following explanatory variables: sex, age, rural versus urban 
residence, district, durable assets, labour migration to Russia, belief in curability of TB, 
use of self-treatment, sputum smear result, and the type of facility first visited. 
Methods 
Study population 
As DOTS expansion was under way in Tajikistan and in order to produce meaningful 
evidence for the future, we included only districts with an established DOTS program 
(started in July 2006 at the latest) in the study. Two regions were excluded because 
they were accessible only by air at the time of the study, Badakhshan and Sughd. 
Among the 24 remaining districts (‘rayons’), twelve were purposefully selected to 
represent urban, rural, lowland and mountainous settings (Figure 5.1). 
Table 5.2. Reasons for drop-out 
Reason Number of cases (% of drop-outs) 
Wrong or insufficient address 18   (23) 
Not found at home or in hospital when visited 17   (22) 
Died   5     (6) 
Initial defaulter   3     (4) 
Already in continuation phase when visited 25   (32) 
Did not consent 10   (13) 
Total 78 (100) 
 
Questionnaire and Interviews 
All patients who fulfilled the inclusion criteria and who were registered in the twelve 
study districts were recruited into the study. Our inclusion criteria were: enrolled for 
TB treatment in the period 1 December 2006 to 31 March 2007, new pulmonary 
tuberculosis case (sputum smear positive or negative) and at least 15 years old. Data for 
this study were collected alongside a study on household costs of an episode of TB[18]. 
The latter study included two interviews with each patient. For the present study, only 
data from the first interview were analysed. Patients were visited in hospital or at their 
homes during the intensive phase of treatment, written informed consent was obtained 
and a trained interviewer administered a questionnaire. The questionnaire included 
detailed questions about the onset of symptoms, health care seeking behaviour 
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(including traditional healers and self-treatment), the timing of health care seeking 
steps, diagnostic investigations that were conducted and household assets. Onset of 
symptoms was self-reported and concerned any symptoms likely to be due to TB, most 
importantly cough. Patient delay was defined as the period from onset of symptoms 
until the first visit to a formal health care provider. Formal health care providers 
included all the facilities listed in table 5.1, but not traditional healers nor pharmacies, 
as they are not allowed to diagnose and treat patients in the Tajik health system. Health 
system delay was defined as the time from the first visit to a formal health care 
provider to the start of treatment. 
Interviewers were trained during a fortnight before conducting interviews on their own 
and were supervised at least twice per month through joint interviews with the main 
researcher. Specific emphasis was given to support the patients in their recall efforts, 
including the use of a calendar of locally important events. Data were entered in 
FileMaker (version 8.0v1, FileMaker Inc, USA, 1984-2005). 
Data Analysis 
All analyses were conducted in Stata IC/10.1 for Macintosh (Stata Corporation, USA, 
1985-2008). We carried out a principal component analysis on 15 household asset 
variables and three housing characteristics variables to construct a wealth index using a 
well established and validated method[19-20]. The wealth index was used to assign 
patients to quintiles of socio-economic status (SES). 
For each patient, we listed every health care seeking step and identified common 
patterns in the history of health care seeking up to the start of anti-TB chemotherapy. 
Particular attention was given to the timing and the place of the sputum smear 
examination. 
In order to investigate delay, we built Cox proportional hazards models with delay as 
time-to-event. Two separate models were built for patient and system delay, because 
predictor variables are likely to differ. Sex, age (categorised into four groups), 
residence, SES quintiles, district, and labour migration were included in both models. 
Belief in curability of TB and use of self-treatment were included only in the model on 
patient delay. Sputum smear status and the type of facility visited in first instance were 
included only in the model for system delay. Knowledge of symptoms was not 
included, as the encounters with health care professionals could change this variable 
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between the times when it acts (before the first visit to a formal provider) and when it is 
measured (during treatment). We selected the best model by subsequently excluding 
factors with p>0.2 in the likelihood-ratio test from the full model, until no more factors 
could be excluded. The respective univariate models were also built and the hazards 
ratios of factors were compared between univariate and multivariate models in order to 
investigate potential confounding. The present study has received approval from the 
Ministry of Health of the Republic of Tajikistan in a memorandum of understanding 
signed 18th October 2006. 
 
Figure 5.1. Location of study districts among all districts with a DOTS program in 
July 2006 in Tajikistan. District codes: 1=Tursunzoda, 2=Shahrinaw, 3=Hissor, 
4=Varzob, 5=Rudaki, 6=Danghara, 7=Qurghonteppa, 8=Vakhsh, 9=Farkhor, 10=Vose, 
11=Muminobod, 12=Shurobod. 
 
Results 
Study population and health care seeking 
The study identified 282 eligible patients, of whom 78 dropped out (Table 5.2) and 204 
were interviewed (Table 5.3). The patients who dropped out were virtually identical to 
included patients in terms of the proportions of smear-positive (60%in both cases) and 
male patients (54% versus 56%), but differed somewhat in their age-distribution and in 
terms of residence. The proportion of patients who were at least 45 years old was 36% 
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among dropouts versus 16% amongst the study sample. The proportion of rural patients 
was 79% versus 90%. 
Self-treatment was used by 64 patients (31%) before the start of anti-TB chemotherapy. 
A large variety of self-treatments were used, ranging from honey and different herbs 
over meat and fat of boar or dog to opium and allopathic medicines. Self-treatment was 
used both before and after the first visit to a formal health care provider. Only one 
patient (0.5%) reported having visited a traditional healer before the first visit to a 
formal health care provider and four more patients did so after such visit. 
Table 5.3. Demographic characteristics of study sample 
 Women Men Total 
Profession  n  (%)  n  (%)  n  (%) 
Unemployed   9 (10) 20 (18) 29 (14) 
Student   4   (4) 12 (11) 16   (8) 
Housewife 52 (58)   0   (0) 52 (25) 
Retiree   5   (6)   2   (2)   7   (3) 
Employee in industry   1   (1)   7   (6)   8   (4) 
Employee in private service   0   (0)   2   (2)   2   (1) 
Owner of business   0   (0)   0   (0)   0   (0) 
Police   0   (0)   3   (3)   3   (1) 
Health Care Worker   1   (1)   1   (1)   2   (1) 
Civil service (other than 
police and health) 
  3   (3)   5   (4)   8   (4) 
Petty Trader   3   (3) 19 (17) 22 (11) 
Labour Migration to Russia   1   (1) 30 (26) 30 (15) 
Farmer 11 (12) 13 (11) 24 (12) 
Total  90 (100) 114 (100) 204 (100) 
    
Age    
15-24y 34 (38) 44 (39) 78 (38) 
25-34y 23 (26) 40 (35) 63 (31) 
35-44y 16 (18) 14 (12) 30 (15) 
45y and older (max 72y) 17 (19) 16 (14) 33 (16) 
Total   90 (100)  114 (100)  204 (100) 
    
Residence    
Rural 79 (88) 105 (92) 184 (90) 
Semi- or Peri-urban   3   (3)     8   (7)   11   (5) 
Urban   8   (9)     1   (1)     9   (4) 
Total  90 (100) 114 (100) 204 (100) 
 
The first formal health care facility approached was a Rural Health Centre for 36 
patients (18%), a central district hospital for 39 patients (19%) and the district TB 
facility for 41 (20%) patients (Table 5.4). None of the study subjects visited a private 
clinic. Each facility that was visited was visited approximately twice on average (Table 
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5.4, right-hand column). Patients made 4.8 (±s.e. 0.17) visits to formal health care 
facilities on average before anti-TB chemotherapy was started. It is noteworthy that the 
district TB facilities were visited at some stage before initiation of anti-TB 
chemotherapy by a large majority (86%) of patients. Of the 28 patients who had not 
visited their district TB facility, 15 lived in Danghara district and all 15 had visited the 
Central District Hospital. In Danghara there was no separate TB facility as it had 
already been integrated in the Central District Hospital. 
Table 5.4. Health care facility visited by TB patients 
 
#patients visiting 
facility in first 
instance 
mean #visits 
(all patients) 
 
#visits among 
patients who 
visited† 
Medical house   22 (10.8%) 0.23 1.88 
Rural Health Centre   36 (17.7%) 0.45 2.04 
Polyclinic   17   (8.3%) 0.28 2.19 
Private clinic     0   (0.0%) 0.00 0.00 
Central District Hospital   39 (19.1%) 0.83 1.77 
Republican Hospital   41 (20.1%) 0.53 1.96 
District TB facility   15   (7.4%) 1.86 2.16 
Health facility in Russia   20   (9.8%) 0.25 2.60 
Other facility*   14   (6.9%) 0.39 1.65 
Sum 204 (100%) 4.83 N/A 
†Mean number of visits among those patients who visited the respective facility. 
*Including a health care facility reserved to staff of a large industrial company and 
Ministry of Defence facilities. 
 
Table 5.5. Results of the multivariate Cox proportional hazards model on patient 
delay (n=168) 
Factor Hazards Ratio§ Lb95%CI† Ub95%CI° p-value 
Male sex* 1.000 NA/ NA/ NA/ 
Female sex 0.745 0.523 1.061 0.103 
     
SES quintile NA NA NA 0.132¶ 
SES quintile 1* 1.000 NA NA NA 
SES quintile 2 0.661 0.409 1.067 0.090 
SES quintile 3 1.045 0.645 1.694 0.859 
SES quintile 4 0.614 0.365 1.032 0.065 
SES quintile 5 0.712 0.432 1.174 0.183 
§A hazards ratio >1 means a shorter delay, a hazards ratio <1 points to a longer delay 
relative to the comparison group. 
†Lb95%CI=Lower boundary of 95%-confidence interval 
°Ub95%CI=Upper boundary of 95%-confidence interval 
*Comparison group 
¶Based on log-likelihood ratio test 
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Delay 
The median patient delay was 21.5 days (range: 0 to 410 days; mean: 45.7 days). 
Thirty-six patients were excluded from the analysis of patient delay, because they 
reported either no symptoms, a chronic pulmonary condition, or because they were 
unable to assign at least an approximate date to both the onset of cough and the first 
visit to a health care provider. The median reported system delay was 16.0 days (0 to 
339; 42.2). One patient was excluded from the analysis of system delay because he 
could not assign a date to the first visit to a formal provider. The median total delay 
from onset of cough until start of anti-TB chemotherapy was 53 days (2 to 542; 81.8). 
Note that mean delays are not additive because of the 36 patients excluded from 
analysis of patient delay, but not system delay. 
Determinants of Delay 
None of the factors included in the model on patient delay proved significant. Sex 
(hazards ratio women to men 0.745, p=0.103) and SES quintile (p=0.132) were retained 
in the final model (Table 5.5). The final model on system delay included the factors 
‘first facility’ and ‘district’ (In order to check for potential confounding, the 16 
univariate models that are relevant to the above two multivariate models were also 
computed. The univariate models on patient delay showed consistent results with all 
hazards ratios in the same direction and in a similar range (Table 5.7). Among the 
univariate models on health system delay (Table 5.8), the factor ‘labour migration’ 
showed a strong association in the univariate model (hazards ratio 0.563, p=0.006) but 
showed no significant relationship (at the p=0.2 level) in the multivariate model and 
was consequently excluded. 
Table 5.6). The proportional hazards assumption was not violated (based on Schoenfeld 
residuals, p=0.91). There was a striking relationship between first visiting a district TB 
specialist and system delay: the median was six days versus 23 days for all other 
facilities combined. Also, visiting first a Central District Hospital was associated with a 
short system delay. Visiting first a Medical House, Rural Health Centre, Polyclinic or a 
facility in Russia was associated with longer system delays. Patients who had first 
visited a health facility in Russia had the longest system delays of all. It was found that 
most patients were advised at the health facility in Russia to travel to Tajikistan for 
treatment – often already with a diagnosis or at least suspicion of TB. Several patients 
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reported that the Russian health system made no treatment available to them. 
In order to check for potential confounding, the 16 univariate models that are relevant 
to the above two multivariate models were also computed. The univariate models on 
patient delay showed consistent results with all hazards ratios in the same direction and 
in a similar range (Table 5.7). Among the univariate models on health system delay 
(Table 5.8), the factor ‘labour migration’ showed a strong association in the univariate 
model (hazards ratio 0.563, p=0.006) but showed no significant relationship (at the 
p=0.2 level) in the multivariate model and was consequently excluded. 
Table 5.6. Results of the multivariate Cox proportional hazards model on health 
system delay (n=203) 
Factor Hazards Ratio§ Lb95%CI† Ub95%CI° p-value 
District NA NA NA 0.0191¶ 
Danghara* 1.000 NA NA N/A 
Farkhor 0.917 0.490 1.716 0.786 
Hissor 1.243 0.639 2.417 0.522 
Muminobod 0.412 0.208 0.817 0.011 
Qurghonteppa 1.502 0.623 3.623 0.365 
Rudaki 1.516 0.837 2.744 0.170 
Shahrinaw 1.293 0.291 5.738 0.735 
Shurobod 1.335 0.600 2.968 0.479 
Tursunzoda 0.966 0.509 1.835 0.916 
Vakhsh 1.462 0.769 2.781 0.247 
Varzob 0.953 0.334 2.720 0.928 
Vose 0.879 0.488 1.584 0.669 
     
First facility NA NA NA <0.00005¶ 
District TB facility* 1.000 NA NA NA 
Medical House 0.325 0.183 0.580 <0.0005 
Rural Health Centre 0.418 0.255 0.688 0.001 
Polyclinic 0.409 0.216 0.773 0.006 
Central District Hospital 0.704 0.435 1.136 0.151 
Republican Hospital 0.646 0.341 1.226 0.181 
Health facility in Russia 0.212 0.117 0.383 <0.0005 
Other facility‡ 0.365 0.185 0.721 0.004 
§A hazards ratio >1 means a shorter delay, a hazards ratio <1 points to a longer delay 
relative to the comparison group. 
†Lb95%CI=Lower boundary of 95%-confidence interval 
°Ub95%CI=Upper boundary of 95%-confidence interval 
¶Based on log-likelihood ratio test 
*Comparison group 
‡Including health care facilities reserved to staff of a large industrial company or the 
Ministry of Defence, respectively. 
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Table 5.7. Results of univariate Cox proportional hazards model on patient delay 
(n=168) 
Factor Hazards Ratio§ Lb95%CI† Ub95%CI° p-value 
Male sex* 1.000 NA/ NA/ NA/ 
Female sex 0.834 0.613   1.136 0.250 
     
Age NA/ NA/ NA/ 0.562 
15-24y* 1.000 NA/ NA/ NA/ 
25-34y 0.870 0.598   1.265 0.466 
35-44y 0.827 0.527   1.299 0.409 
45y and older 0.728 0.458   1.157 0.179 
     
Residence NA/ NA/ NA/ 0.831 
Semi- or peri-urban* 1.000 NA/ NA/ NA/ 
Rural 0.903 0.459   1.777 0.767 
Urban 0.751 0.288   1.961 0.559 
     
SES quintile NA/ NA/ NA/ 0.221 
SES quintile 1* 1.000 NA/ NA/ NA/ 
SES quintile 2 0.669 0.414   1.080 0.100 
SES quintile 3 1.116 0.693   1.798 0.651 
SES quintile 4 0.730 0.454   1.175 0.195 
SES quintile 5 0.828 0.520   1.319 0.428 
     
District NA/ NA/ NA/ 0.755 
Danghara* 1.000 NA/ NA/ NA/ 
Farkhor 0.898 0.468   1.724 0.747 
Hissor 0.639 0.315   1.297 0.215 
Muminobod 1.023 0.496   2.111 0.95 
Qurghonteppa 0.833 0.334   2.079 0.696 
Rudaki 0.717 0.393   1.307 0.277 
Shahrinaw 4.935 0.643 37.845 0.125 
Shurobod 1.507 0.636   3.573 0.351 
Tursunzoda 0.859 0.449   1.645 0.647 
Vakhsh 0.751 0.390   1.446 0.392 
Varzob 0.544 0.184   1.607 0.271 
Vose 0.873 0.492   1.549 0.642 
     
No migration* 1.000 NA/ NA/ NA/ 
Labour migration 0.889 0.565   1.400 0.612 
     
Lack of belief in 
curability* 
1.000 NA/ NA/ NA/ 
Belief in curability 1.121 0.827   1.518 0.462 
     
No self-treatment* 1.000 NA/ NA/ NA/ 
Self-treatment 1.011 0.727   1.406 0.949 
§A hazards ratio >1 means a shorter delay, a hazards ratio <1 points to a longer delay 
relative to the comparison group. 
†Lb95%CI=Lower boundary of 95%-confidence interval 
°Ub95%CI=Upper boundary of 95%-confidence interval 
*Comparison group 
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Table 5.8. Results of univariate Cox proportional hazards models on health 
system delay (n=203) 
Variable Hazards Ratio§ Lb95%CI† Ub95%CI° p-value 
Male sex* 1.000 NA/ NA/ NA/ 
Female sex 1.201 0.908 1.589 0.200 
     
Age NA/ NA/ NA/ 0.270 
15-24y* 1.00 NA/ NA/ NA/ 
25-34y 0.777 0.556 1.087 0.141 
35-44y 1.126 0.736 1.721 0.584 
45y and older 0.810 0.535 1.226 0.319 
     
Residence NA/ NA/ NA/ 0.682 
Semi- or periurban* 1.000 NA/ NA/ NA/ 
Rural 1.066 0.579 1.965 0.836 
Urban 1.441 0.594 3.494 0.419 
     
SES quintile NA/ NA/ NA/ 0.442 
SES quintile 1* 1.000 NA/ NA/ NA/ 
SES quintile 2 0.946 0.608 1.471 0.804 
SES quintile 3 1.004 0.646 1.558 0.987 
SES quintile 4 0.781 0.501 1.219 0.277 
SES quintile 5 1.205 0.779 1.865 0.402 
     
District NA/ NA/ NA/ 0.368 
Danghara* 1.000 NA/ NA/ NA/ 
Farkhor 1.043 0.564 1.930 0.892 
Hissor 1.189 0.631 2.240 0.593 
Muminobod 0.680 0.362 1.279 0.232 
Qurghonteppa 1.725 0.734 4.052 0.211 
Rudaki 1.553 0.895 2.694 0.118 
Shahrinaw 0.857 0.201 3.653 0.835 
Shurobod 1.418 0.650 3.092 0.380 
Tursunzoda 1.284 0.696 2.368 0.423 
Vakhsh 1.526 0.822 2.831 0.180 
Varzob 1.311 0.495 3.472 0.586 
Vose 1.180 0.684 2.038 0.551 
     
No migration* 1.000 NA/ NA/ NA/ 
Labour migration 0.563 0.375 0.846 0.006 
     
Sputum smear negative* 1.000 NA/ NA/ NA/ 
Sputum smear positive 1.153 0.870 1.530 0.322 
     
First facility NA/ NA/ NA/   0.0003 
TB facility* 1.000 NA/ NA/ NA/ 
Medical House 0.425 0.249 0.724 0.002 
Family Doctor 0.442 0.281 0.697 <0.0005 
Central District Hospital 0.768 0.492 1.196 0.243 
Policlinic 0.562 0.317 0.996 0.049 
Republican Hospital 0.613 0.338 1.111 0.107 
Russia 0.302 0.175 0.524 <0.0005 
Other‡ 0.478 0.259 0.882 0.018 
§A hazards ratio >1 means a shorter delay, a hazards ratio <1 points to a longer delay 
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relative to the comparison group. 
†Lb95%CI=Lower boundary of 95%-confidence interval 
°Ub95%CI=Upper boundary of 95%-confidence interval 
*Comparison group 
‡Including health care facilities reserved to staff of a large industrial company or the 
Ministry of Defence, respectively. 
 
Discussion 
This study investigated the influence of health services delivery rooted in the Soviet 
tradition of vertical TB control programs on delay to TB treatment. To our knowledge 
there have been no similar studies previously. We found generally moderate delays in 
our study sample. Much longer delays for certain subgroups of patients highlight the 
need for improvements in the organisation of health services delivery. These 
improvements include the implementation of an international referral system between 
Russia and Tajikistan. 
Limitations 
As in any study on self-reported delay, there is potential recall and reporting bias: 
patients might not remember exactly (or even realise) when the first symptoms started, 
thus they might report delay incorrectly. We have tried to minimise recall and reporting 
bias by supporting the interviewees in their recall work–among others using a calendar 
of local events–and by carefully training interviewers to be non-judgmental in the 
inquiries about delay. 
Residence broken up into the three levels rural, semi- or peri-urban and urban, is a very 
approximate measure of geographical accessibility. However, during the pilot study 
patients could not give estimates of the distance in kilometres from their place of 
residence to the nearest health care facility. We therefore included residence in our 
models on patient and system delays–a factor which may include other information in 
addition to geographical accessibility. The small number of patients from urban and 
peri-urban areas made it difficult to detect statistical differences by residence. Medical 
Houses and Rural Health Centres exist in very remote places and it is likely that 
remoteness contributed to the long delays found in patients who first visited one of 
these two facility types. Residence, which was included in the analysis, could only 
partly account for this because many district centres (where a TB facility and a hospital 
are situated) were also classified as rural. 
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The sample of patients for our study did not span a full year. Consequently, we cannot 
exclude that delays differ during other seasons. 
It is possible that some patients went by without ever being registered in the TB 
registry–for instance if patients relied on self-treatment or informal providers 
exclusively. The present study might consequently underestimate some aspects of 
difficulty in access and delay to TB treatment. This could affect our secondary finding 
that this study did not find evidence of the very strong barriers to access that might 
explain the low case detection rate in Tajikistan. However, such underestimation of 
difficulties in access is most likely for Tajik TB patients in Russia, which would 
reinforce our findings if anything. 
Health care seeking 
Patients in our study group made on average 4.8 visits to a formal health care provider 
up to anti-TB chemotherapy. This is more than the two to three visits that the 
diagnostic pathway requires, namely two visits to conduct sputum smear examination 
(usually at the district TB facility) and possibly one additional visit at the peripheral 
level, from where patients are referred. However, it is less than what was found for 
example in urban Zambia, where TB patients made 6.7 health care visits on 
average[21]. 
In this study there was a lot of variability in the facility type, where the first contact 
with the health system took place: eight of the nine facility types accounted for a 
considerable proportion (6.9% or more) of first contacts each. This is a broader variety 
than found by Mfinanga et al[22] in Tanzania. Strikingly, almost all patients visited the 
district TB facility at some time during health care seeking. Especially primary care 
providers tend to refer patients to TB specialists rather than diagnosing TB themselves. 
At the district TB facility, usually both chest x-ray (CXR) and sputum smear 
examination were conducted. Similar to a study in the Philippines[23], we found that 
almost all patients had had a CXR – despite national and international guidelines not 
requiring CXR for sputum smear positive patients. 
Eighty-six percent of patients reported a visit to the TB specialist. Fifteen patients who 
did not report such visit came from Danghara and had visited the Central District 
Hospital there, which includes a TB ward. Hence, the proportion of patients who have 
been seen by a TB specialist is likely even higher than 86%. 
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The patients in our study sample reported very limited use of informal providers. Social 
desirability bias could be suspected. However, interviewees freely reported their 
experiences in other areas where social desirability bias could be suspected such as in 
the area of informal payments. We therefore believe that social desirability bias is not 
the reason for the low use of informal providers reported, but that TB patients in 
Tajikistan really preferred formal health care providers. 
Delay 
Given the heavily resource-constrained setting, the total delay found in this study is 
moderate. It is longer than those reported in the Philippines and in China (median delay 
of one month in both cases[15,23]), but much shorter than found in studies in high-
incidence settings, where the median delay ranged from 80 to 120 days[7,11-13,24]. 
This result is encouraging and to a certain extent surprising. The estimated case 
detection rate according to data of the World Health Organisation is very low[1] and 
suggests that TB patients face major barriers to care and many of them remain 
undetected. The reasonable median delay found in this study does not necessarily 
support this view. 
Determinants of delay 
District and type of first facility visited were significant determinants of health system 
delay. Muminobod is a mountainous district and this may be one of the reasons why 
treatment delays were longest there (cf. figure 5.1). On the other hand, the similarly 
mountainous neighbouring district of Shurobod was among the districts with relatively 
short delays. Differences between districts may account for a multitude of factors 
including differences in socio-economic conditions, accessibility, or practices in the 
health centres in the district. The type of the facility where the first formal health care 
contact took place was the strongest predictor of system delay. Visiting first a tertiary 
hospital or TB specialist is associated with shorter delays. This is consistent with 
findings from other settings, although there is considerable variation[11-16,25]. 
Making the first visit to a Central District Hospital was also significantly associated 
with shorter delay. While a history of immigration has been shown to influence delay 
in western countries[25-26], this study shows for the first time that developing active 
TB while being a temporary migrant worker abroad leads to long system delays: 
patients who first visited a facility in Russia had the longest delays of all. This is not 
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surprising given that these patients fell ill in Russia and had to travel back to Tajikistan 
to start anti-TB chemotherapy. About 10% of all TB patients receiving treatment in the 
study area had developed active TB in Russia. This may also be relevant for citizens of 
several other Central Asian and Caucasian countries who migrate to Russia to find 
work. The moderate delays of many patients are encouraging, but improvements are 
needed for patients first presenting to Medical Houses, Rural Health Centres and 
especially facilities in Russia. 
The consistent results of the univariate analyses compared to the multivariate analysis 
support the view that these results are not due to confounding. The factor ‘labour 
migration’ is an exception in the sense that it shows a significant impact on health 
system delay in the univariate but not in the multivariate analysis. There is strong 
correlation between ‘labour migration’ and having visited a facility in Russia. This 
does, however, not affect our conclusions. 
In order to reduce delays for Tajiks who develop active TB while working in Russia, an 
international referral system should be developed. The Russian TB program and 
international organisations involved in TB control in Russia should investigate the 
options of foreigners who develop TB while in Russia. If the situation is as described 
by the patients in our study sample, there are disincentives to early presentation to the 
Russian health system, because the patient cannot expect treatment. Rather, presenting 
to the Russian health system will mean that patients will have to spend money to return 
to their home country. Such a disincentive is likely to lead to delayed diagnosis and 
consequently to extended periods of infectiousness in the community. 
As mentioned above, most providers other than TB specialists are reluctant of 
diagnosing TB and would rather refer the patient. This is related to the vertical TB 
control program inherited from the Soviet Union and the resulting notion that TB 
patients should be diagnosed and treated outside the general health services. The large 
difference in the hazards ratios from the peripheral facilities to the TB facility point at a 
need to shorten referral pathways and referral times for TB patients from the periphery. 
This needs to be achieved without jeopardizing the short delays that patients experience 
at the TB facilities. A good possibility would be the diagnosis of TB in the peripheral 
facilities without referral. At least for part of the districts, a sputum collection plan 
exists, whereby peripheral facilities are required to collect three sputa from a TB 
suspect and then organise transport to the district TB facility, where microscopic 
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examination is conducted. Due to the Soviet tradition of over-reliance on CXR and to 
doubts about accuracy of sputum smear microscopy, sputum collection at the periphery 
hardly ever takes place. 
Lönnroth et al[27] have pointed out that the perceived financial consequences of 
seeking health care affect the decision of whether and when to initiate health care 
seeking. Community members, TB patients and health care providers in four districts of 
Tajikistan identified financial costs of health care seeking as the main obstacle to 
obtaining a diagnosis and treatment[28]. Consequently, a better understanding of 
illness-related costs and resulting mitigation strategies may also contribute to shorter 
delays. 
Conclusions 
Before being diagnosed, TB patients visit a broad range of different health facilities. 
While the median total delay until start of treatment is moderate for most patients, 
improvements are needed for certain subgroups. Those patients who develop TB while 
working in Russia have the longest health system delays. Those who first present to 
peripheral primary care facilities or polyclinics have long system delays, too. 
Improvements for both subgroups are possible through better organisation of health 
care delivery. An international referral system for migrant workers developing active 
TB in Russia is urgently needed and is in the interest of both countries. Primary care 
providers should be enabled and encouraged to diagnose TB and start patients on 
treatment. Strengthening of sputum smear examination and collection of specimens at 
primary care facilities should be considered. 
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Abstract 
Background: Illness-related costs incurred by patients constitute a severe economic 
burden for households especially in low-income countries. High household costs of 
illness lead to impoverishment; they impair affordability and equitable access to health 
care and consequently hamper tuberculosis (TB) control. So far, no study has 
investigated patient costs of TB in the former Soviet Union. 
Methods: All adult new pulmonary TB cases enrolled into the DOTS program in 12 
study districts during the study period were enrolled. Medical and non-medical 
expenditure as well as loss of income were quantified in two interviews covering 
separate time periods. Costs of different items were summed up to calculate total costs. 
For missing values, multiple imputation was applied. 
Results: A cohort of 204 patients under DOTS, 114 men and 90 women, participated in 
the questionnaire survey. Total illness costs of a TB episode averaged $1053 (c. $4900 
purchasing power parity, PPP), of which $292, $338 and $422 were encountered before 
the start of treatment, during intensive phase and in continuation phase, respectively. 
Costs per month were highest before the start of treatment ($145) and during intensive 
phase ($153) and lower during continuation phase ($95). These differences were highly 
significant (paired t-test, p<0.0005 for both comparisons). 
Conclusions: The illness-related costs of an episode of TB exceed the per capita GDP 
of $1600 PPP about two-and-a-half times. Hence, these costs are catastrophic for 
concerned households and suggest a high risk for impoverishment. Costs are not 
equally spread over time, but peak in early stages of treatment, exacerbating the 
problem of affordability. Mitigation strategies are needed in order to control TB in 
Tajikistan and may include social support to the patients as well as changes in the 
management of TB cases. These mitigation strategies should be timed early in 
treatment when the cost burden is highest. 
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Background 
Illness often leads to substantial economic burden for the patients and their households, 
especially in resource-poor settings and in the absence of social support mechanisms 
[1, 2]. Economic costs of illness at the household level–below referred to as household 
costs–have strong implications for issues of poverty and equitable access to health care. 
A review found that ill-health, especially long-lasting disease including tuberculosis 
(TB), puts households at high risk of impoverishment [1]. Poor households are deterred 
from the use of health care due to household costs, preventing the health services from 
reaching those most in need [3]. In the case of TB, where the main control and 
prevention measure consists of treating active disease [4], it must therefore be 
expected, that high household costs have a negative impact on TB control. 
There have been many studies on cost-effectiveness of different TB control strategies, 
mainly investigating the costs to the health system. Important findings of these studies 
include the feasibility and cost-effectiveness of short-course TB chemotherapy on a 
predominantly ambulatory basis [5-10]. Far fewer studies measured the costs to 
households [11-13]. One of the first studies to comprehensively measure household 
costs found that the costs of an episode of TB in Thailand amounted to 20% of annual 
household income in the poorest third of patients and thus were devastating [12]. Other 
studies also found that household costs of an episode of TB were considerable–ranging 
from $186 to $1457 in Tanzania depending on treatment duration and around $920 in 
China [13-14]. A number of studies investigated reasons for delay to treatment and 
consequently measured only the costs up to diagnosis and registration with the TB 
control program [15-17]. Also when studying the economic impact on households, this 
strategy may be tempting, based on the rationale that TB treatment should be free of 
charge afterwards. However, those studies that measured costs after enrolment in TB 
control programs invariably found considerable costs during treatment [1, 12-14]. In 
his review, Russell [1] found that “health expenditures tended to be lumpy, coming in 
peaks that intensified cost burdens over a few days or weeks”. However, to our 
knowledge so far no study looked at the distribution of household costs of TB over 
time other than differentiating before diagnosis and after diagnosis. 
Tajikistan is the poorest republic of the former Soviet Union with a per capita gross 
domestic product (GDP) of $1600 purchasing power parity (PPP, 2007 estimate) [18]. 
The country’s infrastructure was severely damaged during the civil war from 1992 to 
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1998. Many villages and even whole districts are cut off in winter from electricity 
supply and transportation axes in this mountainous country. The economy of Tajikistan 
is highly informal and it has been observed that the grey economy is more important in 
several respects than the official economy [19]. Corruption is widespread and 
Transparency International ranks Tajikistan number 151 out of 180 countries in their 
perceived corruption index [20]. Temporary labour migration to Russia is very 
common, especially among young men. The health system is still very specialised, 
hierarchical and at least nominally comprehensive as in the Soviet Union [21]. 
Profound health sector and health financing reform is ongoing. Patients have to pay 
predefined fees for specific services above the primary care level, with different fee 
rates depending on referral or non-referral of the patient from primary care level. 
Informal payments are widespread also in the health system and out-of-pocket 
payments may constitute as much as 80% of total health funding [22]. In a recent 
survey in two districts piloting a new primary care model, almost half of the patients 
who had visited a family doctor reported that they had made an informal payment [23]. 
Involvement of the private sector in health care is very limited and virtually nonexistent 
outside the capital. The WHO estimate of TB incidence was 204 cases per 100,000 per 
year in 2006 [24], while the national TB control program estimated incidence between 
160 and 180 cases per 100,000 per year. The country began DOTS implementation in 
2002 and DOTS coverage reached 100% by the end of 2007. A study in ten districts of 
Tajikistan showed that the hospitalisation rate of TB patients was high (58%) and that a 
positive sputum smear result was the main predictor of hospitalisation [25]. For 
patients who are not hospitalised, the program foresees facility-based observation of 
treatment. 
In most settings in the former Soviet Union anti-TB drugs are provided for free, but 
patients have to pay for other services including additional medicines, x-rays and 
laboratory services and potentially face major financial barriers [26]. In urban Ukraine, 
total illness-related costs of TB varied from $57 to $450 depending on the TB control 
strategy and on the locality [27]. These costs were often outweighed by the social 
benefits provided to TB patients. Overall, very little is known about illness-related 
costs of TB in the former Soviet Union. This study aimed at quantifying household 
costs of an episode of TB in Tajikistan, with special attention to the time period, when 
costs were incurred. 
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Methods 
Study population 
Only districts with an established DOTS program were considered for inclusion in the 
study. Two regions were excluded because they were accessible only by air at the time 
of the study, Badakhshan and Sughd. In close collaboration with the Republican Centre 
for TB control of Tajikistan, 12 districts were purposefully selected to represent 
different urban, rural, lowland and mountainous settings. All pulmonary TB patients at 
least 15 years of age who were registered for the first time (i.e. “new” patients 
according to WHO definition) in the 12 study districts in the period from 1st December 
2006 until 31st March 2007 were eligible for study participation. Patients who had 
defaulted from treatment before the first interview were excluded. Patients who 
defaulted during or at the end of the intensive phase were excluded from the second 
interview, as they could not possibly give information on the continuation phase. 
Questionnaire and Interviews 
Patients were visited in hospital or at home during the intensive phase of treatment, 
written informed consent was obtained and the first interview conducted. Three to four 
months later, the same patients were visited for a follow-up interview. The first 
interview covered the period before diagnosis, starting from the time point, when the 
patients experienced the first symptoms, and the intensive phase. The follow-up 
interview covered the continuation phase. The costs from the day of interview until the 
end of the respective phase were extrapolated, assuming a duration of four months for 
the continuation phase. The questionnaires were adapted from a questionnaire used for 
the quantification of costs of HIV/AIDS [28]. They were piloted and finalised prior to 
the start of data collection. They are available from the authors upon request. 
Completing an interview took about one hour on average. The questionnaires included 
detailed questions about health care seeking, about the costs incurred by patients and 
their households and about household assets. Household costs included medical 
expenditure (for drugs, medical fees and laboratory tests), non-medical expenditure (for 
transport, special food items, modification of housing, traditional healers, self-
treatment and any other reported expenditures), and loss of income due to the inability 
to work. To quantify loss of income, patients were asked about the actual reduction of 
income that they themselves and caretakers had experienced due to absence from their 
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usual income-generating activities for a day. This daily income reduction was then 
multiplied with the number of days away from work. If patients did not know the 
income reduction for one day, but could give an estimate for the total income reduction 
until the day of interview, the total estimate was registered and divided by the number 
of days away from work during data entry. Where income was in-kind, like sometimes 
in agriculture, the monetary value was estimated. Information on treatment outcome 
could not be obtained, as treatment was not completed at the time of the interview. 
Interviewers were trained for two weeks before conducting real interviews and 
supervised at least twice per month through interviews conducted together with the 
main researcher. Specific emphasis was given to support the patients in their recall 
work, including the use of a calendar of locally important events, to motivate the 
patient to provide accurate information on costs and to ask back if reported costs were 
unexpectedly high or low for local context. Data were entered by the main researcher in 
FileMaker (version 8.0v1, FileMaker Inc, USA, 1984-2005). 
Data Analysis 
All analyses were conducted in Stata IC/10.1 for Macintosh (Stata Corporation, USA, 
1985-2008). Individual cost items were summed up to the categories of medical costs, 
non-medical costs, and lost income–for each of the three phases of treatment separately 
(before start of treatment, intensive phase, and continuation phase). For conversion of 
Tajik Somonis to international US$ PPP, we used data provided by the World Bank 
[29]. 
Table 6.1. Characteristics of study participants 
Age Mean      31years 
 Range 15-72years 
   
Form of TB Pulmonary 204 (100%) 
 Sputum smear positive 122   (60%) 
   
History of TB disease New cases 204 (100%) 
   
Delay until start of 
treatment 
Median patient delay 21.5days 
 Median health system delay    16days 
 Median total delay    52days 
   
Hospitalisation Hospitalised patients 153 (75%) 
 Median duration of hospitalisation 39days 
   
Direct observation of 
treatment 
Median number of visits for 
treatment observation 
53 visits 
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In order to avoid the problems associated with complete case analysis and as 
recommended by Manca and Palmer [30] for similar problems, we used multiple 
imputation to deal with missing observations, implemented in the function “ice” in 
Stata [31-32]. The algorithm in “ice” assumes normally distributed variables; this was 
assured through transformation to normal scores. The statistical comparisons of costs 
during the different phases were done with a paired t-test because we were mainly 
interested in the pair wise comparisons (n=204 for all comparisons). To correct for the 
fact that we conducted three t-tests, we decreased our significance level to 1.67%. We 
plotted the residuals and checked visually whether the distributions were normal. In 
order to normalise the distribution of residuals, we used log-transformation. 
We conducted a principal component analysis on 18 variables to construct a wealth 
index following the methodology described by Filmer and Pritchett [33]. The 18 
variables included 15 household assets and three housing characteristics. To improve 
validity of the wealth measure, we used continuous variables, where this was possible, 
and we did not recode any categorical variables as dummies [34]. Subjects were 
allocated to five quintiles by their wealth index. To investigate the internal consistency 
of our measure of socio-economic status (SES), we plotted the mean of each asset 
variable against SES quintile and found that the asset variables were highly consistent 
with expectations. The study has received ethical approval from the Ministry of Health 
of the Republic of Tajikistan. 
Results 
In the 12 study districts, 282 eligible patients were registered for treatment during the 
recruitment time. Seventy-eight (28%) of them were not interviewed, because they did 
not consent (10 patients; 3.5%), were not at home or in hospital when visited (17; 
6.0%), had died (5; 1.8%), were initial defaulters (3; 1.1%), were already in the 
continuation phase at the time point when visited by the research team (25; 8.9%), or 
the address in the registry was wrong or insufficient (18; 6.4%). The remaining 204 
(72%) patients, 114 (56%) men and 90 (44%) women, were found, provided informed 
written consent and were interviewed. Their mean age was 31 years and they reported a 
median delay of 52 days until start of treatment; 122 (60%) were sputum-smear 
positive patients and 153 (75%) were hospitalised at some stage during the disease 
(Table 6.1). Among women, most identified themselves as housewives (58%) or 
farmers (12%). Among men, most reported temporary labour migration to Russia 
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(26%) or unemployment (18%). 
The mean total household costs of an episode of TB were $1053 (±standard deviation 
$1601; median $378). Patients reported household costs of $292 (±620; 54) before the 
start of DOTS treatment, costs of $338 (±575; 139) during the intensive phase, and 
$422 (±705; 95) during the continuation phase (Figure 6.1). Thus about ¾ of costs were 
encountered after the patients were enrolled in the DOTS program. Direct costs 
amounted to $152 (±219; 47), $147 (±213; 108), and $97 (±111; 53) for the period up 
to start of DOTS treatment, intensive phase, and continuation phase, respectively. Thus 
direct costs amounted to $396 (±357; 282) in total over all periods and constituted 38% 
of total costs, the rest being lost income. Table 6.2 shows that direct costs most notably 
included costs for drugs (27% of total direct costs), transportation (25%), and special 
foods (29%). Drugs that were paid for mainly included vitamins and IV rehydration. 
The mean expenditure for the anti-TB drugs (which are officially provided for free) 
was very small: $0.35. Special foods included among others different kinds of meats 
and animal fats that were not consumed during times of good health or only in smaller 
amounts. Indirect costs were mainly incurred by patients themselves: 93 (79%) out of 
117 patients with complete information spent some time away from usual income-
generating activities. The median amount of time away from work was 135 working 
days. For those who worked seven days a week this would correspond to 4.5 months, 
for those who worked five days a week to 6.3 months. Among caretakers, 44 (36%) out 
of 122 cases with complete information spent a median of 24 working days away from 
work. 
Household costs were not evenly spread over time. Costs incurred during one month 
were $145 (±296, median 37) before start of DOTS treatment, $153 (±256, 62) during 
the intensive phase, and $95 (±159, 21) during the continuation phase (Figure 6.2). 
Thus costs incurred during one month were significantly higher before start of 
treatment (paired t-test, p<0.0005, n=204) and during the intensive phase (p<0.0005), 
both compared to the continuation phase. The residual plot suggested that a few 
observations might violate the assumption of normality. We therefore conducted a 
sensitivity analysis excluding these observations. Both differences were still highly 
significant (and in the same direction). The difference in monthly costs before start of 
treatment compared to the intensive phase was also significant (p=0.001), but much 
smaller. While lost income was relatively constant across the three periods, direct costs 
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Figure 6.1. Household 
costs of an episode of 
tuberculos in three 
separate periods of 
treatment. Direct costs 
(white), lost income (black) 
and standard errors of total 
costs are shown. The 
horizontal line denotes the 
annual per capita income 
[18]. 
 
 
 
 
Figure 6.2. Household 
costs incurred during one 
month during three 
separate periods. Direct 
costs (white), lost income 
(black), and standard errors 
of the total are shown. The 
horizontal line denotes the 
monthly per capita income 
[18]. 
per month were about 4.2 times higher before start of DOTS treatment than during the 
continuation phase and about three times higher during the intensive phase than during 
the continuation phase (p<0.0005 for both comparisons). The difference between the 
period before the start of treatment and the intensive phase was not significant 
(p=0.089). Thus costs were most acute during early stages of treatment. This was 
particularly the case for direct costs. However, patterns varied considerably for 
individual line items (Table 6.3). Costs of drugs were highest during the intensive 
phase and lowest before start of treatment. Costs of diagnostic and laboratory tests, and 
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Table 6.2. Composition of household costs 
Cost item Mean 
in US $ 
Standard 
Deviation 
Percentage of direct 
costs 
Indirect costs 657 1391 N/A 
    
Direct costs 396 357 100% 
Medical costs 154 148 39% 
Drug costs 107 105 27% 
Costs of diagnostics and lab tests 18 19 4.5% 
Costs of medical fees 29 64 7.3% 
Non-medical costs 242 286 61% 
Transportation 100 162 25% 
Special foods 113 202 29% 
Self-treatment & traditional 
medicine 
16 41 4.0% 
Other expenses 13 26 3.3% 
 
Table 6.3. Variation of selected costs items over time [in US $] 
Cost item Before start 
of treatment 
Intensive phase Continuation 
phase 
 Mean SD§ Mean SD§ Mean SD§ 
Drug costs 21.3 39.9 51.7 74.7 34.3 56.1 
Costs of diagnostic and lab tests 7.8 16.2 7.4 8.7 2.5 3.9 
Costs of medical fees 15.2 60.8 9.2 15.8 4.8 14.4 
Transportation 71.2 139 8.2 12.9 20.4 26.4 
Special foods 31.4 68.7 67.5 173 14.5 66.3 
§SD=Standard deviation. 
 
Figure 6.3. Household costs by socio-economic quintiles. Direct costs (white), lost 
income (black), and standard errors of the total are shown. The horizontal line denotes 
the annual per capita income [18]. 
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similarly costs of medical fees, were highest before start of treatment and lowest during 
the continuation phase. Costs of transportation were by far highest before start of 
treatment. 
Costs varied considerably by SES. Those in the lower three SES quintiles incurred less 
than half of the costs of the highest SES quintile on average–$735, $773 and $621 
respectively versus $1735 (Figure 6.3). This difference was mainly due to higher 
income loss in the higher SES quintiles, the mean income loss in the wealthiest quintile 
being almost three times that of the poorest. Medical direct costs were similar across all 
SES quintiles; non-medical costs of the wealthiest quintile were double those of the 
poorest ($351 versus $168). 
Discussion 
The mean total household costs of a TB episode amounted to $1053, corresponding to 
$4894 PPP. While a considerable part of the scientific discussion on household costs 
has concentrated on the period before diagnosis [15-17], this study found that costs 
during treatment account for three quarters of total costs–in a setting with free TB 
drugs. Monthly costs were most acute before treatment and during the intensive phase. 
The total costs presented here do not yet take into account that patients may incur costs 
after the end of treatment; especially further loss of income for those who have lost 
their jobs. 
The study may seem only partly representative of Tajikistan, as two regions had to be 
excluded. One of the regions (Badakhshan) is remote and very sparsely populated. The 
other one (Sughd) had only eight districts with an established DOTS program at the 
time of the study (versus 34 districts with DOTS in the whole country) and was only 
accessible by air in winter. The study is representative of an area of Tajikistan, from 
where 80% of all cases under DOTS came in the year up to the study. 
As other studies on household costs, this study also relied on self-reported costs–it is 
thus not excluded that patients forgot or overestimated some of the costs [7]. By using 
two interviews for separate periods of treatment, this study limited recall time and 
recall bias. Further we tried to limit the potential problem of overestimation by training 
the interviewers for this situation. 
The mean total household costs found in this study were even higher in terms of PPP 
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than those found in other studies [12-14]. There may be several reasons for the high 
costs found in this study and these are discussed in the following. One reason may be 
our methodology that reduced recall bias. Further, there is a habit among TB specialists 
in Tajikistan to hospitalise many TB patients and to prescribe many drugs for perceived 
iatrogenic problems and symptomatic treatment (own data, unpubl.). Hospitalisation 
itself does not usually have to be paid for, and this is consistent with the fact that costs 
of medical fees, which include hospitalisation fees, are relatively low (cf. table 6.2). 
However, hospitalisation may be linked to other services like the provision of 
additional medication. Additional drugs, including those for symptomatic treatment, 
have to be paid for and it seems likely that these have led to the very high costs of 
drugs during the intensive phase (cf. table 6.3). Only a small minority of patients 
reported payments for anti-TB drugs. Costs of transportation were very high before the 
start of treatment and this may point to another reason for high costs. Thirty-one 
patients (15%) had developed active TB while being migrant workers in Russia. These 
patients encountered high transportation costs for their return to Tajikistan. An analysis 
of the difficulties faced by migrant workers who develop active TB in Russia is 
presented in a separate publication [35]. Informal payments that occur in the health 
system are a further potential reason for high costs. Disaggregating formal and informal 
payments was not possible in our study, among others because a health financing 
reform was ongoing during the time of the study–including formalisation of some 
informal payments. However, as reported above, the mean payments for anti-TB drugs 
were very small. 
Household costs were approximately three times higher than the per capita GDP and 
thus must be considered catastrophic for affected households. As TB 
disproportionately affects poorer segments of society this burden may be even more 
catastrophic in the typical TB-affected household than average GDP values indicate. 
Direct costs were relatively similar for all SES quintiles, while indirect costs, which 
depend on income, were three times higher in the wealthiest compared to the poorest 
quintile. This is suggestive of a regressive cost burden at least for direct costs. 
Monthly costs were especially high before enrolment in DOTS treatment and during 
the intensive phase. Monthly costs were significantly higher during these two periods 
than during the continuation phase. This pattern was very clear for direct and total 
costs, but less so for lost income, which was more constant over the different phases of 
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treatment. Patients who stopped working often did so for the duration of four months 
and more. This suggests that they did not only stop working during the time of acute 
illness, but for the whole treatment. Tajik doctors often recommend them not to work 
during treatment and for up to two years afterwards. Seasonality of income may have 
led to underestimation of lost income especially before the start of treatment, because 
patients were enrolled into the study in the winter months, which is the season when 
least work is available. Consequently, the observed pattern of higher costs during early 
stages of treatment may even be stronger in reality. The spread of costs over time 
affects the ability of households to cope with these costs [1], and our findings suggest 
that the problem of affordability of services is most acute in early stages of treatment. 
The high costs found in this study suggest that sheer poverty and inability to cope with 
the economic burden of treatment negatively affect treatment adherence and treatment 
outcomes, as has been suspected in other contexts [12, 36]. Farmer et al [37] have 
shown that mitigation strategies including incentives for adherence can improve 
treatment adherence among TB patients. Donors and program managers need to 
implement effective mitigation strategies to enable patients to adhere to DOTS and to 
avoid severe impoverishment. The present study shows that these mitigation strategies 
must be timed early in treatment, when most of the costs are incurred. A recent study 
from Russia has identified types of incentives that are preferred by TB patients [38]. 
Additional strategies to reduce the economic burden of TB disease on households 
might target the high costs for drugs, which are related to the prescription patterns 
including common use of symptomatic treatment. Studies from Russia have shown 
features in the management of TB that are also found in Tajikistan, including high 
hospitalisation rates and widespread use of symptomatic treatment [39-40]. 
Furthermore similar factors influence hospitalisation in Russia and Tajikistan [25, 41]. 
These parallels suggest that some of our results may also apply to Russia and other 
post-Soviet countries. 
Conclusions 
During an episode of TB, patients and their households face costs of approximately 
$4900 PPP. Comparison with the per capita GDP of $1600 PPP shows that these costs 
are catastrophic for the households concerned and suggest a high risk for 
impoverishment. Costs are not equally spread over time, but are highest in early stages 
of treatment, exacerbating the problem of affordability. Free TB drugs do not lead to 
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free treatment and non-TB drugs, transport, and loss of income are very important cost 
drivers for patients. Mitigation strategies are needed in order to control TB in Tajikistan 
and may include social support to the patients as well as changes in the management of 
TB cases. Mitigation strategies need to be timed early in treatment when the cost 
burden is highest. The provision of food supplements to TB patients may contribute to 
somewhat alleviate the economic burden. However, our results suggest that these 
should be delivered soon after a TB diagnosis. Reducing the use of non-TB drugs 
should be considered. 
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Abstract 
Objective: To investigate factors influencing expenditure levels and the use of 
potentially detrimental coping strategies among tuberculosis (TB) patients. For the 
purpose of the present study, potentially detrimental coping strategies included 
borrowing money and selling assets. 
Design: Questionnaire survey with an initial and a follow-up interview of each adult 
new pulmonary TB case registered over a period of four months. Conducted in twelve 
districts with DOTS in central, western and southern Tajikistan, one of the poorest 
countries in the world. 
Results: Patients and their households faced mean expenditures of US$396 related to a 
TB episode. In a multivariate mixed-effect regression, the main determinant of out-of-
pocket payments–either over the whole course of the disease or after enrolment in 
DOTS treatment–was receiving complementary treatment besides the anti-TB drugs. 
Hereby, complementary treatment refers mainly to vitamins and rehydrating infusions. 
Further important factors were duration of hospitalization and treatment delay. Sex 
showed no association with expenditure. To cope with the costs of illness, two thirds of 
patients employed a potentially detrimental coping strategy. TB patients raised on 
average US$23 through credits, US$57 through borrowing money without interest and 
US$102 through selling assets. 
Conclusion: The catastrophic out-of-pocket payments faced by TB patients and their 
households are correlated with i) receiving complementary treatment, ii) delay to 
treatment and iii) duration of hospitalisation. More parsimonious use of complementary 
treatment and hospitalisation could reduce illness-related costs for patients. 
Consequently, the use and rationality of complementary treatment and hospitalisation 
should be reassessed and adapted correspondingly. 
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Introduction 
Tuberculosis (TB) patients encounter substantial costs during the course of their 
disease–despite anti-TB chemotherapy offered for free in most settings (Saunderson 
1995, Habib & Baig 2006, Kamolratanakul et al. 1999, Wyss et al. 2001, Aspler et al. 
2008, Jackson et al. 2006). In most countries of the former Soviet Union anti-TB drugs 
are provided for free, but patients have to pay for other services including additional 
medicines, x-rays and laboratory services (Mosneaga et al. 2008). In Tajikistan, 
household costs of an episode of TB amounted to almost US$5000 purchasing power 
parity (Ayé et al. 2010a). Expenditure and loss of income associated with TB put poor 
households at risk of impoverishment (Russell 2004) and have been identified as a 
major barrier to TB services (Wei et al. 2009). Several studies observed differing costs 
depending on socio-economic status and hospitalization (Russell 2004, Kamolratanakul 
et al. 1999, Saunderson 1995); others have shown that the provision of treatment 
observation influences costs to the patients (Saunderson 1995, Floyd et al. 1997). The 
only study so far that statistically tested such observed differences, found clinic-based 
observation of treatment, longer patient-delay and male sex to be the main determinants 
of higher household costs in urban Zambia (Aspler et al. 2008). At the time of the 
study, there was no alternative to clinic-based treatment observation in Tajikistan. 
Several authors have pointed out that the investigation of household costs of disease is 
incomplete if coping strategies employed by households are ignored (Russell 2004, 
McIntyre et al. 2006). The most immediate response to illness-related costs is to use 
cash income and savings, but this option is not available to all households (McIntyre et 
al. 2006, Russell 1996). Further common coping strategies are borrowing and selling 
assets. Borrowing can increase the level of debt; sale of assets decreases the resilience 
to future economic shocks (Russell 2004). This is particularly true for the sale of 
productive assets, because this reduces future household income. While there are many 
more coping strategies (cf. Sauerborn et al. 1996, Obrist et al. 2007), available studies 
emphasize that selling productive assets and taking out loans often negatively affect 
future income and can lead to impoverishment (Russell 2004, Leive & Xu 2008, 
McIntyre et al. 2006, Russell 1996). For the purpose of this article, the term 
“detrimental coping strategies” refers to selling assets and taking out loans. The present 
study aimed at identifying determinants of TB-related out-of-pocket payments and the 
use of detrimental coping strategies in Tajikistan. 
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Methods 
Study setting 
WHO (2009) estimated tuberculosis (TB) incidence for the year 2007 at 231 cases per 
100’000, while the national TB control program’s estimate is 160 to180 cases per 
100’000. The internationally recommended strategy for TB control, DOTS, was 
introduced in Tajikistan starting 2002 and coverage reached 100% by the end of 2007. 
However, hospitalization rates remain high: 58% in a study in ten districts (Thierfelder 
et al. 2008). Data for this study were collected alongside two studies investigating i) 
delay to TB treatment and ii) the timing of costs of illness (Ayé et al. 2010b, Ayé et al. 
2010a). Out of all districts with an established DOTS program in the Khatlon and 
Republican Subordination regions of Tajikistan, twelve districts were selected–
representing urban, rural, lowland and mountainous settings. All adult (≥15 years) new 
pulmonary TB patients who were registered in the twelve study districts in the period 
from 1st December 2006 until 31st March 2007 were eligible for the study. The study 
participants received TB treatment according to the national guidelines of Tajikistan. 
This involved an intensive phase of treatment lasting two months and a continuation 
phase lasting four months. If sputum smear conversion was not achieved after two 
months, the intensive phase was prolonged by one month. 
The research team visited patients in hospital or at home during the intensive phase of 
treatment, obtained written informed consent and administered the first questionnaire. 
Three to four months later, a follow-up questionnaire was applied to the same patients. 
The first questionnaire asked about costs encountered from first symptoms to onset of 
treatment and during the intensive phase. The follow-up questionnaire asked about 
costs encountered during the continuation phase. For analysis, we extrapolated costs 
from the day of the interview until the end of the respective phase. The questionnaires 
included detailed questions about the costs incurred by patients and about household 
assets. Household costs included medical and non-medical expenditure. 
Statistical analysis 
Three statistical models were built in order to achieve the objectives of the present 
study and are described below. The three outcome variables were: i) total TB-related 
expenditure, ii) TB-related expenditure after onset of treatment and iii) TB-related 
detrimental coping strategies. 
Chapter 7 – Determinants of household expenditure for tuberculosis 
 96 
All analyses were conducted in Stata IC/10.1 (Stata Corporation, USA, 1985-2008). 
We applied multiple imputation to our dataset to deal with missing observations as 
recommended by Manca & Palmer (2005) for similar problems and in order to avoid 
the problems of complete-case analysis (Schafer 1997). We built a wealth index based 
on 18 asset variables (Filmer & Prichett 2001). Details on these two steps have been 
presented elsewhere (Ayé et al. 2010a). 
The factors influencing direct costs to households were identified through a mixed-
effects linear regression. We reduced the number of repeated significance tests by 
identifying a basic model at the outset and by considering only a limited number of 
predictor variables (Grafen & Hails 2002). We built our basic model around five 
variables. A variable identifying individual DOTS centres had to be included in the 
model based on the design of the survey and was included as a random effect. Three 
variables that had previously been shown to influence household costs were identified 
from the literature, namely sex (Aspler et al. 2008), socio-economic status (Russell 
2004, Kamolratanakul et al. 1999) and hospitalization (Saunderson 1995, Russell 
2004). Socio-economic status was included as a continuous variable, the wealth index 
described above. Hospitalization, one of the case management factors of main interest, 
was also included as a continuous variable, namely the log-transformed duration of the 
hospital stay in days. The fifth variable, the second of the main variables of interest 
relating to TB case management, was a binary denoting patients that had received 
complementary treatment, including medication for perceived iatrogenic problems. 
Two further variables were considered in addition to the basic model: the sputum smear 
result and the total delay from onset of symptoms to treatment–both as proxies for the 
severity of disease and as continuous variables. Both the length of hospital stay and the 
delay until onset of treatment were log-transformed because the relationship was 
expected to have the shape of a saturation curve rather than a linear increase. The full 
model was run, its validity was checked by visually examining the residual errors and 
then the model was simplified by excluding factors with p>0.2. However, the five 
factors included from the outset were retained even if their p-values were above the 
threshold (Grafen & Hails 2002). 
In order to test more specifically the influence of a case management decision on the 
costs incurred subsequent to this decision, a similar mixed-effects regression model 
was built, but the outcome variable included only those expenditures that were incurred 
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after the onset of anti-TB chemotherapy (referred to as “during treatment” below). 
Explanatory variables and criteria for model simplification were identical to the 
previous model. 
Further, we built a mixed-effects model on the amount of funds mobilized through 
detrimental coping strategies. Taking out loans (with or without interest) and selling 
assets were considered detrimental coping strategies, but not the use of household 
income and savings. The explanatory variables were the same as in the models on 
expenditure, but an additional variable was considered, a binary identifying patients 
who had worked in Russia until falling ill. This was included because it was thought 
that it could have a major influence on the amount of cash available at the household 
level. 
For all three models, we plotted the residuals and checked visually whether they were 
approximately normally distributed. Residuals were close to normally distributed when 
expenditure data (first two models) were log-transformed and when funds mobilized 
through detrimental coping strategies (third model) were root-transformed. 
The study has received ethical approval from the Ministry of Health of Tajikistan. 
Results 
The study identified 282 eligible patients. Reasons for drop-out and demographic 
characteristics of the 204 patients who consented and were interviewed are listed in 
Tables 7.1 and 7.2, respectively. 
Expenditure over the whole course of disease 
As reported previously (Ayé et al. 2010a), mean total costs of an episode of TB 
amounted to US$1053 (US$4900 PPP) in the twelve study districts. This study 
concentrated on direct costs, i.e. expenditures. Of the total amount, on average US$396 
(±standard deviation US$357; median US$282) were direct costs, the rest being lost 
income due to the inability to work. Mean expenditure for drugs was US$107 (±105; 
72), including mean reported expenditure of US$0.35 for the anti-TB drugs. The full 
multivariate linear regression model for total expenditure was run and simplified as 
described in the methods section (sputum smear result was excluded). The final 
multivariate regression model showed that the delay until onset of treatment and
 
Chapter 7 – Determinants of household expenditure for tuberculosis 
 98 
Table 7.1. Reasons for drop-out 
Reason Number of cases (% of drop-outs) 
Wrong or insufficient address 18   (23) 
Not found at home or in hospital when visited 17   (22) 
Died   5     (6) 
Initial defaulter   3     (4) 
Already in continuation phase when visited 25   (32) 
Did not consent 10   (13) 
Total 78 (100) 
 
Table 7.2. Characteristics of the 204 study participants 
Age [years] 15 to 24 25 to 34 35 to 44 ≥45   
Women 34 23 15 17   
Men 44 40 15 16   
Total 78 63 30 33   
       
Profession House-
wife 
Migrant 
worker† 
Farmer Petty 
trade 
Un-
employed 
Other 
Women 52   1 11   3   9 14 
Men   0 30 13 19 20 32 
Total 52 31 24 22 29 46 
       
Setting Urban Peri- and semi-
urban 
Rural   
Women 8   3   78   
Men 1   8 106   
Total 9 11 184   
†These patients had returned after labour migration to Russia. 
 
Table 7.3. Results of the mixed-effects linear regression on total expenditure (in 
US$, log-transformed); n=204 
Factor 
 
Coefficient/ 
slope 
S.E.§ 
 
p-value 
 
fmi† 
 
sex    0.147 0.132        0.263 0.160 
wealth index      0.0449   0.0347        0.196 0.130 
days in hospital (log-transformed)      0.0163     0.00910        0.073 0.131 
delay in days (log-transformed)    0.231 0.604 *** <0.0005 0.151 
complementary treatment    0.744 0.280   ** 0.008 0.128 
intercept  3.91 0.392 *** <0.0005 0.139 
DOTS centre (estimate for 
variance-covariance matrix) -1.17 0.420 N/A 0.178 
§S.E.=standard error 
†fmi=fraction of missing information. The fmi is a measure of the information 
contained in the missing data in a multiply imputed dataset (Schafer 1997). 
*denotes significance levels 
 
 
complementary treatment were the main determinants of expenditure (Table 7.3). On 
average, a doubling of the delay led to an increase in total expenditure by 17%. 
Receiving complementary treatment led to an increase in total expenditure by a factor 
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of 2.10. Complementary treatment most commonly included Aloe Vera 1% 1ml, 
glucose 5% infusion, vitamin C 1% 1ml, vitamin B1, B6 and B12 (in single and 
compound formulation), calcium gluconate 10% 10ml, and Polyvinylpyrrolidone 6% 
infusion. There was a statistical tendency for increased costs with longer hospital stay 
(p=0.073). A slight departure from linearity was observed in the influence of the 
sputum smear result on total expenditure. A sensitivity analysis with sputum smear 
result as a categorical variable showed fully consistent results. 
Expenditure during anti-TB therapy 
The regression model on expenditure during treatment could not be simplified. The 
delay was not significantly associated with direct costs during treatment. However, 
receiving complementary treatment and duration of hospital stay during treatment 
significantly increased expenditure (Table 7.4). Receiving complementary treatment 
led to 2.12 times higher expenditure. Patients hospitalized for one week had 50% 
higher expenditure compared to patients who were not hospitalized. Patients 
hospitalized for two months had 5.6% higher expenditure than patients who were 
hospitalized for one week only. 
There was no statistical relationship between sex and expenditures during treatment. 
Also the factor sputum smear result showed no statistical relationship with expenditure 
in either of the two models. 
Coping strategies 
Two thirds (65.7%) of patients relied on a detrimental coping strategy to handle the 
costs of tuberculosis. The mean credit taken up by patients’ households over the course 
of the whole treatment amounted to US$22.7, the mean amount of borrowing (without 
interest) was US$56.9, and the mean amount of money raised through sale of assets 
was US$102. The mean total amount for all detrimental coping strategies was US$182. 
The mixed-effects linear regression did not show any statistically significant 
relationships (Table 7.5). There was a weak statistical tendency (p=0.096) for patients 
with higher wealth indices to raise less money through detrimental coping strategies. 
Patients who had returned from Russia due to their TB showed a statistical tendency 
(p=0.069) for raising more funds through detrimental coping strategies than patients 
who had not been to Russia. 
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Discussion 
Limitations 
Like other studies investigating household costs of illness, we also had to rely on self-
reported costs. Consequently, recall and reporting bias cannot be excluded (e.g. 
Saunderson 1995). We limited recall bias by means of conducting two interviews, 
which reduced recall time. Interviewers were trained to recognize unusually high costs 
for specific items and to ask back comparing the reported costs to local prices for 
comparable items. Another limitation is that we have only analyzed two coping 
strategies, while many more exist (Obrist et al. 2007). We have focused on those 
financial coping strategies that bear risks for future impoverishment. 
Expenditure 
The main factor leading to higher expenditure related to tuberculosis was receiving 
complementary treatment; further important factors were longer hospital stay and 
longer treatment delay. The latter two factors were each significantly associated with 
higher costs in one of the two time periods investigated, but only showed a tendency 
(p<0.1) in the other time period. A similar finding was made in Lusaka, Zambia, where 
longer patient delay led to higher costs (Aspler et al. 2008). The present study looked at 
total delay rather than patient delay only. Including two proxies for severity of disease 
had very little influence on the estimated coefficients or significance levels of different 
factors–with the exception of the factor hospitalization in the model on costs during the 
whole episode. Thus, it seems unlikely that these findings be confounded by severity of 
disease. The strong influence of complementary treatment is most likely related to a 
tradition among Tajik (and other post-Soviet–Mosneaga et al. 2008) TB doctors to 
frequently prescribe additional medication, often several types of drugs (see above). An 
additional reason could be that doctors supplement their meager incomes through 
prescribing and/or selling additional drugs. It has been described for other post-Soviet 
countries, that doctors practice in public premises but for private revenue (Mosneaga et 
al. 2008). The use of additional medication in our study population exceeds 
international standards by far (WHO 2003) and its rationality is doubtful. For the 
patients, additional medication is associated with the costs of the drugs themselves, and 
with traveling to the health facility for a prescription and to the pharmacy. Reducing 
the use of complementary treatment and of hospitalization could be simple measures to 
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decrease the costs to TB patients in Tajikistan. Expenditure was not associated with sex 
in either of the two models. In fact, the p-values were high and the two estimated 
coefficients in the opposite direction. In Zambia male TB patients spent more money 
for diagnosis and treatment (Aspler et al. 2008). In our study, men and women have 
incurred similar expenditure over the course of disease. 
Table 7.4. Results of the mixed-effects linear regression on expenditure during 
anti-TB chemotherapy (in US$, log-transformed); n=204 
Factor 
 
Coefficient/ 
slope 
S.E.§ 
 
      p-value 
 
fmi† 
 
sex    -0.0586 0.128        0.646 0.141 
wealth index     0.0344   0.0357        0.335 0.204 
sputum smear result     0.0796   0.0613        0.196 0.260 
days in hospital during treatment 
(log-transformed) 
 
    0.0256 
 
    0.00945   ** 0.007 0.192 
delay in days (log-transformed)     0.0994   0.0601        0.099 0.178 
complementary treatment   0.752 0.299     * 0.012 0.261 
intercept 3.98 0.419 *** <0.0005 0.236 
DOTS centre (estimate for 
variance-covariance matrix)  -0.947 0.332 N/A 0.123 
§S.E.=standard error 
†fmi=fraction of missing information. The fmi is a measure of the information 
contained in the missing data in a multiply imputed dataset (Schafer 1997). 
*denotes significance levels 
 
Table 7.5. Results of the mixed-effects linear regression on detrimental economic 
coping strategies (in US$, root-transformed); n=204 
Factor 
 
Coefficient/ 
slope 
S.E.§ 
 
p-value 
 
fmi† 
 
sex -4.82 3.09 0.120 0.286 
wealth index -1.22   0.733 0.096 0.200 
sputum smear result 8.19 4.49 0.069 0.365 
days in hospital during treatment 
(log-transformed)   0.269   0.196 0.170 0.273 
complementary treatment 3.31 5.67 0.559 0.135 
intercept 16.5 5.91 0.005 0.143 
DOTS centre (estimate for variance-
covariance matrix) 2.83   0.048 N/A 0.427 
§S.E.=standard error 
†fmi=fraction of missing information. The fmi is a measure of the information 
contained in the missing data in a multiply imputed dataset (Schafer 1997). 
 
 
Coping strategies 
About two thirds of households employed at least one detrimental coping strategy. The 
mean amount raised was US$182. This high amount suggests that costs associated with 
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an episode of TB push affected households deeper into poverty. The proportion of 
households employing detrimental coping strategies is higher than found in 15 African 
countries, where among hospitalized patients (independent of diagnosis), about 50% 
reported borrowing and/or selling assets (Leive & Xu 2008). Most commonly, the 
assets sold were cattle, sheep or goats. These are productive assets and confirm our 
choice to treat sale of assets as a potentially detrimental coping strategy. 
While none of the investigated factors was significantly associated with detrimental 
coping strategies, some aspects are worth discussing. The factor “migration to Russia” 
showed a tendency towards higher use of detrimental coping strategies–rather contrary 
to expectation. It was assumed that patients who recently returned from Russia would 
on average have more cash available, because wages are several times higher in Russia 
than in Tajikistan. However, the data showed a tendency only and should be interpreted 
with care. The long treatment delays experienced by migrants developing TB in Russia 
could have contributed to higher costs (Ayé et al. 2010b). 
In conclusion, patients and their households face major expenditure during an episode 
of TB and two thirds of affected households employ detrimental coping strategies that 
potentially impair future income. Hence household costs of TB are catastrophic. Both 
sexes experience similar expenditure in this setting. The main factors associated with 
higher expenditure are receiving complementary treatment in addition to anti-TB 
chemotherapy, longer treatment delay and longer stay in hospital. Complementary 
treatment, which is probably questionable on medical grounds, had the strongest 
effect–more than doubling expenditure. Reduction of additional medication and limited 
hospitalization are simple interventions at the level of case management that could lead 
to lower expenditure for patients. In view of the high costs, such mitigation strategies 
are urgently needed. Similar health system characteristics and the common use of 
complementary treatment for TB patients suggest that this factor would also play a role 
for TB patients in other post-Soviet countries (Mosneaga et al. 2008). Studies on the 
impact of these measures on treatment outcomes in the local context would be highly 
informative. 
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Abstract 
Objectives 
In Tajikistan the prevalence of tuberculosis has tripled since the collapse of the Soviet 
Union and political independence in 1991. TB control relies increasingly on the 
Directly Observed Short Course Strategy favouring outpatient care for patients, but 
there are 2000 TB hospital beds available. An analytical cross-sectional study was 
carried out to assess predictors for hospitalisation and treatment-outcome. 
Methods 
Stratified, single stage cluster sampling was used to include 1495 adult patients with 
pulmonary TB during 2 calendar years (2005-06) from the registries of 10 TB-centres 
chosen by simple random sampling. The primary outcome was referral to hospital. 
Logistic regression was conducted to test associations with the study-outcome using 
linearization and a variance formula.  
Results 
Prevalence of hospitalisation for tuberculosis was 58%. The odds of patients with 
smear-positive tuberculosis being referred were three times those of smear-negative 
patients (OR 2.99 [95% CI 1.81-4.96]). Other predictors for hospitalisation were the 
availability of TB hospital-beds within the same district (OR 2.15 [95% CI 1.22 to 
3.76]) and male gender (OR 1.46 [95% CI 1.07-2.48]). The overall treatment success 
was 80%.  
Conclusions 
Hospitalisation of patients with pulmonary tuberculosis was determined by positive 
sputum smear, supply of hospital beds, and gender. Reducing hospitalisation with 
support of national guidelines is not expected to have a negative impact on treatment 
outcome and spread of disease, but could lead to improved efficiency and effectiveness 
of health service delivery for pulmonary tuberculosis in Tajikistan. 
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Introduction 
Following the breakdown of the Soviet Union, there has been a significant increase in 
the incidence of tuberculosis (TB) in the five countries of former Soviet Central Asia. 
Tajikistan with an estimated annual prevalence rate of 298 per 100,000 in 2006 has the 
highest burden of TB in the region (1). In a country where 64% of the people are living 
below the poverty line (2) re-emerging TB has been attributed to poverty, a damaged 
health infrastructure as consequence of the collapse of the Soviet health care system 
and a devastating civil war. In contrast to Sub-Saharan Africa, TB is not driven by a 
generalised HIV/AIDS-epidemic, which is still at an early, concentrated stage in 
Tajikistan (3). 
Tajikistan inherited a health care system from the Soviet Union. Its main features were 
an emphasis on hospital based- rather than primary care with a vertical organisation of 
infectious disease control and vaccination services. With the loss of the subsidies of 
Soviet times and the economic decline over the last years, the country increasingly 
faces problems in maintaining the state-run health infrastructure (4). 
Particularly in TB-care, the former Soviet Union maintained European traditions from 
the 19th century: frequent and long-term inpatient-stays in specialised TB-sanatoriums, 
often in isolated places on the edge of the towns. Recent data from Samara, Russia, 
showed that supply driven factors, social factors (5) and seasonal factors (6) influence 
referral to hospital.  
For Tajikistan there is no conclusive data on hospitalisation for TB, but previous 
evaluations suggest persistently high hospitalisation rates (7). Officially, potential 
infectiousness in patients with sputum smear positive tuberculosis is regarded as a 
sufficient single factor to justify hospitalisation according to national regulations by the 
Ministry of Health (prikazes 78 & 192). The American College of Chest Physicians 
however clearly focuses on ambulatory care, stating that “Infectiousness alone is not an 
indication for hospitalisation” (8). Also the DOTS strategy by the WHO favours 
outpatient care (9). 
For individual patients in Tajikistan, high costs, loss of work and disruption of family 
structures are negative consequences of the hospital stay. Moreover, inpatient 
conditions for TB care are particularly poor, involving renovation need of facilities, 
frequent lack of heating in the winter due to electricity cut-offs and food-shortage for 
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patients (7). 
In spite of a rising burden of tuberculosis in Tajikistan, little research has been carried 
out. A database-search on the MESH-terms “tuberculosis” and “Tajikistan” showed 
only 10 publications, mostly from the era of the Soviet Union. Seven publications were 
in Russian; only three of them dated from after 1990; none of them related to 
hospitalisation for tuberculosis. This study aimed to identify predictors for 
hospitalisation and treatment-outcome of patients with pulmonary TB in Tajikistan. 
Methods 
Sampling strategy 
A stratified sampling approach was chosen including three regions of Tajikistan, 
covering 70% of the country’s population, considering probable differences in 
demographic composition, disease pattern and hospitalisation rates between urban and 
periurban/rural TB-centres. The urban stratum comprised the towns of Dushanbe and 
Qurghonteppa, and the periurban/rural stratum included all districts within a 50 km 
radius around each of the two towns. Because they were better accessible to the 
research team it was decided to include proportionally more urban centres, to maximise 
the efficiency of data collection. The sampling frame comprised 8 urban and 23 
periurban/rural TB-centres. A single-stage cluster sampling scheme was used, with TB 
centres as clusters. In each cluster all adults (aged ≥ 18 years) registered with 
pulmonary TB during 2005-06 were included. Four urban centres and six 
periurban/rural centres were selected using simple random sampling (SRS) representing 
a 50% and 26.1% probability of inclusion in the sample for patients living within the 
catchment population of the periurban/rural centres respectively. 
Data collection 
Data on hospitalisations were collected from the TB registry-books of the National TB 
control program, available in the TB-centres. Hospitalisation was defined as referral to 
the hospital which is documented for each patient in the 2003 version of the WHO TB-
registry form. Treatment success was the combined outcome of patients who had 
recovered according to smear result or had completed the treatment. Data about the 
centres were collected separately using a questionnaire completed by each centre head.  
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Analysis strategy  
Data were weighted during analysis to allow for sampling design. Analyses were 
conducted with and without the design-setting in order to compare adjusted with 
unadjusted results (10). 
Weighted proportions estimates with 95% confidence intervals (CI) were computed by 
Pearson’s chi squared test and included a second order Rao or Scott correction to 
account for the survey design (11). Univariable analyses of associations between all 
potential predictors and the study outcomes were performed using logistic regression. 
Tests for trend were computed using logistic regression for the design adjusted 
approach. A likelihood ratio (LR) test was used to investigate interaction between 
confounding factors in the final model. Variables were included in multivariable 
logistic regression models using a forward stepwise approach. To assess the association 
between smear-status and referral to hospital the centre-variables (distance, availability 
of electricity, availability of TB-beds) were not included as these are health-services 
variables and have no association with the exposure of mycobacteria in the sputum of a 
patient. All analyses were conducted in Stata Release 9.0 (STATA Corp., College 
Station, Tx, USA). 
Results 
The study sample comprised 1495 adult patients, 45% of them women. Ages ranged 
from 18 to 84 years (median age 32 years). An estimated 65% of patients were for the 
first time notified with tuberculosis and 58% had positive sputum-smear status. The 
degree of smear-positivity according to AFB-classification varied (Table 8.1). 58% of 
patients attended TB centres between April and September with 33% presenting 
between April and June. The overall prevalence of hospitalisations was 58% percent. 
Two thirds of patients with positive smear results were referred to hospital compared 
with 39% with negative results (Figure 8.1). Hospitalisation increased with increasing 
sputum smear results from 60% in smear degree 1 to 76% in smear degree 3 (p<0.001). 
Among all patients for whom treatment was available, 80% had successful treatment 
and 6% of patients died. In patients with repeated treatment 75% were successfully 
treated. 
The prevalence of hospitalisation ranged from 27% in Varzob to 73% in Tursunzade. 
Centres with TB-hospitals in the rayon (district) referred on average 62% of patients to
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Table 8.1. Characteristics of patients enrolled in the study 
N=1495   n % 
      
Agegroup (years) 18-27 564 37.73 
 28-37 372 24.88 
 38-47 284 19.00 
 47-max 275 18.39 
  missing     0   0.00 
Gender  male  818 54.72 
 female 676 45.22 
 missing     1   0.07 
Disease classification new notification 987 66.02 
 re-treatment 443 29.63 
  missing   65   4.35 
Smear Status negative  521 34.85 
 positive  884 59.13 
  + 457 30.57 
  ++ 152 10.17 
  +++ 275 18.39 
 not carried out   60   4.01 
  missing   30   2.01 
Seasonality of 
Presentation winter (oct-mar) 613 41.22 
 quartal (oct-dec) 280 18.73 
 quartal (jan-mar) 333 22.27 
 
summer (apr-
sep) 874 58.46 
 quartal (apr-jun) 486 32.51 
 quartal (jul-sep) 388 25.95 
  missing     8   0.54 
Hospitalisation  no 680 45.55 
 yes 812 54.39 
  missing     1   0.07 
Treatment Outcome failure  204 13.70 (20.46)* 
 bad outcome 62   4.15 
 non-compliance 60   4.01 
 died  82   5.48 
 success 793 53.00 (79.54)* 
 recovered  418 27.96 
 completed  375 25.08 
 not available 385 25.75 
  missing 113   7.50 
* proportion among available treatment-outcome  
 
 
hospital, whereas centres without TB-hospitals within the rayon referred 45% to 
hospital (p<0.001) (Figure 8.2). Treatment success ranged between centres from 62% 
to 94%. The odds of treatment-success in patients referred to hospital compared to 
outpatients ranged from 0.36 (95% CI: 0.16-0.82) to 1.39 (95% CI 0.61-3.15). 
Chapter 8 – Factors determining hospitalisation 
 111 
Prevalence of hospitalisation in the rural/periurban stratum was higher than in the urban 
stratum (60% vs. 46%; p<0.001). Overall treatment success was similar in both strata 
(80% vs. 79%). The odds of treatment success among patients referred to hospital was 
0.69 (95% CI: 0.43-1.09) in the urban centres and 0.42 (95% CI: 0.26-0.66) in 
periurban/rural centres. 
Predictors for Hospitalisation 
Patients with a positive sputum smear status were almost three times more likely to be 
referred to hospital compared with patients with negative sputum-smear (OR 2.99, 95%  
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Figure 8.1. Prevalence of Hospitalisation by Sputum Smear-Status. 
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Figure 8.2. Prevalence of Hospitalisation per TB-centre by Availability of TB-
hospitals. 
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Table 8.2. Predictors for Hospitalisation (design-adjusted findings) 
 Univariate Analysis  Multivariate Analysis† 
Variable OR  95% CI p-value    OR  95% CI p-value 
     D 
Smear Status        
positive 2.99 1.81-4.96   0.001  2.93 1.91-4.49 <0.001 
 + 2.31 1.62-3.29    0.001  2.25  1.69-3.00 <0.001  
 ++ 2.84 1.53-5.25   0.004  2.78 1.57-4.92   0.003 
 +++ 4.81 2.41-9.57   0.001  4.74 2.55-8.79 <0.001  
negative  1       1   
Agegroup (years)   <0.001*      0.036* 
18-27 1.90 1.18-3.07   0.014  1.60 1.06-2.44   0.031 
28-37 1.89 1.41-2.55   0.001  1.87 1.32-2.65   0.003 
38-47 1.45 1.05-1.99   0.027  1.49 1.06-2.10   0.027 
48-max 1       1   
Gender        
male 1.46 1.07-2.00   0.023  1.49 1.08-2.05   0.02 
female 1       1     
Disease 
classification        
re-treatment 0.90 0.71-1.14   0.354     
first notification 1          
Seasonality of 
Presentation        
winter (oct-mar)  1.11 0.69-1.80   0.607     
summer (apr-sep) 1          
quartal (oct-dec) 0.75 0.52-1.08   0.116     
quartal (jul-sep) 0.91 0.63-1.31   0.587     
quartal (apr-jun) 0.70 0.41-1.19   0.166     
quartal (jan-mar) 1          
TB-beds in rayon        
yes 2.15 1.22-3.76   0.014     
no  1          
Distance TB-centre 
& Hospital   <0.001*     
< 10 km 4.43 2.84-6.92 <0.001     
10-20 km 2.03 1.18-3.49   0.016     
> 20 km 1          
Electricity available        
no  1.18 0.51-2.73   0.654     
yes 1          
*p-value for test for trend 
†Results of Multivariate Analysis, adjusted for Age and Gender 
 
CI 1.81 to 4.96; table 8.2). Patients with the most severe degree of sputum-smear 
positive results (+++) were almost five times as likely to be referred to hospital 
compared with patients without tubercle-bacteria in their sputum (OR 4.81, 95% CI 
2.41 to 9.57). There was evidence for a trend in the odds of hospitalisation per unit
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Table 8.3. Predictors for Treatment-Success (design-adjusted findings) 
Variable OR 95% CI p-value  OR 95% CI p-value 
  Univariate Analysis   Multivariate Analysis† 
Smear Status        
positive 0.46 0.32-0.65   0.001  0.53 0.35-0.79 0.007 
 + 0.46 0.29-0.77   0.008  0.51 0.30-0.86 0.019 
 ++ 0.51 0.33-0.81 0.01  0.59 0.35-0.99 0.04 
 +++ 0.43 0.26-0.69   0.004  0.52 0.30-0.87 0.02 
negative  1      1   
Hospitalisation        
yes 0.49 0.32-0.77 0.006  0.62 0.35-1.06 0.075 
no 1      1     
Agegroup (years)        
18-27 1.49 0.95-2.36 0.074     
28-37 0.97 0.75-1.26 0.842     
38-47 1.3 0.93-1.81 0.099     
48-max 1         
Gender        
male 0.63 0.39-1.01 0.055     
female 1         
Disease classification        
re-treatment 0.8 0.65-1.00 0.051     
first notification 1         
Seasonality of 
Presentation        
winter (oct-mar)  1.07 0.72-1.60 0.672     
summer (apr-sep) 1         
quartal (oct-dec) 0.7 0.42-1.17 0.154     
quartal (jul-sep) 0.81 0.42-1.55 0.489     
quartal (apr-jun) 0.79 0.58-1.07 0.116     
quartal (jan-mar) 1         
TB-beds in rayon        
yes 0.755 0.30-1.88 0.5     
no 1         
Distance TB-centre & 
hospital   <0.001*     
< 10 km 0.1 0.06-0.15 <0.001     
10-20 km 0.28 0.20-3.84 <0.001     
> 20 km 1         
Electricity available        
no 1.29 0.54-3.09 0.515     
yes 1         
*p-value for test for trend 
†Results of Multivariate Analysis, adjusted for Smear-Status  
 
increase in sputum-smear (p-value for trend p=0.001). The youngest patients were 
more likely to be sent to hospital compared with the oldest patients: OR 1.9 (95% CI 
1.18 to 3.17). There was evidence for a trend in the odds of hospitalisation per unit 
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decrease in age-category (p<0.001). Men were more likely to receive treatment in 
hospital than women (OR 1.46, 95% CI 1.07 to 2.48). Patients were more than twice as 
likely to be referred to hospital if an associated TB hospital was located within the 
same rayon as the TB centre (OR 2.15, 95% CI 1.22 to 3.76). Patients from centres 
<10km from the associated TB hospital were more likely to be referred to hospital 
compared with patients from centres >20 km away (OR 4.43, 95% CI 2.84 to 6.92). 
There was evidence for a trend with decreasing distance (p<0.001). Season was not 
associated with the outcome, comparing winter or summer (OR 1.11, 95% CI 0.69 to 
1.80) and comparing four quarters of the year (Table 8.3). There was no evidence that 
patients re-treated for tuberculosis were any more likely to be referred to hospital (OR 
0.9, 95% CI 0.71 to 1.14). Referral to hospital was not found to be associated with 
availability of electricity (OR 1.18, 95% CI 0.51 to 2.73). 
Predictors for Treatment Success 
Patients referred to hospital were half as likely to have a successful treatment compared 
with patients treated as outpatients (OR 0.49, 95% CI 0.32 to 0.77; table 8.3). Patients 
with positive sputum-smear status were also half as likely to have a successful 
treatment outcome compared with those with negative smear-status (OR 0.46, 95%CI 
0.32 to 0.65). There was suggestion that younger patients (aged 18-27 years) were more 
likely to have treatment-success (OR 1.49, 95% CI 0.95 to 2.36) compared with the 
oldest (aged ≥48 years). There was no good evidence that men were any more likely to 
have treatment success than women (OR 0.63, 95% CI 0.39 to 1.01). Patients who were 
treated repeatedly for TB had less treatment success than those treated for the first time 
(OR 0.8, 95% CI 0.65 to 1.0). Patients treated in a centre <10 km of the associated TB-
hospital had reduced chances of treatment success (OR 0.1, 95% CI 0.06 to 0.15) 
compared with those treated by centres >20km away. No evidence was found for 
associations between seasonality of presentation, availability of TB beds within the 
rayon, and availability of electricity. 
Adjusted Analyses  
In a multivariate model the association between sputum-smear and hospitalisation was 
reduced from OR 2.99 to 2.93 adjusting for age and gender (Table 8.2). In the adjusted 
model, the strength of association between age and gender and referral to hospital did 
not change considerably in comparison to the crude analysis and is unlikely to be due 
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to chance. Adding further variables (i.e. disease-classification, seasonality) did not 
improve the model. The distance variable was not included because residual 
confounding was considered likely to cause the observed difference in the treatment 
outcome. 
Hospitalisation was found to be associated with decreased treatment success, but could 
have been due to chance after adjusting for smear-status (OR 0.62, 95% CI 0.35 to 
1.06) in the design-based analysis. The association between sputum-smear and 
treatment-success remained unchanged and is unlikely to be due to chance (Table 8.3). 
In the model of sputum smear and hospital referral no evidence was found for an 
interaction between gender and age (p=0.56). In the design-adjusted model, tabulations 
and logistic regression carried out separately for the two gender subgroups did not find 
evidence that the effect of age on hospitalisation differed between men and women.  
Discussion 
This cross-sectional study showed that hospitalisation was determined by smear-
positive TB, age, gender and supply of TB-beds. Having adjusted for potential 
confounding factors, a positive smear result remained the main predictor for referral to 
hospital. In-patient management of smear positive patients is in accordance with Tajik 
National Recommendations (Prikazes 192 & 78). One reason often cited for initial 
hospitalisation is concern that the patient is infectious and must therefore be isolated 
from family and community. However, patients with drug-susceptible organisms 
become non-infectious within 2 weeks (14). Moreover, it could be shown that 
tuberculosis developed no more frequently in contacts of home-treated patients than in 
contacts of patients treated in a sanatorium, suggesting that infection occurred before 
the start of the treatment (15). 
Also a sizeable proportion of patients with smear negative results (40%) was sent to 
hospital. Concern of increased infectivity of an open tuberculosis does not apply to 
these patients and there is no evidence that inpatient treatment for TB is more effective 
than outpatient treatment (16). US-guidelines (8) and the WHO-developed DOTS-
strategy (9) focus much more on outpatient care for tuberculosis. 
More young patients were referred than older age groups. This is remarkable because 
commonly older patients develop more severe and complicated disease, leading to 
increased hospital-admission in the older age-groups (17). Thus, findings from our 
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sample suggest that smear results were of more relevance for hospitalisation than older 
age and associated severity of disease. More young people presenting with a positive 
smear-result in this study might be linked to the fact that they are better able to 
expectorate sputum. 
In accordance with findings from Russia, men were more likely to be referred (5). This 
association remained after adjusting for all other predictors for hospitalisation. There is 
no evidence from the literature and from clinical practice that tuberculosis is more 
severe in men. This suggests that there are social reasons inclining health care 
providers to hospitalize men: men are less self-sustained when they are sick at home in 
the Tajik culture. It is also known that drugs and excessive alcohol consumption, which 
are risk factors for hospitalisation in patients with TB (17), are more common in males 
(18). Men had significantly more smear positive results than did women, which 
supports findings from other developing countries where women were less likely to test 
smear-positive than men (19). Cultural inhibitions about producing deep sputum in 
public places and lack of knowledge about TB diagnosis in women have been 
suggested as possible causes.  
One explanation for a great variability in hospitalisation prevalence among centres 
might be a difference in supply of TB beds among participating rayons. Centres with 
TB-hospitals within the rayon were more likely to refer patients to hospital. This 
supply-driven hospitalisation for tuberculosis in Tajikistan presents an analogy to 
findings from Russia (5) and Ukraine (20).  
The overall treatment success of 80% confirms previous findings in Tajikistan (7). 
Successful TB treatment outcomes were below the 85% threshold of the WHO-target, 
but showed better performance than the 74.4% estimate of treatment success for 13 
European countries, including the former USSR (21). There was considerable variation 
in treatment success among centres, with periurban/rural centres being inferior to urban 
centres. This might be due to less favourable conditions in periurban/rural centres than 
in urban centres. Two centres had not yet adopted the DOTS strategy and were 
therefore without a standardised registry including any information on treatment-
outcome. As the global treatment success rate under DOTS has been high since the first 
observed cohort (12), bias towards a more favourable treatment outcome overall might 
therefore have been introduced. This study utilised routinely collected registry data. 
The reliability of smear results depends on the sensitivity of the AFB sputum 
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diagnostic technique used to diagnose TB. Judgements about the quality of the smear 
microscopy cannot be made in this study. Given that health-workers are responding to 
performance targets of the national programme, the possibility of overestimating cure 
rates cannot be excluded (12).  
Patients referred to hospital were less likely to have a successful therapy outcome 
compared with patients treated with ambulatory care. Reduced treatment success in 
patients with positive smear results has been reported elsewhere (22). However, the 
inferiority in outcome of hospitalised patients still remains surprising since compliance 
with TB-therapy (DOT) should lead to improved clearance of TB-bacteria. The 
reduction in favourable outcomes among in-patients may be due to sicker patients 
being admitted. A predictor of clinical severity of disease would have been valuable to 
have included in the multivariable analysis.  
Centres were chosen by means of simple random to ensure generalisability of the 
study-findings. Because all adults with pulmonary TB registered during the two year 
period were included, selection bias is unlikely. Therefore, study findings can be 
generalised to the general population of Tajikistan in three of five regions of the 
country, covering about 70% of the population. We recommend that smear-positive 
pulmonary TB should not be imperative for hospitalisation. Hospitalisations in smear 
negative-patients should be evaluated in more detail. In each of these cases it should be 
questioned if hospitalisation is necessary. Instructing women in a gender-sensitive way 
could improve smear-positive case detection as has been shown in a recent pragmatic 
RCT in Pakistan (19). Hospitalisation for tuberculosis should not be based on TB-bed 
supply only. Rather, the number of tuberculosis-beds should be evaluated and adapted 
to the needs of a post-soviet health care system in the process of reforms and TB 
control measures should progressively be integrated into primary care services. Further 
research in form of a prospective study is needed to analyse conditions and duration of 
hospital stay as well as TB infection in household-contacts of hospitalized patients.  
In Tajikistan, the DOTS-strategy has reached 100% coverage at the end of 2007. 
Accordingly, treatment for tuberculosis has to be shifted increasingly to outpatient 
services. However, hospitalisation prevalence in this study showed to be still high with 
great differences between included TB-centres. Existing recommendations by the 
Ministry of Health and the National TB-Programme should be modified in focussing on 
outpatient care leaving hospitalisation to defined conditions. This approach 
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disseminated to TB health care personnel in the frame of the DOTS-training, is 
expected lead to a harmonization between rayons and a more effective and efficient-
control of pulmonary TB in Tajikistan. 
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Abstract 
Background: In order to enable tuberculosis patients to adhere to treatment, they 
receive food supplements in several districts within the DOTS program of Tajikistan. 
Objective: To study awareness about food supplements among tuberculosis patients. 
Further, to investigate whether tuberculosis patients receive the foreseen food 
supplements and to estimate monetary benefits and potential payments related to food 
supplements. 
Methods: Questionnaire survey with initial and follow-up interview among new 
pulmonary tuberculosis patients in twelve study districts in Tajikistan, complemented 
by information from the organisations implementing food distributions. 
Results: Eighty out of 116 eligible patients knew about the food supplements, eleven 
knew the exact number (three). At the time of the follow-up interview, patients had on 
average received 1.7 food supplements and this number was significantly higher for 
those patients who were interviewed later in treatment. In two districts, the number of 
food supplements received was significantly lower due to considerable delay in the 
food distributions. Patients estimated the total value of three food supplements at 
244USD and reported payments of 18USD. 
Conclusions: The patients’ awareness about their eligibility for food supplements and 
the regularity of food distributions need further improvement. Overall, the food 
supplements constitute a big contribution (225USD on average) for the household 
budget of each tuberculosis patient. 
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Introduction 
The health system of Tajikistan has inherited its basic structure from the Soviet Union. 
It is focused on the specialist level and at least nominally is very comprehensive 
(World Bank 2004). The Ministry of Health of the Republic of Tajikistan is leading 
health sector reform in Tajikistan, whereby among others primary health care is being 
strengthened and a system of co-payments is introduced for selected services. The 
introduction of co-payments aims at the formalisation of informal payments, which are 
widespread and make up a considerable part of total health spending (Cashin 2004, 
Falkingham 2004). A recent study in Tajikistan found that about 45% of patients at the 
primary care level had made an informal payment to the provider (Tediosi et al 2008). 
It is clear that in this context, disease exerts a heavy economic burden on vulnerable 
households and this is particularly true for a long-lasting illness like tuberculosis (TB). 
The economic burden is an important reason for patients to interrupt treatment (Greene 
2004, Dodor & Afenyadu 2005, Hill et al 2005, Mishra et al 2005, O’Boyle et al 2002). 
A focus group study on access and adherence to TB treatment identified costs of illness 
at the household level as the key barrier in the context of the Tajik DOTS program 
(Ayé 2006). A questionnaire survey found that total household costs of an episode of 
TB amounted to 1050USD (4900USD purchasing power parity) on average (Ayé et al. 
2010). More than a third of households sold assets and almost half of households took 
out loans to cope with the financial demands of treatment. Such a catastrophic 
economic burden may prevent patients from adhering to treatment and make other 
household members more vulnerable to disease. The TB incidence in Tajikistan was 
recently estimated at 231 cases per 100’000 population per year (World Health 
Organisation 2009) and 8.6% of new TB cases were estimated to be multidrug-resistant 
(Zignol et al 2006). These high rates show an urgent need to enable TB patients in 
Tajikistan to access and adhere to treatment. 
TB control programmes have used different strategies to improve treatment adherence. 
Among these strategies is the requirement for direct observation of treatment (DOT) at 
least in the intensive phase included in the DOTS strategy. However, a review of 
randomised controlled trials could not show a positive effect of DOT on TB treatment 
outcomes (Volmink & Garner 2007). In order to improve treatment outcomes, 
additional or other measures are needed to ease the economic hardship that the disease 
and its treatment exert on households, including cash payments to patients, meals 
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alongside TB treatment, travel vouchers and provision of food supplements to patients’ 
households. Such measures have been shown to effectively reduce defaulter rates and 
to improve treatment outcomes (Farmer et al 1991). However, it remains difficult to 
disentangle the influence of the single components of such interventions on treatment 
outcomes and diverse approaches have been employed (Macq et al 2003). 
Five months after the start of the DOTS programme in the first two pilot districts 
(rayons) of Tajikistan, a scheme of food supplements was started by Project HOPE and 
the World Food Program (WFP) of the United Nations Organisation (Mohr et al 2005). 
Initially, TB patients who were vulnerable according to WFP definition were eligible. 
Food supplements have since been given in several districts and about 300 TB patients 
and their family members have received food supplements each year in the four Project 
Sino pilot districts. 
Food supplement distribution programmes commonly encounter problems of 
accountability. Therefore, we studied the following research questions:  
1) Are TB patients aware about their entitlement to food supplements and do 
adherent patients receive food supplements as they should? 
2) What is the estimated local market value of the food supplements that patients 
receive? 
3) Do patients report formal and/or informal payments in relation to the food 
supplements and what is their extent? 
Methods 
Food supplements in the DOTS program in Tajikistan consist of wheat flour, vegetable 
oil, peas and salt, the exact amount depending on the family size. The food 
supplements are brought to distribution centres, from where the patients organise 
transport to their homes themselves. In districts with food supplement provision, all TB 
patients are eligible for food supplements as long as they adhere to the treatment 
regimen. Six districts in the study area had a program of food supplements. The latter 
are distributed three times to each patient, the first food supplement usually being 
provided after the completion of the intensive phase of treatment. Food distributions 
were organised quarterly. Correspondingly, the third food supplement would variably 
be received two to five months after the end of treatment. Information on how often 
food distributions took place was collected from Project Sino and Project Hope, who 
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carry out the food distributions together with WFP. 
The patient-level data for the present study was gathered in the framework of the study 
on costs of illness at the household level mentioned above (Ayé et al 2010). We 
collected information on the reception of food supplements and on expenses associated 
with food supplements. The study was conducted in twelve districts of Tajikistan, six 
of which had a programme of food supplements. In the other six districts, no food 
supplements were provided at the time of the study. We conducted two interviews with 
each patient who was enrolled – the first one in the intensive phase of TB treatment and 
the second one two to four months later in the continuation phase. In the first interview, 
patients were asked whether they would be eligible for food supplements during their 
TB treatment. In the second interview, patients were asked whether and how many 
times they had received food supplements, what the approximate value of these food 
supplements on the local market was, and how much they had spent to receive the food 
supplements and for the transport to bring them home from the point of delivery. Thus, 
most information about food supplements is self-reported by the patients. The date 
when the patient had started treatment and the date when the continuation phase was 
started, were recorded, too. 
For the analysis, the proportion of patients who had received zero, one, two and three 
food supplements respectively were computed. A linear regression model was built 
including the time since start of treatment (in days) as a continuous variable and a 
categorical variable for the district as independent variables and the number of food 
supplements received as the dependent variable. Further, the mean amount of money 
spent to be eligible for food supplements (informal payments) and for transportation to 
pick them up and bring them home were calculated. The mean was used rather than the 
median, because the distributions of the paid amounts were not particularly skewed and 
therefore the mean was an appropriate measure. 
Results 
Number of food supplements received by patients 
The study spanned the period from December 2006 to August 2007. During this period, 
four food distributions took place in each of the districts with the exception of two 
districts. Only three distributions took place in the latter two districts. All the food 
distributions took place between 26th March and 27th June 2007. Consequently, there 
Chapter 9 – Food supplements for tuberculosis patients 
 125 
were gaps in food distribution from December 2006 to March 2007 and from June 2007 
to August 2007. These gaps were due to characteristics of the contracting process 
between the organisations involved. 
For the main study, 282 eligible patients were registered. The number of patients 
involved and drop-outs are shown in figure 9.1. In the districts, where there are no food 
supplements, 54 out of 88 patients (61%) knew that they were not entitled (Table 9.1). 
On the other side, 116 patients (57%) lived in districts, where food supplements are 
provided and thus were entitled to food supplements. Eighty (69%) of the 116 patients 
were aware about their entitlement. Eleven patients (9%) knew that they were entitled 
to three food supplements. 
 
 
 
Figure 9.1. Flow-
chart of the 
number of eligible 
patients, drop-
outs and number 
of patients 
providing data for 
the analysis.  
 
 
 
 
At the time of the second interview, on average 167 days into treatment, 143 patients 
could be found and interviewed again. On average, eligible patients had received 1.7 
food supplements by this time. Twenty-four patients indicated they had already 
received all three food supplements (30% of the eligible patients). Sixteen patients 
(20%) indicated they had received two food supplements, 34 patients (42%) one, and 
seven patients (8.6%) none (Figure 9.2). All patients who had received either no or 
only one food supplement were residents of the same two districts. 
The regression analysis including the factors district and time since start of treatment, 
showed a significant increase in the number of food supplements received over time
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Table 9.1. Awareness of tuberculosis patients about their entitlement to food 
supplements at the time of the first interview 
Awareness of food 
supplements 
#patients 
interviewed 
#patients who knew 
whether they were 
entitled or not 
#patients who knew 
correct number of 
food supplements 
Districts with food 
supplements (6 
districts) 
116 80 
(69%) 
11 
(9%) 
Districts without 
food supplements 
(6 districts) 
88 54 
(61%) 
n/a 
Total (12 districts) 204 121 
(59%) 
n/a 
 
 
 
 
 
Figure 9.2. Percentage of 
patient who had received 
0, 1, 2 and 3 food 
supplements. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.3. Number of 
food supplements 
received by patients in 
the six study districts 
(A-F). Note that 
districts A and B 
contributed only four 
patients combined, all 
of whom had received 
three food 
supplements. 
 
 
(Table 9.2). In two districts, the number of food supplements received was significantly 
lower than in the other four districts (Figure 9.3), and the factor district was highly 
significant (log-likelihood ratio test; p<0.0001). The residuals were checked visually 
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and did not show a major departure from normality. The result that fewer food 
supplements were received in two districts corresponds with the information of the 
implementing organisations indicating that in these two districts three instead of four 
food distributions had taken place during the study period. 
Table 9.2. Results of the linear regression on number of food supplements received 
(n=81) 
 Coefficient/slope S.E. p-value 
Time since start of treatment [days]        0.00452     0.00169 0.009 
District2 -1.67 0.164 <0.0005 
District3    0.472 0.518 0.366 
District4   -0.178 0.186 0.342 
District5    0.330 0.314 0.296 
District6 -1.69 0.162 <0.0005 
Factor District n/a n/a <0.0001 
Intercept  1.95 0.322 <0.0005 
 
Patients from districts without food supplement provision expressed bitter grieve about 
the inequity that they were not entitled to the same benefits as patients from other 
districts. For example, Hissor district does not have food supplements, but is encircled 
by three districts, all of which have food supplements (Dushanbe, Rudaki and 
Shahrinaw). There were also episodes of patients who accused TB doctors of theft. 
They had witnessed that food supplements were given to TB patients in other districts, 
but never received any themselves, because they lived in a district without food 
supplements. They had wrongly concluded that the doctor had taken possession of their 
food supplements. 
Monetary Value and Expenditures 
Patients were also asked to estimate the value of the food they had received. The mean 
value (the median value was almost identical) of one food donation was estimated at 
81USD (±s.e.=4.0USD). The most valuable items in the food donations were the bags 
of flour. Patients mostly estimated that the local market price of one bag of flour (50kg) 
lay between 16.0 to 18.9USD. Depending on family size, patients often received three 
to five bags of flour. The estimated local market value of three food supplements, 
associated expenditure and the household costs of an episode of TB are shown in figure 
9.4. 
On the question, whether they had paid anything (or made any in-kind gifts) in order to 
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be eligible for food supplements, 13 out of 68 patients (19%) reported having paid to be 
eligible for food supplements. The mean self-reported payment of those who did pay 
was 1.1USD (±0.61) per food supplement. 
On average, patients paid 4.9USD (±0.43) each time for the transport to pick up and 
bring home the food donations. These were mostly made to hire a car to bring the 
heavy food supplements from the distribution points (up to three per district) to the 
patients’ homes. 
 
 
Figure 9.4. Value of 
and expenditures 
made for three food 
supplements in 
comparison with 
direct and indirect 
household costs of 
illness (source: Ayé et 
al. 2010). 
 
Discussion 
Study results indicate that almost all the scheduled food supplement distribution cycles 
have taken place, although in some cases delayed by several months. Patients were not 
well aware of their entitlement to food supplements at the beginning of the TB 
treatment. At the time of the second interview patients had on average received 1.7 
food supplements, with a clear trend for more food supplements for those who had 
been on treatment for a longer time period. The total benefit received through food 
distributions amounted to about 225USD and informal payments were limited. 
Limitations of this study include the relatively early time point, when the second and 
last interview with the enrolled patients was conducted. Given the long and often 
irregular intervals between food distributions, we were consequently not able to make 
final conclusions about the proportion of patients who had received food supplements 
and all food supplements. A regression model was used to test the increase of food 
supplements received over time. Linear regression is not theoretically appropriate, 
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among others because the number of food distributions is censored at three. However, 
the deviations from these assumptions were minor in this case, where a majority of 
patients were below the maximum number of three food supplements – provided the 
model is only used for interpolation but not for extrapolation. This study did not 
investigate the exact amount of food that was received. Informal discussions with 
beneficiaries showed that many patients were aware that food supplements were given 
based on the number of household members up to a threshold of seven household 
members. Patients also reported the use of scales during food distributions as foreseen 
by the programmes. 
The awareness of patients about their entitlement to food supplements was low at the 
time of the first interview. Being uncertain, whether they will receive food 
supplements, may make patients believe that they should pay informally in order to 
increase their chances of receiving these benefits. More detailed discussions with 
patients revealed that most of them have heard about or even witnessed the distribution 
of food supplements. However, they were not very confident that they themselves 
would also receive food supplements. The irregular intervals at which food 
supplements are distributed probably contribute to the patients’ uncertainty. 
The extent of the patients’ uncertainty, whether they will receive food supplements or 
not, does not seem justified in the light of the study findings: almost a third of patients 
in the study had already received all three food supplements before the end of the 
treatment. It seems likely that a majority of those who had received only a part of their 
food supplements at the time of the interview have received the remaining ones after 
the interview. The fact that there was a clear statistical relation between the number of 
food supplements received and time in treatment also points in this direction. However, 
the latter relation was weaker than expected. The regression slope estimated in the 
statistical model suggests that it would take patients about 1.8years to receive all the 
three food supplements rather than nine to eleven months as would be expected if food 
distributions were on time. This clearly shows that further efforts are needed to ensure 
the timeliness of the food distributions. The seven patients who reported not having 
received any food supplements by the time of the interview warrant discussion. They 
point towards the possibility that a small proportion of patients might be denied food 
distributions altogether. Alternative explanations include that these patients would have 
been non-adherent and therefore not eligible for food distributions. However, this was 
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not investigated in this study. After patients have received food supplements once, the 
likelihood of not receiving the other food supplements is assumed to decrease, because 
they meet fellow patients and representatives of the health system and at least two 
involved organisations there – consequently they will be better aware of their 
entitlement afterwards. 
Assuming that all patients did receive three food donations in the end, the programme 
contributed 244USD on average to each patient’s household budget, according to the 
patients’ estimates. Subtracting the mean payments reported in direct relation to the 
food supplements, this amount comes to 225USD. In order to put this amount into 
context, we compared it to the costs of an episode of TB at the household level. Hereby 
it must be born in mind that the methods to measure these costs differed somewhat and 
that direct comparison should be interpreted with caution. The total illness-related costs 
at the level of TB patients’ households were found in the main study to be around 
1050USD (Ayé et al. 2010). Correspondingly, the food supplements made a substantial 
contribution to the household budgets of patients during times of economical hardship. 
The contribution to the household budget fell, however, well short of balancing the 
total household costs. 
Reducing and mitigating economic and structural barriers to treatment has been 
suggested to improve treatment outcomes (Greene 2004). An operational study on food 
supplements for TB patients in Tajikistan using a plausibility-design concluded that 
food supplements have likely led to improved treatment outcomes (Mohr et al 2005). 
Financial or in-kind incentives with or without food supplements have been shown to 
improve treatment outcomes (Bock et al 2001, Davidson et al 2000, Farmer et al 1991). 
In a different context and program, conditional cash transfers and food fortification 
have led to improved physical and cognitive development (Fernald et al 2008). 
Furthermore, good nutrition is important both in the prevention of adverse reactions to 
the treatment regimen and in the interaction of TB and the immune system (World 
Health Organisation 2003, Schwenk & Macallan 2000). Historically, nutritious food 
has been the only “treatment” of TB and cholesterol-rich diet has been shown to 
contribute to bacteriologic sterilisation in TB (Pérez-Guzmán et al 2005). 
While this study did not investigate the influence of food supplements on the treatment 
outcomes, we have shown that food contributions contribute to mitigating the 
impoverishment associated with an episode of TB. The dire need and economic 
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hardship of TB patients that have been documented (Ayé et al. 2010) are clearly 
alleviated by the contribution of food supplements. It is very likely that food 
supplements enable patients to better adhere to the treatment. Hence, food supplements 
are a valid option to contribute to the reduction of impoverishment and the 
improvement of treatment outcomes including adherence in TB control programmes in 
Tajikistan and elsewhere. 
From the study results it can be concluded, that a large majority of TB patients have 
received food supplements as foreseen by the programme, albeit sometimes with delays 
of several months. The study showed no indication of large proportions of food 
supplements failing to reach the patient. However, monitoring should be further 
strengthened especially in two districts. Three food supplements make a contribution to 
the patients’ household budgets of about 225USD and contribute to the mitigation of 
TB-related impoverishment. It seems likely that this has contributed to better treatment 
outcomes and nutritional status. The absence of food supplements in certain districts 
constitutes an inequity and is bitterly felt by the affected patients. In some instances, it 
also negatively affects the relationship of trust between patients and TB doctors. In 
order to improve TB control in Tajikistan it would be advisable to expand food 
supplements to those districts where they do not exist currently. 
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Abstract 
Objectives: We wanted to model the sensitivity of sputum smear microscopy in the 
absence of a gold standard using a rigorous statistical modelling approach and data 
from the External Quality Assessment (EQA). The results should provide evidence for 
the international policy debate on diagnostic standards and for the Tajik program. 
Methods: Registry data from EQA were collected from the national reference 
laboratory and from 38 district laboratories in Tajikistan. Data were extracted and used 
to estimate sensitivity and specificity of sputum microscopy by means of a Bayesian 
formulation of the latent class model fitted via Markov chain Monte Carlo simulation. 
Results: Data from 21’627 individual slide examinations were obtained. The 
sensitivity of examining a single sputum specimen was estimated at 0.53 (95% 
credibility interval 0.43-0.68). Consequently, the sensitivity of examining three 
specimens amounts to 0.90 if all examinations are carried out with equal quality. The 
third serial specimen contributes 13% of all detected cases. 
Conclusions: Routine sputum microscopy is performing reasonably well in Tajikistan 
and its use should be promoted. From a global perspective, the third serial smear could 
make a major contribution to case finding if all three examinations were carried out 
with equal quality. Requiring only two serial smears for diagnosis has a potentially 
serious negative impact on case finding. Consequently, the third smear should not be 
dropped. Measures to strengthen laboratory services and specifically the quality of the 
second and third serial smears should be evaluated and could include blinding of the 
laboratory technician. 
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Introduction 
Sputum smear microscopy (SSM) using Ziehl-Neelsen staining is one of the five 
cornerstones of the DOTS strategy. It is the component of DOTS that most directly 
relates to the detection of tuberculosis (TB) cases. It is a simple and inexpensive 
technique that can be implemented even in settings with limited infrastructure and 
unreliable supply of electricity. However, its low sensitivity is an impediment to TB 
control (Keeler et al 2006). Current guidelines stipulate that three specimens should be 
examined before excluding sputum-smear positive (SS+) TB (Enarson et al 2000). On 
the global level, detection of TB patients is at 57% of estimated incident cases – clearly 
below the target of 70% (World Health Organisation 2009). Even though rapid 
diagnostic tests are commercially available, currently none of these has the potential to 
replace SSM and the latter will remain the mainstay of TB diagnosis in most settings 
(Steingart et al 2007, World Health Organisation 2008, Tuberculosis Division 
International Union Against Tuberculosis and Lung Disease 2005). 
The sensitivity of SSM against the gold standard of culture has been reported to be 20-
65% in settings with well-functioning laboratories (World Health Organisation 1998, 
Urbanczik 1985). In a review of the performance of fluorescence microscopy versus 
SSM, the sensitivity of SSM against culture was 32% to 97% in different research 
settings (Steingart et al 2006a). Under field conditions, sensitivity of SSM against 
culture was found to vary from 8.8% to 46.6% in African laboratories (Aber et al 
1980). Measuring sensitivity and specificity of SSM under routine conditions is 
difficult because culture cannot be conducted at most sputum microscopy points. 
Moreover, an imperfect gold standard affects measures of diagnostic accuracy (Ochola 
et al 2006). 
Several studies pointed out that the yield of the third sputum examination in terms of 
additional identified TB cases is very low (Ipuge et al 1996, Harries et al 2000, Yassin 
& Cuevas 2003, Rieder et al 2005, Mabaera et al 2006). In view of the high average 
workload of TB laboratories it was hypothesized that eliminating the need for the third 
sputum examination could lead to higher quality on the first two sputum examinations 
and would not have significant costs in terms of missed TB cases. 
In view of the low case detection globally, changes in the requirements for diagnostic 
procedures that might potentially reduce case detection should be investigated carefully 
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before implementation. An option that previous scientific studies have not taken into 
account is the improvement of the quality of SSM on the third specimen. It would be 
very important to know how many cases would theoretically be found with the third 
serial smear if all smears were conducted with equal diligence. This proportion could 
be computed if the sensitivity of SSM under routine conditions were known. 
The DOTS program of Tajikistan reached 100% coverage in 2007 (World Health 
Organisation 2009). The treatment success rate among 2006 new SS+ cases was 84%. 
The official estimate for case detection of new SS+ cases was 30% in 2007 – far below 
the global target of 70%. The proportion of SS+ among new pulmonary TB cases was 
51%. Providers and program managers have doubts about sensitivity of SSM as carried 
out in Tajikistan. An External Quality Assessment (EQA) collects data on the 
reliability of SSM, but it does not constitute a gold standard and analysis of the data has 
so far been limited. 
We wanted to model the sensitivity of sputum smear microscopy in the absence of a 
gold standard using a rigorous statistical modelling approach and data from the 
External Quality Assessment (EQA). Based on the results we aimed at providing 
evidence for the policy on diagnostic standards and for the Tajik program. 
Methods 
Study Area and Data Collection 
According to the national guidelines for TB control in Tajikistan, every patient 
presenting to health services with cough for more than two weeks has to be referred for 
sputum smear examination. Three sputa are collected (spot-morning-spot) and 
examined at one of the 96 DOTS laboratories. Within the monitoring activities for the 
DOTS program EQA of SSM is conducted. The main component of EQA is blinded re-
checking of slides from all DOTS laboratories at the national reference laboratory 
(NRL). A NRL technician takes a predefined number of slides from the district to the 
NRL, the number being determined according to a standard (Association of Public 
Health Laboratories & Centers for Disease Control and Prevention 2003). The slides 
are selected by starting at an arbitrary number and then taking additional slides at 
regular interval, the interval being defined by dividing the total number of slides 
examined by the number of sample slides needed. The result of the original reading of 
the slides does not play a role in slide selection. The selected slides are re-checked by a 
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NRL laboratory technician who is blinded to the result of the original reading. In case 
of disagreeing results, a senior NRL technician will conduct a second check, knowing 
that the first two results differed. The second reading was not used for the present 
analysis, because it was only available for a specific subset of slides. 
We retrospectively collected all forms of the EQA of sputum examination that were 
available at the level of the NRL covering the period 2004 to 2007 inclusive. The study 
included all districts, from which at least 100 individual results were available at the 
level of the NRL, and collected the laboratory journals of the original examinations on 
a field visit (from each laboratory if there were several laboratories in the district). 
Data Entry 
All data were entered in EpiData Entry 3.1 (Epidata Association 2008) using a data 
entry mask with quality and consistency checks. Three research assistants conducted 
double-entry of the data from EQA. The two datasets were then compared and 
reconciled by the main researcher using the hard copy of the data. For each examinee, 
year, quarter, code of the laboratory, registration number, result of reading in periphery, 
result of reading at NRL, and remarks were entered. For the district laboratory journal 
data, double-entry was conducted for a random sample of nine laboratories (1045 
records) to validate the data. The error rate was 1.30%. The laboratory journals include 
additional data compared to the NRL forms, including sex, age, date of each 
examination and the results of other slides from the same examinee. After data entry, 
data were imported into Stata IC/10.1 for Macintosh (Stata Corporation, USA, 1985-
2008) and the results of all sputum examinations were recoded to a binary variable, 
whereby scanty positive slides were included in positive. 
Case definition and analysis 
We have pointed out in the introduction that microscopy is less efficient than culture in 
detecting TB. It is not only less efficient overall, but tends to detect only a subset of TB 
cases detected by culture. Therefore the case definition, for which we model sensitivity, 
is “pulmonary TB with a bacillary load above the detectability threshold”. The 
detectability threshold has been estimated at 5’000–10’000 bacilli/ml (Toman 2004a). 
Statistical analysis was conducted in WinBUGS (version 1.4, Imperial College & 
Medical Research Council, UK, 1996-2003). We modelled the sensitivity of SSM by 
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means of a Bayesian formulation of the latent class model, which allows for estimation 
of sensitivities and specificities in the absence of a gold standard if at least two tests are 
applied to the same individuals (Hui & Walter 1981, Ochola et al 2006). The model 
assumes an unobserved true prevalence of TB with a detectable bacillary load for each 
population, common sensitivity and specificity across the populations for each test and 
conditional independence of test results given the true disease status. Missing values, 
for instance if a patient did not submit all sputum samples, do not constitute a major 
A separate true prevalence was modelled for each district. Note that the modelled true 
prevalence refers to the population of examinees whose slides were sampled for EQA, 
not to the general population. Separate sensitivity and specificity parameters were 
estimated for first, second and third serial examinations and for the examination at the 
reference laboratory, because the literature suggests that these differ. The second serial 
smear is almost invariably an early morning specimen and early morning specimens 
have been reported to have higher yield (Toman 2004b). It is commonly thought that 
the third serial smear may be carried out with less care and motivation and 
consequently its accuracy may be lower (Yassin & Cuevas 2003, Rieder et al 2005). 
Consequently, a total of 46 parameters were estimated: 38 prevalences, four 
sensitivities and four specificities. 
The model was fitted using Markov chain Monte Carlo simulation. Details on the 
model are available upon request from the corresponding author. To investigate the 
sensitivity of our results to the priors, we ran the model with four different sets of 
priors. This is referred to as the four ‘runs’ below. 
Results 
The 55 laboratories in the 40 study districts had submitted 7’079 sputum smear slides 
to the NRL for EQA in total. We were able to obtain journals of 51 of the above 55 
laboratories, and to match 5’884 individual records (83% of 7’079) from the laboratory 
journals with their EQA results (Figure 10.1). The mean number of examinees from 
one district was 155. Demographic data was available for 5’856 examinees. The mean 
age was 39 years (standard error 0.27) and there were 46% women. The 5’884 
examinees yielded results of 21’627 slides. The positivity rate among the 21’627 slides 
was 16.7%. 
The estimates for all the 46 parameters estimated by the model were extremely similar 
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for the four different runs of the model. The confidence intervals for the same 
parameter across different runs showed almost complete overlap. The modelled true 
prevalences of positive slides in the EQA samples from the 38 districts were between 
0.06 and 0.53 with the exception of two extreme values of 0.013 (range among the four 
runs: 0.0128-0.0132) and 0.72 (0.71-0.73). 
 
 
 
Figure 10.1. Flow-chart 
showing number of 
laboratories in Tajikistan 
and in the study. 
 
 
The estimates for the specificities ranged from 0.985 to 0.998. The ranking was 
consistent among the four runs with the highest specificity on the third serial 
examination, the second highest on the first serial examination and the second-lowest 
specificity on the second serial examination. The estimate for the specificity of the 
examination at the NRL was consistently the lowest. The sensitivities were estimated 
between 0.501 and 0.585. Again the ranking was absolutely consistent among the four 
runs with the first serial examination having the lowest sensitivity, then the 
examination at the NRL, then the second serial examination and the third serial 
examination having the highest sensitivity. These results are counterintuitive, as the 
highest accuracy might have been expected at the NRL because the laboratory 
technicians there have considerably more experience than the technicians at the district 
level. Also the fact that the third serial examination fares better in both specificity and 
sensitivity than the first and the second serial examination is a surprise. However, while 
these differences were consistent between the four runs, the credibility intervals 
showed very wide overlap. Given that the differences between the runs were negligible, 
results are presented as the combined credibility intervals for the sensitivities and 
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specificities. 
Using the model results and the assumption of independence, the combined sensitivities 
of two and three serial smears were 0.78 and 0.90, respectively. The relative difference 
between the two sensitivities is 13%. Hence, reducing the requirement for the 
diagnostic procedure from three serial smears to only two serial smears is therefore 
expected to lead to a decrease of smear-positive case finding by about 13%. 
Discussion 
The present study estimated sensitivity and specificity of sputum smear examination by 
the Ziehl-Neelsen technique using a novel rigorous statistical approach. We used a 
Bayesian formulation of the latent class model to compute data that are routinely 
collected in many TB control programs around the world. This approach had been used 
to assess other diagnostic tests, e.g. for malaria (Ochola et al 2006), but not so far in the 
area of TB. Consequently our approach could readily be applied to other settings, too. 
The study contributes to the surprisingly limited knowledge about the routine 
performance of the most important diagnostic test for TB globally. 
Limitations 
Our study has several limitations, which are discussed in the following. The slides 
sampled for EQA are not a perfect random sample of the slides examined in our study 
districts. However, as the interval for sampling is defined only at the moment of 
sampling and as the starting point is arbitrarily chosen by the monitoring team, i.e. an 
outsider, we believe that the influence of non-random sampling can safely be neglected 
for the purpose of our analysis. 
The assumption of the model that sensitivity and specificity are the same in all settings 
is of course not perfectly true, as there may be variation in the performance of different 
laboratories. However, there are several factors contributing to the homogeneity of the 
study laboratories. The TB program is very vertically organised and all districts were 
directly supervised directly by the national level at the time of the study – without an 
intermediate regional level. All lab technicians have undergone the same training 
course and are similarly equipped. As a result, the studied laboratories have comparable 
standards, which improves the validity of the model. Computing separate sensitivities 
and specificities for each laboratory is impossible in the absence of a gold standard, as 
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the model would be over-parameterised. 
The model assumed that the examination at the NRL was an independent examination. 
Strictly, this would require that a separate specimen be collected from the patient, 
rather than using a slide that was already viewed at the district laboratory. This 
deviation from the model assumptions is expected to lead to an overestimation of the 
sensitivities and specificities. The exact extent of this overestimation is unknown. 
Validation using a prospective design where actually a separate specimen is collected 
from the patient could clarify this issue. Irrespective of validation, our conclusions 
regarding the need of a third serial specimen would only be reinforced if the sensitivity 
of a single smear were lower. 
The final significant limitation is linked to the way sputum smear examination is 
implemented in most routine programs. In most laboratories performing sputum smear 
examination, the laboratory technician is not blinded towards the previous results from 
the same suspect. This could lead to a bias when examining the second or the third 
serial smear. Our finding that the estimated accuracy of second and third serial smears 
was consistently better than that of first smears and of the examination at the NRL 
could point to such a bias. While the differences were far from significant in our model, 
it has to be kept in mind that the model is not designed to detect a directional bias in the 
original data. Validation using a prospective design and blinding of the laboratory 
technician would provide crucial information on this aspect. 
Implications for national and international policy 
Based on the results of 21’627 individual slides, our parameter estimates for the 
sensitivity of a single sputum smear examination were around 0.53. The combined 
estimate for three serial examinations was 0.90. Sensitivities reported in international 
guidelines are 0.35 for a single slide and between 0.6 for pauci-bacillary cases and 0.90 
for patients with a high bacillary load for three slides combined (Toman 2004b). Hence 
our estimate for a single slide was considerably above the previously reported values. 
As laboratories see a mixture of pauci-bacillary cases and patients with high bacillary 
load, the expectation for three slides combined is actually a weighted mean of the 
above-mentioned values. Our finding of 0.90 does not indicate major problems with the 
quality of sputum smear examination in our study setting. This is contrary to ideas 
revealed in discussions with health care providers, TB program managers and in some 
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reports (Neher 2005, Vrakking & Talevski 2008). 
It has been suggested to reduce the requirement for the diagnostic procedure using 
Ziehl-Neelsen examination from three to two serial slides in international guidelines 
(Yassin & Cuevas 2003, Rieder et al 2005). Reducing the requirements from three to 
two sputum specimens would contribute to relaxing the heavy strains on often under-
funded and under-staffed laboratory services in high-incidence countries. However, 
access to diagnosis would not be improved per se as patients would still need to travel 
twice to the health facility to submit two sputum samples. Moreover, our results 
suggest that such a change might lead to a decrease in case finding of 13% compared to 
three serial smears implemented with equal quality. Given that TB programs worldwide 
are struggling to achieve the target of 70% case detection, a decrease of 13% is 
unacceptable. While our findings will need to be confirmed by research in other 
settings and possibly also using prospective study designs, we recommend not to 
proceed with a reduction from three to two slides for TB diagnosis. Other measures 
will need to be taken to solve the problematic issue of overloaded laboratories in some 
settings (Harries et al 2000, Rieder et al 2005). These may involve increased funding, 
staffing and recognition for the laboratory, an often underestimated component of 
functioning TB control. Fluorescence microscopy and different sputum processing 
methods have shown promising results at least in some settings (Torrea et al 2008, Van 
Deun et al 2008, Steingart et al 2006b). Measures for retention and motivation of 
laboratory staff, including appropriate salaries, have to be considered and put in place. 
As to the perspective of the Tajik DOTS program, our results suggest that sputum 
smear examination is working reasonably well. As argued in the limitations section, we 
cannot exclude a slight overestimation of the sensitivity. Consequently, further efforts 
to improve the quality of sputum smear examination are useful. Interestingly, the 
modelled accuracy of the NRL examination is lower than the accuracy of examinations 
in the periphery. Potential bias in the examination of second and third specimens in the 
periphery could lead to this pattern. Laboratory specialists need to be made aware of 
the importance of unbiased examination of the second and the third serial specimens. 
Moreover, clerical errors when sampling slides and registering original results for EQA 
are a possibility. It is therefore important, that the monitoring team sampling slides for 
EQA pay attention to avoiding any clerical errors. 
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Conclusions 
We have modelled for the first time sensitivity and specificity of sputum smear 
examination in the absence of a gold standard. Modelling of sensitivity and specificity 
using a Bayesian approach and routinely collected data from the EQA is feasible and 
provides valuable insight. Sensitivity of sputum smear examination under routine 
program conditions in 38 predominantly peripheral laboratories in Tajikistan was 
estimated at 0.53 for a single slide. None of the possible combinations of the three 
serial examinations at the periphery and the NRL examination showed statistically 
significant differences in terms of significance. If all examinations were carried out 
with the same quality, the third specimen would yield an incremental gain of 13% of all 
cases. Consequently we do not recommend changing international requirements of 
three serial specimens for diagnosis. 
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11. General Discussion and Conclusions 
11.1. Outline of the chapter and summary of findings 
This thesis investigated factors influencing access to care for TB in Tajikistan. Seven 
studies were conducted and their results are briefly summarised below. In the following 
sections, the methods employed and the relevance of the findings are discussed in more 
detail. The findings are discussed from the viewpoint of academic research as well as 
from the stance of program implementers and policy makers. 
The initial qualitative study (chapter 4) found a striking agreement among community 
members, TB patients and health care providers, that the main determinants of access 
to TB care are factors relating to affordability, the economic component of access. 
Factors relating to the other four main components of access to care – availability, 
accessibility, acceptability and adequacy – were not considered equally important, 
neither in the open discussion, nor in a confidential participatory approach. While there 
was agreement on affordability being the main barrier to care, a diverse range of 
opinions was found about the actual items that caused problematic costs to TB patients. 
A subsequent study on health care seeking found that delays until start of anti-TB 
chemotherapy were reasonable given the resource constraints (chapter 5). However, 
patients who first presented to a peripheral primary care facility or to a facility in 
Russia experienced unacceptably long system delays. Further findings were that sputa 
were hardly ever collected at primary care facilities and that CXR was over-used for 
diagnosis. Effective referral systems from peripheral primary care and from Russian 
facilities are needed to reduce the above-mentioned long delays. Repeated visits to 
peripheral facilities, the distance to the specialised TB facility and paying for CXR are 
features of the health care seeking that may contribute to the economic burden of 
disease. 
Taking into account the results of the qualitative study, two subsequent studies in the 
framework of this thesis concentrated on household costs. The first of these two studies 
(chapter 6) showed that TB patients and their households face illness-related costs of 
USD 1’053 on average, of which USD 396 were direct costs and the rest lost income 
due to the inability to work. In terms of PPP, this corresponds to approximately USD 
4’900. These costs exceed the per capita GDP by a factor of three and must therefore be 
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considered catastrophic. The cost burden was most acute during early stages of 
treatment, namely before anti-TB chemotherapy was started and during the IP. 
The second study on costs of an episode of TB investigated predictors of higher illness-
related costs at the patient level (chapter 7). This study looked at direct costs 
(expenditure) of TB (see also section 11.2.2 for a discussion of this approach). A 
regression analysis identified medication that is received in addition to the anti-TB 
drugs as the main predictor of expenditure. Further influential factors were 
hospitalisation and the delay until anti-TB treatment had been started. Three coping 
strategies were identified as being potentially detrimental and increasing the risk of 
impoverishment. Two thirds of the patients in the study employed at least one of these 
three coping strategies. On average, USD 182 were raised using these three coping 
strategies – illustrating major risks for impoverishment. 
Hospitalisation was mainly determined by sputum smear status; to a lesser extent, older 
age and male sex also predicted hospitalisation (chapter 8). This finding is in keeping 
with national guidelines that emphasise the need for isolation of sputum smear positive 
patients. International recommendations, however, do not consider infectiousness alone 
a sufficient indication for hospitalisation. Negative sputum smear was the only 
significant predictor of successful treatment in the multivariate analysis. There was a 
tendency for lower treatment success in hospitalised patients. 
A survey among patients found that a considerable proportion of TB patients had 
already received the three food supplements that they were entitled to – before the end 
of the treatment. The number of food supplements received was significantly associated 
with the time elapsed since start of treatment and with residing in four out of the six 
districts with a food distribution program. Food supplements made a contribution of 
about USD 225 to the household economy. 
Sensitivity of routine sputum smear microscopy in peripheral laboratories in Tajikistan 
was estimated at 53% for a single specimen and at 90% for three serial specimens in 
our Bayesian model. Consequently, it is estimated that the third serial smear would 
contribute 13% of all detected cases, if the three smears were carried out with equal 
quality. These results suggest that sputum microscopy is working reasonably well in 
Tajikistan and that its use can be promoted. Our findings are relevant to the global 
policy discussion on requiring two or three sputum specimens for TB diagnosis. The 
Chapter 11 – General Discussion and Conclusions 
 149 
proportion of cases that are expected to be found with the third specimen only is 
considerable and keeping the requirement for three specimens seems appropriate. Other 
measures to strengthen sputum smear microscopy including increased funding, staffing 
and staff retention programs should be considered. Fluorescence microscopy and 
sputum processing also have potential to improve case finding at least in some settings. 
11.2. Methodology: limitations and strengths 
The studies of the present thesis were based on three main methods: focus group 
discussions (FGDs), a survey with interviewer-administered questionnaires and registry 
analyses. In the following section, the most important limitations and advantages of the 
employed methods as well as the generalisability of the obtained results to the whole of 
Tajikistan and to other countries of the former Soviet Union (FSU) will be discussed. 
11.2.1. Focus Group Discussions 
The initial study used FGDs to study access to TB services. This qualitative method has 
important strengths. It capitalises on the interaction between study subjects and on a 
free discussion among them to enable researchers to explore beliefs and concepts about 
a specific topic (for example TB) and to gain in-depth understanding without 
conducting a full anthropologic study (Kitzinger 1995, International Nutrition 
Foundation for Developing Countries 1994). Studying communities’ or patients’ views 
about an issue as complex as treatment adherence or access to care, may exactly require 
this in-depth understanding (Dick 1999). The FGDs allowed us to explore beliefs about 
TB, awareness about TB services and a comprehensive set of factors potentially 
influencing access to care for TB, including potentially sensitive topics like beliefs 
about TB and its social consequences (cf. Liefooghe et al 1995). We were able to 
recruit a moderator with extensive previous experience in FGDs who contributed 
enormously to the success of the study through his considerate and sensitive manner. 
The open questions used in qualitative research and the environment of trust created 
were conducive of an open discussion where also questions that the research team did 
not directly think of were discussed and answered. This contributes to the exploratory 
nature of FGDs. Limitations of the method include the fact that no quantification of the 
different factors and their associations with the outcomes are possible (Kitzinger 1995). 
Most importantly, the total economic costs – while found to be the most important 
component of access to care in our setting – could not be quantified. Several items were 
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reported by participants of FGDs to play a role in the high costs, but their contributions 
could not be quantified with this qualitative method. As any method relying on self-
reporting, FGDs potentially suffer from reporting bias. Reporting bias is expected to be 
less of a problem for questions relating to knowledge about the disease, but may be an 
issue for aspects of the respondent’s attitudes and especially practices. The so-called 
‘Hawthorne effect’ may occur, whereby study participants behave differently because 
they are aware of being studied. Furthermore, respondents may give responses that 
correspond to the researcher’s views (or what the respondents believe to be the 
researcher’s view) rather than their real attitude and practices (Last 2001). Among the 
topics investigated in our FGDs, the use of traditional home-remedies and healers 
(rather than allopathic medicine) was especially prone to biased reporting. We tried to 
limit such bias by explaining that we were interested in participant’s personal views 
and were not going to assess these as either right or wrong. The fact that the moderator 
was not working in health care but was studying the health care system from an 
external view was a further plus and was openly communicated to the respondents. 
Furthermore, reporting bias is typically reduced when questions are answered 
confidentially. The results of the confidential participatory approach conducted during 
the FGDs, however, were highly consistent with the results from the open discussion. 
Results from other studies support this view. The study on health care seeking and 
delay (chapter 5) also showed the low importance of informal providers. At the same 
time, interviewees freely reported the use of non-medical self-treatments. The free 
reporting – sometimes even of illegal practices like consuming opium – shows that the 
interviewees were able to express themselves freely. In conclusion, we believe that 
reporting bias is not the reason for the low importance of informal providers found, but 
that TB patients in Tajikistan really prefer formal health care providers. 
A further important aspect is the language in which research is conducted. This is also 
true for the interviewer-administered questionnaires discussed below, but the issue is 
particularly important in FGDs and therefore it is discussed in more detail here. As 
explained above, FGDs capitalise on the discussion that happens naturally among 
participants and on their interactions. Simultaneous translation would interrupt the flow 
of discussions considerably (International Nutrition Foundation for Developing 
Countries 1994). Tajikistan is multilingual, Tajik, Uzbek and Russian being the three 
most common languages. The moderator and the transcriber of the FGDs were fluent in 
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all the three languages, which permitted participants to express their ideas in their 
preferred language and contributed to the validity of our results. 
The FGD study was conducted in the four pilot districts where the health sector reform 
is implemented with support from Project Sino. In generalising the results of these 
studies to the rest of Tajikistan, caution is required because it cannot be excluded that 
the study districts differ from other districts. On the other hand, the four study districts 
incorporated a range of very rural, mountainous and semi-urban settings, including 
areas with Uzbek majorities and other areas with almost exclusively Tajik populations. 
There are no reasons to believe that our study districts would be fundamentally 
different from most other parts of Tajikistan. For a few topics, there was an overlap 
with later studies conducted in a larger study area. The results from overlapping 
subjects suggest important findings – including low utilisation of traditional healers and 
the fact that TB patients encounter high costs acting as a barrier to access care – to be 
true for other areas of Tajikistan, too. 
11.2.2. Questionnaire survey 
Descriptive studies, including questionnaire surveys, have several strengths and are 
often the first foray of scientific research on a specific subject that may trigger more 
studies later (Grimes & Schulz 2002a). Their strengths include being relatively 
inexpensive, simple and often quicker to conduct than more rigorous studies. They may 
consequently be more resource-efficient (Grimes & Schulz 2002a). Descriptive studies 
may suffer from three main types of bias: selection bias, information bias or 
confounding (Grimes & Schulz 2002b). In our study, selection bias could have 
occurred because not all eligible patients were found and interviewed. We attempted to 
limit selection bias by including a consecutive sample of TB patients and by making 
considerable efforts to find all patients. Consequently, the drop-out rate was reasonably 
low at 26%. Other studies using complete or probability sampling have had drop-out 
rates of 9%, 30% and 76% (Aspler et al 2008, Lambert et al 2005, Khan et al 2000). 
Two kinds of information bias could have occurred in the study: interviewer bias and 
reporting bias. Our interviewers had not previously worked in the health sector and thus 
were less likely to have strong preconceptions about appropriate health care seeking 
and payments in the health sector. Interviewees of Uzbek and Russian ethnicity were 
interviewed by an ethnic Uzbek who was bilingual Uzbek-Tajik and fluent in Russian. 
Reporting bias related to social desirability has been discussed in the previous section. 
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Another form of reporting bias is recall bias. Aspects of recall bias are probably more 
important in most topics covered in the questionnaires than aspects of the Hawthorn 
effect. Interviewees may have forgotten part of their symptoms, treatment seeking steps 
or incurred costs. 
Recall bias is most likely for small expenditures, for the onset of the first, potentially 
mild, symptoms and for actions that lie a long time back. Recall bias can lead to both, 
under- or overestimation of costs. Underestimation occurs if costs are forgotten 
completely; overestimation may occur if the amount is forgotten and over-estimated at 
the time of the interview (Saunderson 1995). Our survey used several strategies to 
reduce recall bias: among others conducting two interviews, using a calendar of local 
events and asking many precise questions about health care seeking and different line 
items (Lu et al 2009, Lambert et al 2005). The use of two separate interviews – to our 
knowledge unique among studies of illness-related costs – considerably reduced recall 
times. In the first interview, recall times were four months or less for a majority of 
study participants, in the second interview recall times were usually three to four 
months. Recall periods of 6 months or less were found to be "an optimal recall period 
for self-report surveys" in a review of recall bias in regard to health care service 
utilisation (Bhandari & Wagner 2006). The review pointed out that short recall periods 
may lead to overestimation of utilisation because interviewees tend to include 
utilisation that was outside the specified period in reality. For health care expenditure it 
was also found that shorter recall periods yielded significantly higher estimates than 
longer recall periods (Lu et al 2009), but it was not clear which of the two was more 
accurate. Recall periods from two weeks up to one year are commonly used 
(Saunderson 1995, Kamolratanakul et al 1999, Wyss et al 2001, Russell 2004, Lambert 
et al 2005, Lu et al 2009). It is clear that rarer events and bigger expenditures will be 
remembered for a longer time. In our study, we included only new cases in order to 
avoid stronger recall bias and to improve data quality – experience during a pilot study 
had shown that re-treatment cases mixed up episodes from earlier health care seeking 
with their most recent health care seeking experience. 
The last type of bias listed by Grimes & Schulz (2002b), was confounding. 
Confounding could possibly have occurred for the factors ‘additional medication’ and 
‘hospitalisation’ in the statistical model on costs of illness (chapter 7). A likely 
confounding variable for both factors would have been severity of disease. As 
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discussed in the respective chapter, the statistical estimates for the two factors were not 
sensitive to including two proxies for severity of disease in the model. Therefore 
confounding does not appear likely. 
In the paper on delay to TB treatment and its association with health services delivery 
(chapter 5) we argued that including knowledge of symptoms in an explanatory model 
for patient delay until presentation to allopathic medical services was at a risk of being 
flawed. The argument was that the patient’s knowledge is likely to change between the 
moment when this factor acts (at the time when the decision to initiate health care 
seeking is taken) and the moment, when the factor is measured (during the interview, 
i.e. during IP). The encounters between patient and health care provider that take place 
in the meantime are likely to influence the patient’s knowledge about the disease. A 
similar argument could be made for belief in curability, because the health care 
provider is supposed to inform the patient about the curability of TB in the frame of 
patient counselling to foster adherence. We anyway included belief in curability, 
because we felt that people’s beliefs about curability were often very deep-rooted and – 
contrary to knowledge – were more likely to change only gradually or not at all. 
Even when all reasonable practical measures are taken to improve reporting, measuring 
costs remains a difficult task. This is especially true for indirect costs, which have been 
measured using a range of different methods (Russell 2004). One of the main problems 
for measuring indirect costs is that income is mostly informal, often irregular and 
sometimes in kind. Several studies have therefore measured time costs and converted 
these using the ratio of estimates of income (for example national average) and 
working hours (Saunderson 1995, Russell 2004, Wyss et al 2001). This approach has 
been criticised for different reasons, including the uncertainty of national average 
incomes and the fact that average incomes tend to be not representative of the 
subpopulations most at risk of developing TB. Most importantly, however, this 
approach neglects coping strategies like intra-household labour substitution (Sauerborn 
et al 1996, Russell 2004). Intra-household labour substitution can considerably reduce 
indirect costs. A further aspect is that Tajik law requires employers to pay employees 
during sick leave. The long Soviet tradition still has its influence and this often actually 
happens in practice. We therefore decided to ask study participants about the actual 
reduction of income that they have incurred. This led to high variation at the individual 
level (many patients reporting zero lost income because they still received their full 
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wage or because of intra-household labour substitution – other patients reporting high 
income losses, for instance because they had been migrant workers in Russia where 
wages are often 10-20 times higher than in Tajikistan). However, we think that this 
approach gives a more realistic picture of the average costs encountered by patients. 
In our dataset on costs of illness, there was a considerable amount of missing data 
(around 15%). This likely reflects among others the problem of recall bias discussed 
above. Rather than excluding patients with missing data (which could introduce 
selection bias) or replacing missing values with mean values (which could introduce 
selection bias and additionally leads to underestimation of the variance), we chose a 
rigorous statistical technique known as multiple imputation (Schafer 1997, Royston 
2005). Multiple imputation makes use of correlations between different variables in a 
dataset. Based on all available data, it estimates a predicted mean and variance for each 
missing value. The method makes an assumption called ‘missing at random’, which is 
non-testable, but more relaxed than the implicit assumption called ‘missing completely 
at random’ made by complete-case analysis (Schafer 1997). The interested reader is 
referred to the statistical literature for details. Strengths of this method include that all 
available information is used efficiently (by not deleting incomplete cases) and that the 
uncertainty about the true value at the place of a missing value is taken into account 
(Schafer 1997). Multiple imputation method has been recommended for similar 
problems of missing cost data in studies in the health sector (Manca & Palmer 2005). 
Further, the robustness of our statistical findings with p-values often considerably 
below 1% make us confident that the missing data, had we been able to collect it, 
would not have altered our conclusions significantly. 
The question whether the study sample is representative of the whole of Tajikistan has 
already been discussed in single chapters and is not elaborated in detail here. Given the 
time requirements of travelling to patients’ homes (including their location with 
imprecise ‘addresses’), expanding the study area even more would have negatively 
affected our ability to participate in data collection as well as to monitor and support 
the interviewers. Participation in data collection, monitoring and support contributed to 
data quality. We therefore excluded two regions but for the reasons stipulated in the 
discussion sections of the different papers (chapters 5 to 7) think that our findings and 
conclusions are valid in most areas of Tajikistan. An exception might be the thinly 
populated Badakhshan region, where the majority of people are Pamiri, speaking one of 
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several Pamiri languages and adhering to the Ismaili branch of Shiite Islam rather than 
Sunnite Islam as in the rest of Tajikistan. 
Generalising from new pulmonary TB patients to all TB patients requires caution. It is 
likely that re-treatment patients have even higher costs than new patients, because they 
receive more drugs, they may have more complications and their treatment lasts two 
months longer. The extent of the increase of costs for re-treatment compared to new 
patients is unknown and based on the experience from our pilot study (see above) may 
be very difficult to measure. We also did not attempt to measure costs of extra-
pulmonary TB patients. As pulmonary TB is the only commonly infectious form of TB 
and therefore the driver of the TB epidemic, concentrating on pulmonary TB seemed 
appropriate. The only previous study investigating determinants of household costs 
included both pulmonary and extra-pulmonary patients, but did not find a difference 
between the two in terms of costs (Aspler et al 2008). 
For the regression analysis of determinants of illness-related costs, we included only 
direct costs – even though indirect costs were higher. The main reason were the very 
high individual variation (see above), which could have introduced spurious 
relationships. It was expected that a regression including indirect costs would mainly 
identify factors associated with migrant workers in Russia. In other words, indirect 
costs are higher in those with higher income – so direct costs are not only easier to 
measure but may also be a better indicator of costs exceeding the patient’s ability to 
pay. 
11.2.3. Registry analyses 
Among the strengths of registry analyses is the possibility to collect a large amount of 
data in short time and with limited efforts. One of the main limitations is that obviously 
only those variables that are routinely recorded in the registries – usually variables that 
are simple to measure like sex or age – can be used in the analysis. Registry studies are, 
like the two previous types of studies used and discussed in this thesis, observational 
studies. Inference from statistical association to causality cannot be made because 
registry analysis also constitute a form of descriptive studies (Grimes & Schulz 2002b). 
This is true even more so as researchers cannot freely choose the variables that seem 
most sensible, but the choice is restricted to the variables already present in the registry. 
Meaningful analysis also depends on the registries being reasonably complete and 
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accurate. Accuracy thereby also includes data quality. In the FSU, data quality may be 
a very important issue, as hypothesized by Coker et al (2008). As already discussed in 
the discussion section of chapter 8, a variable measuring the severity of disease would 
have been a desirable indicator for the analysis on predictors of both, hospitalisation 
and treatment success. However, severity was not noted in the registry. The registry 
analysis on sensitivity of sputum smear microscopy could have analysed sensitivity and 
specificity of the whole diagnostic procedure even more stringently if the repetitions of 
the test would have been independent and complete replicates. They were not, because 
the EQA does not rely on a new specimen from the patient, but on a slide from the 
laboratory. In order to investigate the sensitivity and specificity of the whole diagnostic 
procedure more stringently, we would have had to experimentally manipulate the setup 
of conducting a sputum smear examination. This would at the same time have 
compromised the routine of the setting and a Hawthorn effect would have been 
possible. Concluding, the registry analyses have their inherent limitations, but overall 
are a valid, parsimonious and efficient approach to gain general insight. 
Both registry analyses presented in this thesis covered relatively large parts of 
Tajikistan. The registry analysis on hospitalisation used a stratified random sample of 
DOTS centres in three areas centred around the cities of Dushanbe, Qurghonteppa and 
Kulob, respectively. It is therefore representative of a considerable part of Tajikistan. 
The registry analysis on repeatability of the microscopy reading of sputum smear slides 
used a complete sample of all the laboratories in Tajikistan that fulfilled the inclusion 
criteria (a limited number of small DOTS centres were not eligible). The study is thus 
representative of all medium-sized and large DOTS centres of the country. 
11.3. Contributions to the understanding of the concept of access to care 
This thesis investigated determinants of access to medical care for tuberculosis in 
Tajikistan with a focus on household costs. The theoretical concept of access to care 
has been developed among others by Aday & Andersen (1974), Andersen (1995) and 
Obrist et al (2007). Our analytical framework, presented in chapter 3, followed mainly 
the latter reference, differentiating five components of access, called the five A’s: 
availability, accessibility, affordability, adequacy and acceptability. To our knowledge, 
the present thesis reports the first application of this framework to TB care. The 
framework proved useful in fostering a deeper understanding of the factors influencing 
access to medical care for TB. Similar to studies on access to malaria treatment in the 
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Kilombero valley in Tanzania, the setting where the concept was developed, we also 
found that health system factors played a pivotal role. 
The main adaptation that we suggest in order to make the model fit the context of a TB 
program is to view treatment adherence as a form of continued utilisation. Like 
utilisation, treatment adherence would then be an outcome of access to care rather than 
of quality of care. This is despite the fact that good quality of care including 
interpersonal skills of providers and appropriate counselling contribute to adherence. 
This adaptation is warranted on theoretical grounds, because DOT requires patients to 
go to the health care facility and to interact with providers much in the same way as for 
a consultation, but also on the grounds of our findings. Our FGDs showed that 
community members, patients and providers perceived the same factors to be important 
for diagnosis as for treatment adherence. The studies on costs of illness showed that the 
problem of affordability occurs throughout treatment – despite an exemption 
mechanism that was well functioning. This view of treatment adherence is shown in 
figure 11.1. 
The perception of need for care is closely interlinked with socio-cultural concepts of a 
disease, beliefs and knowledge about the disease. These again are important factors of 
acceptability. We therefore suggest that the perceived (as opposed to the objectivistic) 
need for care be understood as a part of acceptability and thus access. Adherence 
requires a continued perception of the patient that she or he needs care. This is in 
keeping with the requirements for adherence listed by Jones et al (2000). 
A further factor that is necessary for people to be able to utilise medical care is 
awareness about health care services, a factor that was not made explicit in the original 
concept (Obrist et al 2007). People need to have at least a basic knowledge about where 
health care facilities are located and what kind of services these facilities offer. This 
basic knowledge has been termed ‘Awareness about health care’ in our theoretical 
framework (Figure 11.1). In our FGDs, participants showed generally good and often 
surprisingly detailed knowledge about different health care services in their district. 
It is important to realise that the five A’s cannot be completely separated from one 
another, but are closely interlinked. For example, for patients who are able to pay for 
different means of transport accessibility is expected to be less of an issue than for 
those who are unable to pay – so that affordability and accessibility can be traded off 
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against each other. Patients who are able to pay may even travel from a rural area to the 
capital, where more services are available than in rural locations. For instance the 
credibility of health services in the sense of the perceived technical quality of care is 
linked to availability of essential drugs at the facility (Mamdani & Bangser 2004). And 
the availability of drugs is also not always clear-cut. Drugs that were initially 
unavailable at a facility could later be organised if the patient was willing and able to 
pay (Mamdani & Bangser 2004). 
 
Figure 11.1. Representation of the position of ‘access’ between need for medical 
care and its utilisation. 
 
11.3.1. Determinants of access to care 
The FGD study showed that community members spontaneously associated cough with 
a number of diseases, including TB. They were also aware of the two means of 
diagnosis used in Tajikistan, sputum examination and CXR, and of the district TB 
facilities, where TB services are available. Community members emphasised that TB 
requires (allopathic) medical treatment. Economic barriers to TB services were the 
most important barriers in accessing TB care identified in the FGD study. The 
participants of all three respondent groups agreed on this. The finding is further 
supported by the high absolute costs found in the subsequent questionnaire survey 
among TB patients. This is not to say, that further improvements in patient education 
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and in the interpersonal skills of health care providers were not possible or unnecessary 
– rather it illustrates the urgent need to reduce the economic burden to TB patients. 
Against a background of reviving religious feelings and traditions after independence 
in this predominantly Muslim country, most outside observers would probably have 
expected that women face more barriers to health care than men. Interestingly, we did 
not find any significant differences between women and men in the variables that are 
linked to access in our studies. The case of patient delay is somewhat ambiguous. The 
p-value is just above 0.1 and thus is close to a statistical tendency, even if not 
significance. The estimate of the hazards ratio suggests that women might have 
somewhat longer delays. But then again this comparison is only valid if both sexes 
experience and report symptoms in a similar way. Direct costs of an episode of TB 
were similar for women and men and in the two models the estimates for the influence 
of sex were in the opposite direction. Our sample was large enough for other factors to 
be highly significant, suggesting that there is no considerable difference between the 
sexes. 
While very few previous studies have investigated access to TB care using a 
comprehensive theoretical framework rooted in the concept of access to care, there are 
many studies on delay to TB treatment and on adherence. It was argued in section 1.8.3 
that access to care strongly influences delay until start of TB treatment and literature on 
delay was briefly reviewed there. Important factors commonly associated with longer 
delays included low knowledge or awareness of TB, rural residence, poverty and 
presenting first to a private provider or a low-level government facility (Storla et al 
2008). Based on our studies and theoretical considerations, we have discussed in 
section 11.3 that access to care is a key determinant of adherence to TB treatment. The 
importance of adherence for TB control is widely recognised and many studies 
investigated predictors of adherence. Studies of adherence differ in their definition of 
the outcome and even more strongly in the set of factors that were investigated. These 
differences make comparisons challenging, but some factors have commonly been 
found to be influential. Alcoholism, homelessness, lack of social or family support, the 
interaction between patient and health care worker, and adverse effects of the treatment 
regimen have repeatedly been associated with non-adherence (Wares et al 2003, Baum 
& Lafair 2003, Salles et al 2003, Dodor & Afenyadu 2005, Jakubowiak et al 2007, 
Mateus-Solarte & Carvajal-Barona 2008). Traditional cultural beliefs may influence 
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adherence and access to TB treatment, too (Liefooghe et al 1997, Martins et al 2008). 
Numerous studies have found that one or several variables linked to affordability of 
services (low income or poverty of the patient, being unemployed or working as 
unskilled labourer, crowding, inability to afford additional medicine, facing costs to 
access the clinic, not receiving financial or in-kind support) were associated with non-
adherence (Dodor & Afenyadu 2005, Jakubowiak et al 2007, Mateus-Solarte & 
Carvajal-Barona 2008, Mishra et al 2005, Martins et al 2008). Our finding that 
economic barriers are even more important than any other barriers to access TB 
services may also be true in other countries and settings. 
The co-existence of catastrophically high patient-side costs and reasonably good 
treatment adherence are further evidence, that patients are aware of the importance of 
treatment and treatment adherence. 
11.3.2. Costs and the influence of health system factors 
Several of the findings related to household costs of an episode of TB are worth 
discussing in regard to academic research, mainly the high absolute level of these costs, 
their timing, and the factors that predicted higher costs. 
Costs of USD 4’900 PPP are far higher than the costs found in any other study on 
patient-side costs of a TB episode. As briefly discussed in chapter 6, the shorter recall 
period (which was about half as long than in many other studies because two interviews 
were conducted with each patient), Soviet traditions persisting in the management of 
TB patients in Tajikistan and the pervasiveness of informal payments in the Tajik 
health sector (Cashin 2004, Falkingham 2004, Tediosi et al 2008) are likely factors to 
have contributed to this finding. Our strategy of conducting two interviews with each 
patient considerably shortened recall periods and makes us confident that our results 
give a reasonably accurate picture of the economic burden faced by TB patients. 
The more important reasons are likely rooted in the Soviet tradition of TB care. Like in 
other post-Soviet countries there is a continued allegiance to the Soviet system in 
Tajikistan (Atun & Coker 2008). This includes the virtually exclusive reliance on TB 
specialists for TB diagnosis, the over-use of CXR, widespread hospitalisation during IP 
(sometimes also during CP) and the prescription of usually several types of additional 
drugs to the large majority of patients. As reported in chapter 5, primary care doctors in 
Tajikistan are reluctant to diagnose TB themselves. After decades of separation of TB 
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control in a separate vertical structure, many primary care providers do not yet consider 
diagnosing TB to be part of their responsibilities. Consequently patients are referred to 
the TB specialist, usually meaning that they have to pay for transport to the district 
centre. Both, diagnosis and follow-up of treatment success often rely on CXR, for 
which the patients usually have to pay, because there is not enough CXR film available. 
The last two factors mentioned above, hospitalisation and additional medication, have 
been shown in chapter 7 to be significantly associated with higher costs of illness. 
Hospitalisation has been shown in chapter 8 to be mainly due to the perceived need for 
isolation of the patient, which is not in accordance with international guidelines. Drugs 
commonly involved in additional medication are listed in chapter 7. Among others they 
commonly include vitamin B6. According to the World Health Organisation (2003), 
vitamin B6 should be given routinely to all patients if the general health status of the 
population is low – which is probably the case in Tajikistan. The rationality of other 
drugs commonly prescribed is more doubtful and in view of the high costs should be 
reviewed carefully. It seems likely that a considerable reduction will be possible. A 
further potential reason for the high costs is the pervasiveness of informal payments in 
the Tajik health system. The present thesis did not focus on the distinction between 
formal and informal payments. The distinction is difficult because health financing 
reform was ongoing. Until 2005, all health care was stipulated to be free of charge 
(Mahon & Tediosi 2007). In 2005 a co-payment system was introduced but soon 
withdrawn. The second version of the co-payment program was introduced during the 
time of our data collection in several pilot districts. At the time of writing this thesis, a 
move to user fees is under discussion (Ministry of Health of the Republic of Tajikistan 
2009). Due to these ongoing changes, a rigorous distinction between formal and 
informal payments was not possible and was not attempted. However, patients were 
asked about the part of drug expenditure that was made in connection with the anti-TB 
drugs: only a small minority reported payments and these were usually small. 
Summarising, the high costs are related mainly to the additional services provided, 
which are rooted in the Soviet tradition of TB management. It seems likely that TB 
patients in many parts of the FSU would face the same problem, mainly because these 
countries still have similar health systems and the delivery of TB services follows the 
same tradition (Atun & Coker 2008, Atun & Olynik 2008). A further similarity is the 
widespread occurrence of informal payments in the health sector of many countries of 
the FSU (Ensor & Savelyeva 1998, Thompson et al 2003, Thompson 2004). 
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Patients with other long-lasting diseases or chronic conditions are likely to face similar 
problems as TB patients. If their condition requires regular visits to a physician and/or 
to a pharmacy to buy drugs they are likely to face both, direct and indirect costs, to a 
considerable extent. Additionally, other conditions are usually not eligible for free 
treatment, which may lead to even higher costs for drugs. As an example, cancer 
patients conceivably face an equally high or even higher economic burden. 
Affordability is also likely to be an issue for milder conditions. In a population survey, 
roughly half of those who self-reported need for medical care in the preceding two 
weeks, did not obtain it – mainly because they could not afford it or felt that self-
medication was sufficient (Falkingham 2004). Patients in primary care spent about 
USD 12.5 for a visit to the doctor and for obtaining prescription medicines from the 
pharmacy (Tediosi et al 2008). Most of this amount was spent for the medicines. Even 
if patients with milder diseases are less likely to incur costs as high as those of TB 
patients, their costs may still have considerable implications for affordability of 
medical care and deter them from using health care altogether. 
A second important aspect is the timing of the costs of a TB episode. More than 70% of 
costs were faced during anti-TB treatment. This is more than in other studies, where 
half or less than half of the total costs were encountered during anti-TB treatment 
(Saunderson 1995, Kamolratanakul et al 1999). Regular trips to the facility for DOT, to 
pick-up drugs, or to visit the patient in hospital, additional medication and loss of 
income are some of the most important items that lead to high costs despite free anti-
TB chemotherapy. Monthly costs were highest during IP, which was unexpected in 
view of the free anti-TB chemotherapy. The large differences in monthly costs between 
the three periods investigated in the present thesis reinforce the insight that costs of ill-
health tend to come in peaks (Russell 2004). Peaks of costs affect the affordability 
over-proportionately and the distribution of costs of TB over time deserves more 
attention in the research on affordability of TB services. Understanding the timing of 
costs is also important in order to target mitigation strategies. The food supplements 
provided to TB patients in Tajikistan are a valid and important mitigation strategy (see 
also chapter 9). As will be argued in the next section, the food supplements are 
designed as an incentive, rewarding the patient after she or he has completed several 
months of treatment. This is based on the logic that the patient needs to be convinced 
and motivated to complete treatment. An alternative view focussing on the sheer 
inability of the patient to afford and thus to adhere to treatment has been proposed for 
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example by Greene (2004). If this alternative view is taken, mitigation strategies should 
preferably be aimed at enabling the patient rather than motivating the patient and 
should consequently be targeted to early stages of treatment, when the highest cost 
peak occurs, rather than after. The timing maximising the effect of mitigation strategies 
is a subject for future research. 
A further, not directly related, question for future research concerns the penitentiary 
sector. In the framework of the present thesis, we were not able to include the 
penitentiary sector in any of our studies. The provision of medical services in the 
penitentiary sector was a separate vertical program run by the Ministry of Justice rather 
than the Ministry of Health during Soviet times. Virtually nothing has been published 
about access to medical care in the penitentiary sector of Tajikistan. 
11.3.3. Improving TB diagnosis in low-resource settings globally 
Diagnostic tools to measure the humoral immune response (serological tests) have been 
reviewed repeatedly (Steingart et al 2007, WHO 2008) and it was consistently found 
that none of the available tests has the potential to replace sputum smear microscopy. 
Consequently, the latter will remain at the centre of TB case detection for several years 
at least. This underlines the importance of information on its performance in routine 
application. 
Many efforts in external quality assessment of sputum smear microscopy, but also in 
research, have concentrated on the reading part of the examination. Our results suggest 
that the reading part is functioning reasonably well in Tajikistan. Obtaining a good 
quality sputum specimen from the patient is likely the higher hurdle. The importance of 
a good quality sample has been pointed out in guidelines repeatedly (World Health 
Organisation 2003, Toman 2004). The reason that it has received less attention in 
research may lie in the difficulty of measuring the quality of a sample. A pragmatic 
randomised-controlled trial in Pakistan, however, found a positive influence of 
instructions to produce better samples on case detection (Khan et al 2007). 
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11.4. Findings relevant to programs and policy – and possible implications 
11.4.1. General situation of TB control in Tajikistan 
The Tajik health system and TB control program have delivered treatment to 8081 TB 
patients in 2007 (World Health Organisation 2009). The treatment success rate was 
84% among new sputum smear positive cases. The case detection rate for new sputum 
smear positive cases was estimated at 30%. Both rates have been disputed. The former, 
because biased reporting in order to receive rewards was claimed (Vrakking & Talevski 
2009), the latter because it is based on incidence estimates, which are inherently 
difficult to achieve. The present thesis did not investigate either of the two. However, 
data from the patients who dropped out from the patient survey (compare table 7.1) 
provide a basis for a speculative assessment of mortality and defaulter rates in our 
sample. Out of 292 patients, five had died and three had defaulted approximately one 
month into treatment. Both numbers are below the official statistics, but are likely to 
increase until the end of treatment. The final defaulter and mortality rates in our study 
sample may have been approximately in the range of official statistics. It was pointed 
out in chapter 5 that the moderate delays do not point towards a major problem with 
access, as the staggeringly low case detection rate of 30% suggests. On the other hand, 
moderate median delays do not exclude that there are some subpopulations that lack 
access to the services. Overall, the situation of access to care is likely not as dramatic as 
the low case detection rate suggests and the treatment outcomes may be reasonably 
good. However, in light of the high MDR-TB rates suspected for Tajikistan (Zignol et 
al 2006, see also section 1.3), the program needs to achieve particularly good treatment 
adherence rates to control TB. In any case, considerable further improvements in terms 
of access to care are possible and necessary. 
 
Table 11.1. TB control statistics in the countries of Central Asia° 
Country Total 
population 
TB 
incidence§ 
Case detec-
tion rate∂ 
Proportion 
of SS+† 
Treatment 
success rate* 
Afghanistan 27.1 million 168 64 62 84 
Kazakhstan 15.4 million 129 70 34 72 
Kyrghyzstan 5.3 million 121 60 44 82 
Tajikistan 6.7 million 231 32 51 84 
Uzbekistan 27.4 million 113 46 47 81 
° Source: World Health Organisation 2009. 
§ Estimated incidence of TB (cases per 100’000 population per year). 
∂ Ratio of notified new sputum smear positive cases (SS+) to total estimated SS+ cases. 
† Proportion of sputum smear positive cases among pulmonary cases. 
* Among new sputum smear positive cases. 
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11.4.2. Measures to improve access to medical care for TB 
To improve the population’s access to medical care for TB and probably other 
conditions, a range of issues have to be addressed. A priority aspect is affordability of 
services. The focus on economic barriers is not to say that other factors play no role at 
all: inter-personal skills of the health care workers, good counselling of TB patients at 
the time of diagnosis and again later, management of adverse effects of anti-TB 
chemotherapy and other factors likely also play a role. Furthermore, as has been argued 
above, different components of access to care are interlinked. Access to care is also 
intimately linked to the way health care services are organised and delivered. Examples 
of such links from this thesis are 1) the long health system delays experienced by TB 
patients first presenting to facilities without well-functioning referral systems to a TB 
facility, 2a) the high costs faced by patients who receive additional medication or 2b) 
are hospitalised, and 3) the under-use of sputum smear examination for diagnosis. 
To decrease costs for the patients, delays should be shortened through better referral 
systems for certain subgroups, the use of additional medication and hospitalisation 
should be reduced, and other measures like reduction of the use of CXR and provision 
of food at the hospital should be considered. Where the use of additional medication is 
based on a firm evidence-base and cannot be reduced, additional medication should be 
provided free of care. Measures in this direction have already been taken and the 
Global Fund will provide 25 types of additional drugs for the TB program, including 
some of those mentioned in chapter 7 of this thesis (Z. Maksumova, in litt.). Shortening 
delays will additionally make a significant contribution to TB control by reducing 
transmission directly. Most of the above-mentioned measures can only be implemented 
if the health system is strengthened and in collaboration with implementing partners 
and funding agencies. Primary care providers need to be further trained and involved in 
TB care in order to play a more efficient role in the diagnosis of TB and in order to 
conduct supervision of the treatment of patients that would otherwise have been 
hospitalised. If primary care providers are enabled and feel comfortable to diagnose TB 
based on the results of sputum smear microscopy and to initiate treatment, the referral 
pathway will be considerably shortened for remote rural patients – who were among 
the subgroups with the longest delays. This may include many measures that are 
beyond the scope of this thesis, including among others financial reform: despite a 
recent increase in salaries, primary care providers are still underpaid and unable to 
Chapter 11 – General Discussion and Conclusions 
 166 
subsist on their salaries. While the strengthening of primary care is ongoing, 
hospitalisation rates for TB should be further reduced. As has been shown in chapter 8, 
hospitalisation is mainly based on infectiousness in Tajikistan. Infectiousness is not 
considered a sufficient reason for hospitalisation in international guidelines and a 
reduction of hospitalisation rates can be started without major concerns. In chapter 8 it 
was also shown that hospitalised patients did not have higher treatment success rates – 
if anything, the rates were somewhat lower. Reducing hospitalisation rates may free up 
resources for the ambulatory supervision of TB treatment, but the details of the 
financing have not been studied in the framework of this thesis. 
Organising an international referral system for Tajik citizens who develop active TB in 
Russia is a further measure to decrease delays to treatment. Such a referral system is 
not equally dependent on health system strengthening as other measures. Ideally, the 
patients should start treatment in Russia (where DOTS programs have been 
implemented with external support, too). A transfer to Tajikistan should be considered 
only after smear conversion. 
11.4.3. Provision of food and other material support to TB patients 
Also if the above-mentioned measures are implemented, TB patients will still face 
considerable costs and strategies to mitigate the high household costs of TB will 
continue to be necessary. They include the provision of food supplements to TB 
patients and their household members. The delivery of food supplements was 
investigated in chapter 9 and they were found to be a substantial contribution to the 
patients’ household economies. Recommendations made in chapter 9 include more 
timely distribution of the food items, improved monitoring generally but especially for 
two of the six study districts and expansion of the program of food supplementation to 
districts that currently do not have them. In the meanwhile food distributions have 
already been implemented in an additional two of the twelve districts covered by the 
household survey on private costs of TB. Consequently, food supplements are currently 
provided in eight of the twelve districts covered in the household survey. Countrywide, 
food supplements are provided in 33 of the 64 districts and towns covered under 
DOTS. Hence, expansion has started. Donors and program managers should work 
together to expand the food supplements to the whole country. An earlier timing of the 
food supplements should be considered to enable patients for treatment adherence 
rather than incentivising them. 
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11.4.4. Sputum smear examination and external quality assessment 
As has been illustrated in chapter 5, sputum smear examination is not yet being used in 
primary care facilities, leading to long delays for patients presenting at these peripheral 
facilities. The under-use of sputum smear examination and concurrent over-use of CXR 
is one aspect of the ‘Soviet flavour’ of the DOTS program in Tajikistan. Managers at 
the level of the NTP and doctors at all levels often have doubts about the accuracy of 
sputum smear examination. Doctors further suspect patients to bring sputum of healthy 
people instead of own sputum collected at home (a behaviour that was observed also in 
Western Europe a few decades ago – R. Galeazzi in litt). Our study did not show 
evidence of this. The positivity rate was higher for second slides than for first slides, 
which is not consistent with patients commonly bringing sputum of healthy people. The 
repeatability of the re-reading was relatively high. This suggests that the reading at the 
microscopy is not a major problem. In fact, quality of sputum smear examination is 
possibly higher than previously thought. Piloting interventions to improve the 
instructions for patients to produce high quality sputum should be considered. Most 
importantly, sputum smear examination should be prioritised in order to find infectious 
cases with a cost-efficient measure. The access of the poor and of those living in 
remote places far away from a TB laboratory could be improved by organising sputum 
collection at primary care facilities. In Georgia, former TB laboratories with low 
workload were transformed into sputum collection points and a sputum collection 
system was put in place. This measure resulted in a substantial rise in the case detection 
rate. Tajikistan could possibly improve its case detection considerably by similar, 
simple measures. 
Funding agencies and international consultants have often used the coarse rule of 
thumb that 10% of diagnostic examinations should yield a TB diagnosis as the main or 
only indicator of the quality of sputum smear examination – irrespective of the setting, 
globally (Toman 2004, World Health Organisation 2003, Auer 2008). While many 
have been aware of the limitations of such an approach, there was often no alternative 
in the absence of the capacity to conduct culture for quality control. The novel 
approach presented in this study could become such an alternative, whereby the 
diagnostic accuracy of routine sputum smear examination can be measured in the 
absence of a gold standard. Advantages of our approach include the reliance on data 
that are routinely collected and recorded in programs that have a system for EQA. 
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Moreover, our approach avoids the doubtful assumption that the examination by the 
NRL would constitute a gold standard for comparison (cf. chapter 10). The additional 
effort needed to conduct an analysis as presented here is moderate even in places where 
data of the EQA are not routinely entered in digital format. Where data of the EQA are 
available in digital format, the efforts are minimal. 
11.5. Conclusions 
The analytical framework for access to care in contexts of livelihood insecurity, 
developed in the context of a malaria control program, has proven useful for our studies 
in the area of TB. Adaptations to make the analytical framework fit better to the context 
of access to TB care have been suggested. Most importantly, this concerns the way in 
which we look upon treatment adherence. Adherence was looked upon in the access 
framework as an outcome of the quality of care. In the area of TB control it seems more 
appropriate to regard adherence as continued utilisation and thus an outcome of access 
to care. The theoretical framework used for the study of illness-related costs also 
proved valuable. The studies conducted in the frame of this thesis identified economic 
factors as the main barriers to access medical care for TB. Other components of access 
to care were not found to be equally important. The timing of illness-related costs may 
further have jeopardised affordability: a high cost peak was encountered by most 
patients in the intensive phase of treatment. 
Several characteristics of health care delivery that are rooted in the Soviet health 
system contributed to the high costs faced by patients and to the long delays 
experienced by certain subgroups. The importance of factors related to the Soviet 
history of health care suggests that many of our findings may also apply to other post-
Soviet countries. In order to improve access to TB care and hence TB control in 
Tajikistan and possibly other countries of the former Soviet Union, the economic 
burden for the patients must be reduced as a matter of priority. This will require 
measures on both sides: reducing the costs incurred by patients and increasing their 
ability to cope with these costs. In order to reduce the costs incurred, reducing the use 
of additional medication for the treatment of symptoms and (perceived) iatrogenic 
problems and more strongly advocating and using ambulatory care are the most 
promising measures. Delays to TB treatment were also associated with higher costs and 
shortening delays is likely to contribute to reduced costs, too. For those patients for 
whom additional medication or hospitalisation are medically warranted, medication 
Chapter 11 – General Discussion and Conclusions 
 169 
should be provided for free and free food of good quality should be provided at the 
hospital in order to reduce costs. In order to improve the patients’ ability to cope with 
the costs of illness, the distribution of food supplements should be continued and its 
expansion to other districts should be swiftly completed. The partial implementation of 
some of these measures has already started at the time of writing. 
One aspect of access that contributes to the high costs of illness, but is likely not a 
direct consequence of problems of affordability is the long delays until treatment that 
certain subgroups of patients experience. The delays of patients who first present to 
peripheral primary care facilities or to health care in Russia need to be shortened. This 
can be achieved by improving the referral systems. An international referral system for 
Tajik temporary migrant workers who develop active TB in Russia should be 
implemented to enable them to promptly start treatment. In order to shorten delays for 
patients presenting first to primary care, a further integration of TB services with 
general health care is recommended, whereby general practitioners are supported and 
encouraged to make a diagnosis of TB (based of sputum microscopy) and to start TB 
themselves. The analysis of the sensitivity of routine sputum microscopy in peripheral 
laboratories in Tajikistan showed that its sensitivity is reasonably good and that 
prioritisation of sputum microscopy can be more vigorously pursued. 
The analysis of the sensitivity of routine sputum microscopy also suggested that on 
theoretical grounds a considerable proportion of cases are expected to be found only 
with the third serial smear. While TB programs globally are struggling to achieve their 
detection targets, it is therefore not recommended that the debated policy change from 
three to two serial smears for diagnosis be implemented now. Rather, measures to 
enable laboratories to carry out three smear examinations with high quality should be 
developed and tested. This could increase the yield from third serial smears closer to 
the theoretical maximum and could improve case detection in many settings 
worldwide. 
This thesis investigated determinants of access to care and household costs and it is 
very much hoped that its results will contribute to improved TB control and to a 
reduction of the risk of impoverishment associated with it – in Tajikistan and 
elsewhere. While several areas of priority for action were identified and while it was 
attempted to formulate these clearly, we should not forget that access to care is a 
complex issue and that its components are interlinked. Making TB control work will 
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require many more efforts, strong leadership, commitment and certainly also many 
measures that go beyond the ones studied in this thesis! 
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12. Appendix 
12.1. Discussion Guidelines for Focus Group Discussions 
12.1.1. Discussion Guidelines – Population 
CULTURAL ASPECTS OF TB AND APPROPRIATE CARE FOR TB 
1 WELCOME AND INTRODUCTION 
For the moment, on no account mention the word tuberculosis! 
Pass the following information 
• very happy that you came here and give us your time 
• we want you to feel comfortable here, please feel free to tell us if you do not feel 
at ease 
• research team from project Sino, independent from MoH, independent from 
Republican health institutions 
• project Sino works in four rayons V, D, Sh, T, on strengthening of PHC, on all 
levels: from policy-making, together with general practitioners, on access to care for 
the population, and also in health promotion 
• would like to learn from you, your personal opinions and experience 
• what you say here is confidential, we will not tell anybody, who said what 
• we would like to talk with you about respiratory diseases 
• happy about any input, there is no “right” or “wrong” statements, there are no 
stupid answers 
• your personal opinion counts and we would like to reconfirm that we are going to 
treat it confidentially 
• before we start introducing ourselves personally, if you have suggestions, 
remarks or questions you are welcome to tell us now 
Ask permission to record on tape. If participants unsure, discuss issues. Switch on 
tape. 
“Let’s get acquainted to one another.” Introduce yourself. 
“I have been talking very much, now I don’t want to monopolize the speech any 
longer”. 
Invite participants to introduce themselves one by one. 
2 PARTICIPANTS’ PERCEPTIONS OF TB 
• Please name diseases that have symptoms like the following: strong cough, fever. 
(Make list of all the diseases and of the respective symptoms, ask for differences in 
symptoms) 
 
Introduce the word for tuberculosis. Which of the named diseases is tuberculosis? 
• Are there other names for this disease in your area? Do these names denote 
exactly the same or are there small differences? 
• Are there diseases in your area that are similar to TB in terms of symptoms? 
 
We would like to concentrate on TB now, and mainly on the pulmonary form. 
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• What are the causes that make women and men have TB? (List causes named 
spontaneously. Afterwards: Probe for beliefs that TB were 
o inherited, 
o due to misbehaviour [if yes, dwell on issue and find out what kind of 
misbehaviours], 
o dependent on sex differences, 
o due to bad water, 
o due to wrong food. 
Find out whether factors are considered essential or contributing factors.) 
 
• Do people who have it disclose it to others in the village? (Possibly probe for 
following: “would you want your child to get married to somebody who has had TB 
previously? Are there people in your area who would not want this?) 
• Do you act differently towards somebody who has TB? Do you take precaution 
measures? 
• What should somebody who has TB do about her or his condition? And why 
should she or he do so? 
 
3 HOW DO PARTICIPANTS PERCEIVE CARE FOR TB? DIAGNOSIS 
• What you suggested before, what people with (symptoms of) TB should do: is 
this what the people in your village actually do? 
• Maybe you have heard that the doctors at the RHC ask people with these 
symptoms (see above) to give one sputum sample each on three different days. Are 
people able to give that? 
• Is there a problem for any particular subgroup (f. i. women)? 
• Do some of them rather go to a tabib or a person delivering care other than a 
doctor or a mid-level health worker? Do you think this will help? 
• If we consider somebody who has TB and if we consider that this person should 
go to the doctor at the RHC: what are the factors preventing that this person actually 
does go to the RHC? 
• Will other people in the village know, if somebody receives care for tuberculosis 
from the doctor? Is this a problem for them? Would it be a problem for you? 
 
4 HOW DO PARTICIPANTS PERCEIVE CARE FOR TB? TREATMENT 
• The doctors suggest that people with TB make a treatment for six months – Are 
the patients in your area very convinced to do so? 
• If people do the six-month treatment, do you think they will get cured? 
• Can people in your village do this? 
• Are there some people who are not able to take this six-month treatment? Who 
are these people and why are they unable to take this treatment? 
• Which of these factors are the most important ones? (Participatory Approach) 
 
12.1.2. Discussion Guidelines – Patients 
BARRIERS AND ENABLERS TO ACCESS CARE FOR TB 
1 WELCOME AND INTRODUCTION 
Chapter 12 – Appendix 
 177 
Pass the following information 
• very happy that you came here and give us your time 
• we want you to feel comfortable here, please feel free to tell us if you do not feel 
at ease 
• research team from project Sino, independent from MoH, independent from 
Republican health institutions 
• project Sino works in four rayons V, D, Sh (TB only), T (TB only), on 
strengthening of PHC, on all levels: from policy-making, together with general 
practitioners, on access to care for the population, and also in health promotion; it 
includes a TB component 
• would like to learn from you, your personal opinions and experience 
• talk about TB 
• happy about any input, there is no “right” or “wrong” statements, there are no 
stupid answers 
• your personal opinion counts and we would like to reconfirm that we are going to 
treat it confidentially 
• before we start introducing ourselves personally, if you have suggestions, 
remarks or questions you are welcome to tell us now 
Ask permission to record on tape. If participants unsure, discuss issues. Switch on 
tape. 
“Let’s get acquainted to one another.” Introduce yourself. 
“I have been talking very much, now I don’t want to monopolize the speech any 
longer”. 
Invite participants to introduce themselves one by one. 
 
2 INITIAL CONTACT WITH HEALTH SYSTEM AND EXPERIENCE WITH 
DIAGNOSTIC PROCEDURE 
• Please tell us, which symptoms you had. Which of these symptoms was the most 
important one that made you decide to go and seek health care? 
• Please try to remember in detail the sequence of events until you were diagnosed 
with TB:  
o whom you asked for help to improve your health (family members, tabib, 
MedDom, RHC [SUB/SVA], etc.), 
o when and how your diagnosis was made, 
o where you had to travel, 
o whether you had to provide a sputum sample, 
o whether an x-ray was made, 
o when and by whom you were told your diagnosis. 
• Was it difficult for you to receive diagnosis for TB? What were the factors that 
made it difficult for you to go to the doctor/to diagnostic services? (Make a list of 
factors named spontaneously. Afterwards: Probe for 
o lack of confidentiality of services, 
o neighbours potentially finding out about their disease, 
o unfriendly attitude of health workers, 
o low quality of services, 
o distance to services) 
 
For those who underwent sputum smear microscopy: 
• Did you have difficulties providing a sputum sample? Did it hurt in your throat? 
Did you feel uneasy to produce sputum? Would there be a difference between men 
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and women in this respect? 
• Did you believe that microscopy examination of your sputum would give a good 
diagnosis? 
• Did you have to travel for the sputum delivery? Did you have to pay for 
transport? How much? 
• As you may know, due to their very low salary, doctors have started asking 
money from patients. Although most people know that this happens, we have very 
little knowledge about the amounts paid. It is very important that we understand, for 
which services how much money is paid to find solutions for this problem. In here, 
we can talk about everything and we will never tell anybody who has made which 
statement within this FGD. I would therefore like to invite you to tell, whether you 
had to pay money for the sputum test (encourage each participant to comment on this 
question) 
• How much did you pay? Or did you make any gifts? 
• Did you want to give something, or did you feel that you had to? 
• Did you pay for the X-ray if you had any (encourage each participant with X-ray 
to comment). How much was paid for X-ray? Compare this to the sputum smear 
examination. 
• Let us consider the time from the onset of your symptoms until you knew your 
diagnosis from a doctor. Can we make a complete list of all the expenditures that you 
had, including transport costs, gifts you have given in return for something, etc. etc.? 
(create a table with line-items and amount of money spent on, encourage discussion 
and consolidation of indicated amount) 
• Have you been working at the time when your symptoms started? Did you 
continue working or have you had to reduce or to stop? How did this affect your 
income? 
• We have now been talking about your expenditures for a while. Now, please 
think back and consider all other factors as well. What were the most important 
factors? 
(Let the discussion run for a while. Then use the list of factors hindering access to 
health care, add time constraints, missed income, transportation costs, and payment 
for health services. In confidential participatory approach, rank them by importance). 
 
3 HOW DO PARTICIPANTS PERCEIVE CARE FOR TB? 
You are now on treatment. We would be very interested to learn about your 
experience with the treatment, about your personal view of the treatment. “Wrong” or 
“right” answers do not exist here. Your personal opinion counts and differences 
between personal opinions can be accepted. 
• How convinced are you to do this treatment for such a long time? Do you 
sometimes think that you are already cured and you do not need it anymore? Or are 
you afraid that it anyway wouldn’t help? 
• Except for the conviction with which you do this treatment, are there any factors 
that make it difficult for you to continue treatment? Please also mention factors that 
made it difficult at some stage of the treatment or that you feel may make it difficult 
for you to continue treatment in the future. (Make list of factors mentioned 
spontaneously. Afterwards: Probe for 
o lack of confidentiality of services, 
o neighbours potentially finding out about their disease, 
o unfriendly attitude of health workers, 
o low quality of services, 
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o distance to travel to take treatment, 
o being obliged to stay in hospital, 
o side effects of drugs). 
• Can we again try to make a list of all the expenditures that you had during your 
treatment until now? (Make table with line-items and amounts indicated by 
participants for each line-item, encourage participants to discuss and consolidate the 
amount listed) 
• We have now been talking about your expenditures for a while. Now, please 
think back and consider all other factors as well. What were the factors that mostly 
affected your ability to receive treatment? (Let the discussion run for a while. Then 
use the list of factors hindering access to health care, add time constraints, missed 
income, transportation costs, and payment for health services. In confidential 
participatory approach, rank them by importance). 
• How do the food contributions affect your ability to receive treatment? 
12.1.3. Discussion Guidelines – Providers 
ASPECTS OF DOTS PROGRAMME AS BARRIERS AND ENABLERS TO 
ADHERE TO CARE FOR TB 
1 WELCOME AND INTRODUCTION 
Pass the following information 
• very happy that you came here and give us your time 
• we want you to feel comfortable here, please feel free to tell us if you do not feel 
at ease 
• research team from project Sino, independent from MoH, independent from 
Republican health institutions 
• project Sino works in four rayons V, D, Sh (TB only), T (TB only), on 
strengthening of PHC, on all levels: from policy-making, together with general 
practitioners, on access to care for the population, and also in health promotion; it 
includes a TB component 
• would like to learn from you, your personal opinions and experience 
• talk about TB, factors that influence the way you are able to provide services for 
patients 
• happy about any input, there is no “right” or “wrong” statements, there are no 
stupid answers 
• your personal opinion counts and we would like to reconfirm that we are going to 
treat it confidentially 
• before we start introducing ourselves personally, if you have suggestions, 
remarks or questions you are welcome to tell us now 
Ask permission to record on tape. If participants unsure, discuss issues. Switch on 
tape. 
“Let’s get acquainted to one another.” Introduce yourself. 
“I have been talking very much, now I don’t want to monopolize the speech any 
longer”. 
Invite participants to introduce themselves one by one. 
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2 HOW DO PARTICIPANTS PERCEIVE THE DIAGNOSTIC PROCEDURE 
• Please tell us about the symptoms that trigger patients to come to you and about 
the symptoms that make you suspect TB. 
• How do you proceed with TB suspects? What are all the measures that you take? 
• How do you feel about this procedure? Are you convinced? Does it work? Are 
there difficulties? 
• How does the communication between PHC and the TB services work? 
• Do you prefer sputum smear or Chest X-Ray? 
• Once the test is made (sputum smear or CXR), how does the information come 
back from the TB services to PHC? 
• Do patients experience difficulties with this procedure? Do you have any ideas, 
what the reasons are that patients do not come to seek health care and do not get 
diagnosed? (Make a list of factors named spontaneously. Afterwards: Probe for 
o lack of confidentiality of services, 
o neighbours potentially finding out about their disease, 
o distance to services) 
3 HOW DO PARTICIPANTS PERCEIVE TREATMENT FOR TB? 
• How is treatment usually given to TB patients in your area? (in-patient or out-
patient, do all DOTS patients have to be under DOT, where does DOT take place, 
which drugs are given) 
• Does this procedure work well? Do you think it should be adapted? 
• How do you feel about the workload it puts on you? 
• Can you think about aspects of the programme that make it difficult for the 
patients to receive treatment? (Make a list of factors named spontaneously. 
Afterwards: Probe for  
o lack of confidentiality of services, 
o neighbours potentially finding out about their disease, 
o distance to services) 
The MoH had started the implementation of the Basic Benefit Package. The 
implementation has been stopped, but the most important change was that some 
services would have to be paid for. It is clear, that resources are lacking in the health 
sector. Some services simply cannot be offered for free anymore. How is that with 
services that TB patients consume? 
